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ABSTRACT
Prostate cancer is the most prevalent malignancy in American men, leading to significant
mortality each year. This is in part due to a lack of effective treatments for advanced disease.
The prostate is considered an ideal organ for cancer immunotherapy, because it is both non-
essential and expresses several prostate-specific antigens than could be targeted for an
immunotherapeutic response. However, such therapy is limited by the tolerization of CD8' T
cells in tumors, rapidly abrogating anti-tumor responses. In order to better understand the factors
necessary to induce, maintain and promote productive T cell responses against cancer, this
research has focused on understanding and interrupting critical interactions between CD8* T
cells and immunosuppressive networks within tumors.
As our model system, we explored CD8* T cell recognition of spontaneous prostate
cancer in TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) mice. We
demonstrated that both naYve and effector tumor-reactive T cells are rapidly tolerized in the
prostates and prostate draining lymph nodes (PDLN) of TRAMP mice, and that dendritic cells
are important factors driving their tolerization. We then developed two novel
immunotherapeutic approaches to locally overcome the suppressive influence of dendritic cells.
In one approach, we engineered tumor-reactive T cells to express the immunostimulatory protein
CD40 ligand to mature dendritic cells in the PDLN. This work demonstrated for the first time
that tumor-reactive T cells could be engineered to deliver stimulatory signals to dendritic cells in
tumor environments to enhance the function of adoptively transferred T cells. In a second
approach, we injected ex vivo matured, antigen-loaded dendritic cells into tumors to overcome
the influence of endogenous suppressive dendritic cells. This work demonstrated for the first
time that intratumoral injections of dendritic cells into spontaneous primary tumors could
significantly delay the tolerization of tumor-infiltrating effector T cells and reverse the
tolerization of resident tumor-infiltrating lymphocytes (TILs), generating new potential
therapeutic applications for TILs. These two approaches establish that mechanism-based
immunotherapeutic interventions can be rationally designed to locally interrupt
immunosuppressive networks within tumors. As the TILs enhanced through this work are
representative of those found in cancer patients, such approaches could have significant clinical
impact.
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Chapter 1
Introduction
1.1 Cancer Immunotherapy
1.1.1 Background
Cancer immunotherapy refers to approaches designed to empower or invigorate a cancer
patient's immune system to achieve anti-tumor responses (1). These approaches are based on the
idea that the specificity and power of the immune system can be harnessed to fight malignancies,
as it can be to fight infectious diseases. After a century of research and debate since this idea
was first formulated (2, 3), significant data now exists supporting a critical role for the immune
system in combating malignancies (4).
The concept of cancer immune surveillance was initially heavily criticized, based on
early experimental results suggesting there was no increase in cancer incidence in nude mice,
which lack T cells (5, 6). Later data refuted these findings, showing that severely immune
compromised mice, lacking both innate and adaptive immune responses, have a significant
increase in cancer incidence (4). There is now extensive evidence that immune compromised
mice are more susceptible to both spontaneous and carcinogen-induced cancers (7). Similarly,
there is also evidence that immune surveillance has an important role in controlling human
cancers. Lymphocyte infiltration correlates well with survival for many types of solid tumors (8-
12). Furthermore, the incidence of cancer is increased in some immunodeficient patients, such
as those with HIV and AIDS (13), as well as in patients receiving immunosuppressive drugs
following organ transplantation (14, 15). Finally, cancer patients can develop both adaptive and
innate immune responses against their tumors, suggesting the immune system can recognize
these cells as malignant (7). As the potential impact of antitumor immune responses has now
been established, research is ongoing to develop strategies to initiate, maintain and manipulate
these responses for therapeutic benefit in the clinic.
1.1.2 Clinical experience
Cytotoxic T lymphocytes (CTLs) are the primary immune cells that lyse and kill antigen-
displaying target cells. Thus, most cancer immunotherapy efforts have focused on stimulating
antigen-specific CD8' T cell responses against tumors. In order to achieve significant tumor
destruction, these immunologic responses must meet at least the following three criteria: 1) an
adequate number of tumor-specific immune cells must be generated with highly avid tumor
antigen recognition in vivo, 2) these cells must traffic to tumor environments, and 3) these cells
must maintain their effector functions in tumors, including cytokine production and cytotoxic
killing (16). Both active (cancer vaccines) and passive (adoptive cell transfer) immunotherapies
are being developed to meet these criteria.
Cancer vaccines aim to directly stimulate tumor-reactive T cell responses in vivo and
have long been the major focus of cancer immunotherapy development. Vaccine approaches
have included those based on dendritic cells, synthetic peptides, naked DNA, recombinant
vaccinia viruses, recombinant adenoviruses and recombinant fowlpox viruses. Unfortunately,
over a decade of clinical work with these cancer vaccines has not yet resulted in
immunotherapeutic responses that lead to robust T cell activation and long-term tumor regression
in cancer patients (16). A significant advance was recently made in the field of cancer vaccines
with the success of Sipuleucel-T (APC8015; Provenge; Dendreon, Seattle, WA), a dendritic cell-
based vaccine for the treatment of prostate cancer in which the dendritic cells are loaded with a
therapeutic fusion protein prior to reinjection into patients (17). Earlier this year, Dendreon
presented data from their Phase III IMPACT (immunotherapy for prostate adenocarcinoma
treatment) trial for Sipuleucel-T, demonstrating that they had met the primary trial endpoints by
extending median patient survival by 4.1 months compared with the placebo and improving 3
year survival by approximately 38% (17). This success will likely be an important milestone in
active cellular immunotherapies.
Adoptive cell transfer (ACT) relies on the ex vivo stimulation and expansion of
autologous tumor-reactive T cells, followed by transfer back into cancer patients. Initial clinical
studies with ACT using tumor-infiltrating lymphocytes (TILs) met with limited success (18).
Recent clinical protocols, incorporating lymphodepleting chemotherapy regimens prior to
adoptive transfer of TILs, have significantly increased the response rates in metastatic melanoma
patients. Objective response rates of between 49-72% have now been observed (19). It remains
to be determined whether the clinical successes achieved using ACT to treat metastatic
melanoma can be further enhanced, and whether these successes can also be achieved for the
treatment of other cancers.
Extensive clinical experience with both cancer vaccines and ACT has demonstrated that
robust, curative anti-tumor immune responses are challenging to generate and maintain in cancer
patients. It appears that one of the major challenges in generating these responses is
immunological tolerance. Since tumors grow out of an individual's own tissue, they primarily
express self-antigens to which T cells would likely have been tolerized, either centrally in the
thymus or in the periphery. The mechanisms of tolerance that naturally exist to prevent the
generation of autoimmune disease can also inhibit the generation of adequate anti-tumor
responses (20). Data from melanoma patients supports this idea, as antigen-experienced
melanoma-specific T cells recovered from patients have poor proliferative capacities and
cytotoxic potential following in vitro restimulation, suggesting these circulating T cells have
been tolerized (21). Thus, strategies of tumor immune evasion and tumor-induced T cell
tolerance provide significant impediments to cancer immunotherapy. Common strategies of
immune evasion include direct deletion of tumor reactive T cells, delivery of negative
costimulatory signals, decreased antigen processing and presentation and ignorance. More direct
strategies of tumor-induced tolerance include the production of immunosuppressive factors and
galectins, as well as the influence of actively suppressive cell populations, such as regulatory T
cells, myeloid-derived suppressor cells and dendritic cells. Each of these mechanisms will be
discussed in more detail below.
1.2 Tumor Immune Evasion
1.2.1 Deletion
Direct deletion of tumor-reactive T cells is driven by tumor cell expression of death
receptor ligands, such as Fas ligand (FasL). When Fas expressed on the surface of tumor-
infiltrating T cells engages FasL expressed on the surface of tumor cells, the T cells initiate
apoptotic cell death. In support of a role for this mechanism, the growth of FasL* mouse
melanoma cells is significantly delayed in a Fas deficient mouse model, in which T cells cannot
be killed by FasL (22). Furthermore, downregulation of FasL expression in colon cancer cells
decreases tumor cell growth and increases T cell infiltration in immunocompetent mice (23).
FasL expression has been identified in some tumor cell lines and also in various tumors in situ
(22, 24-26).
Despite significant evidence highlighting a role for FasL in mediating tumor immune
evasion, its influence in the tumor environment has been controversial. FasL expression can also
have antitumor and proinflammatory effects. For example, transfecting a colon cancer cell line
to engineer FasL expression leads to its rapid rejection in vivo, largely due to neutrophil
activation (27). Whether FasL expression ultimately triggers tumor immune evasion or tumor
destruction is likely influenced by the levels of FasL being expressed and by the local cytokine
milieu within the tumor (28).
Other tumor-associated molecules have been implicated in inducing the death of
infiltrating lymphocytes as well, including the ligands TRAIL (TNF-related apoptosis inducing
ligand) (29) and RCAS 1 (receptor binding cancer antigen expressed on SiSo cells ) (30) and the
chemokine RANTES (regulated on activation, normally T cell expressed, and secreted) (31).
1.2.2 Negative signaling
Engagement of negative costimulatory receptors on activated T cells, such as cytotoxic
T-lymphocyte antigen 4 (CTLA-4) and programmed death-1 (PD-1), can rapidly dampen anti-
tumor responses. CLTA-4 is an important negative regulator of T cell responses, and is
upregulated on activated T cells. Following T cell activation, engagement of CTLA-4 triggers
decreases in the production of cytokines and progression through the cell cycle (32). CLTA-4 is
a homolog of the positive regulator CD28, and similarly binds to B7 family members, but with
heightened affinity. CTLA-4 signaling can have important functions in inducing peripheral T
cell tolerance in vivo (33). Furthermore, investigators have shown that blocking CTLA-4
signaling, using anti-CTLA-4 antibodies, significantly enhances anti-tumor immune responses,
both in animal models and humans (34-38).
PD-I is also a negative regulator of T cell activation. Engagement of PD-I by one of its
ligands, PD-Li or PD-L2, generally inhibits T cell function (28, 39). PD-L1 is expressed by
many human tumors, and its expression can induce T cell apoptosis (40). Blocking the PD-1-
PD-Li interaction, using an anti-PD-Li antibody, promotes anti-tumor T cell responses and
tumor rejection (41). Similar results have been observed using tumor-specific T cells that lack
PD-1 (42). PD-Li expression can be a potent strategy by which tumors can avoid immune
detection (28).
Negative costimulatory signals can thus strongly influence the outcome of T cell based
anti-tumor responses.
1.2.3 Decreased antigen presentation
Tumor escape can also be associated with decreased antigen presentation (43-45).
Alterations in the class I presentation pathway can result in either a total loss or a significant
reduction in class I expression levels. This is most commonly achieved through loss of
individual human leukocyte antigen (HLA) alleles, transcriptional regulation or generation of
mutations in the P2-microglobulin gene (28, 46-49). These strategies allow tumors to avoid
detection by tumor-specific CD8* T cells, but potentially leave them more susceptible to NK cell
mediated elimination. Thus, many tumor cells evolve to maintain low to intermediate MHC
class I expression levels to both avoid T cell detection and NK cell elimination, or they undergo
additional mutations to select for NK cell resistance (50). Human tumors commonly
downregulate major histocompatibility complex (MHC) class I, especially in metastatic disease
(51, 52). Decreased antigen presentation can also be achieved through mutations in the antigen
processing machinery, such as subunits of the immunoproteasome (low molecular mass
polypeptide 2 (LMP2), LMP7) or the transporter associated with antigen processing (TAP) (28,
46, 53). In addition to direct decreases in antigen presentation, tumors can further avoid
detection through rapid mutagenesis of tumor antigens themselves, leading to escape variants
that are not recognized by tumor-specific T cells (54).
1.2.4 Ignorance
Ignorance, which refers to tumor cells that are not accessible to T cells (55), can be
achieved by tumor growth in an immune privileged site or by low antigen expression levels, lack
of inflammatory signals or decreased expression of adhesion molecules. Immune privileged
sites, including the brain and eyes, are generally not monitored by immune cells (56, 57). Tumor
cells can also downregulate the expression of adhesion molecules to minimize immune infiltrates
(58-60). The stroma itself can further impede direct interactions between the immune system
and tumor cells (61). Small, early-stage tumors in particular can often escape immune detection
through ignorance. For example, when a single-cell suspension of a viral-antigen expressing
sarcoma cell line is injected subcutaneously, it initiates a strong CTL response; however, when
the same cells are transferred as small tumor fragments, no antigen-specific T cell response is
primed (55).
1.3 Tumor-Induced T Cell Tolerance
1.3.1 Immunosuppressive factors
An important mechanism used by tumors to tolerize CD8' T cells is the production of
immunosuppressive factors, either by the tumor cells themselves or by other immune, stromal or
epithelial cells in the tumor environment (62). These immunosuppressive factors can include
transforming growth factor P (TGF-) (63-68), interleukin-10 (IL-10) (69, 70), vascular
endothelial growth factor (VEGF) (71), macrophage-colony stimulating factor (72, 73) and
prostaglandins (74-77). One of the most common of these in tumor environments is TGF-p (62).
TGF-p can directly inhibit T cell proliferation and differentiation, and can also inhibit the
ability of antigen presenting cells (APCs) to prime T cell responses (64). Since cytokines
produced by activated CD4' and CD8+ T cells are often essential to immune-mediated
destruction of tumors, inhibition by TGF-p can severely inhibit anti-tumor responses (64). The
effector functions of fully-activated melanoma-specific human CD8' T cells are significantly
suppressed in the presence of TGF- (68). Furthermore, elevated levels of TGF-p in the serum
correlate with poor prognosis in numerous cancers, including prostate, gastric, bladder and
colorectal cancers (78-81).
Several investigators have demonstrated that inhibition of TGF-p signaling in T cells can
enhance anti-tumor immune responses. For example, T cells engineered to express a dominant
negative TGF-p receptor type II, thus rendering them insensitive to TGF-, are better able to
mediate tumor rejection (64). Similarly, TGF- insensitive tumor-reactive CD8' T cells can
more effectively induce apoptosis following infiltration into tumors (82). These results suggest
that inhibition of TGF-3 signaling or TGF- P neutralization may be potential approaches to
minimize the immunosuppressive impacts of this mechanism of tolerance.
1.3.2 Galectins
Galectin-carbohydrate interactions are a growing area of interest as potential mechanisms
of tumor-induced tolerance. Galectins are glycan binding proteins characterized by conserved
carbohydrate-recognition domains (CRDs) that mediate carbohydrate binding (83). Similar to
cytokines, galectins produced and released by tumor cells can significantly alter immune
responses, and recent data suggests they may be involved in tumor-induced tolerance and
immune escape (83, 84). Important galectins in regulating immune responses can include
galectins 1 (83, 85-91), 2 (92-94), 3 (93, 94) and 9 (95, 96).
Galectin-1 has been widely studied for its role in tuning immune responses, and has
numerous mechanisms by which it can minimize T cell effector functions (28, 83). For example,
galectin- 1 interactions can block proximal T cell receptor (TCR) signaling (85), induce apoptosis
(87) and suppress cytokine secretion (97). Galectin-1 expression has been correlated with the
aggressiveness of various tumors (83, 98). This observation, coupled with the important
immunomodulatory functions of galectin-1, suggests that tumors could secrete galectin-1 to
suppress anti-tumor responses (83). It has been shown that blocking galectin-1 in vivo enhances
the generation of anti-tumor T cell responses and promotes tumor rejection (99).
Other galectins can have important influences on T cell function as well. Galectin-3 can
minimize the lateral mobility and movement of TCR complexes, by forming multivalent
complexes with specific glycans on the TCR (94). Since TCR mobility is important for
activation, this can have significant immunosuppressive effects. It has also been demonstrated
that galectins 2, 3 and 9 can induce T cell apoptosis (92, 93, 95, 96). Additional work needs to
be done to clearly understand the individual roles these galectins might have in influencing anti-
tumor responses.
1.3.3 Regulatory T cells
Sakaguchi, et al., catalyzed interest in this subset of cells by identifying CD4* T cells
expressing high levels of CD25 that could minimize autoimmune responses in a murine model
(100). Naturally occurring regulatory T cells can now also be identified by additional markers,
such as the forkhead box P3 (Foxp3) transcription factor (101-103) and the surface markers
CTLA-4 (104, 105), glucocorticoid-induced TNFR-related protein (GITR) (106, 107),
lymphocyte activation gene-3 (LAG-3) (108) and neuropilin-1 (109).
Regulatory T cells are thought to use diverse and variable mechanisms to mediate T cell
tolerance, which group into four general modes of suppression: inhibitory cytokines, cytolysis,
metabolic disruption and modulation of dendritic cell function (110). The role of inhibitory
cytokines in the suppression mediated by naturally-occurring regulatory T cells has been
controversial. There is conflicting data that secreted IL- 10, cell surface-associated or secreted
TGF-p and secreted IL-35 may have important roles (104, 111-114). Cytolysis has recently been
shown to be an important suppressive mechanism as well. Regulatory T cells can kill CTLs and
NK cells using granzyme B- and perforin-dependent mechanisms, minimizing tumor cell
clearance (115). They have similarly been shown to kill B cells (116). Regulatory T cells may
also inhibit T cell function simply by competing for critical resources in the environment, such as
IL-2 (117, 118). A newer idea about the suppressive mechanisms used by regulatory T cells is
that they alter dendritic cell function and activation (110). This process likely involves CTLA-4,
which is constitutively expressed by regulatory T cells (119, 120). In the absence of CTLA-4,
the ability of regulatory T cells to dampen T cell activation by dendritic cells is greatly reduced
(121). Furthermore, interactions between CTLA-4 on the surface of regulatory T cells and CD80
and/or CD86 on the surface of dendritic cells conditions the dendritic cells to produce the
negative regulator indoleamine 2,3-dioxygenase (IDO) (110, 122, 123). Secreted molecules,
such as IL-10 and TGF-P, may also be involved in the modulation of dendritic cell function
(110).
There is significant evidence that regulatory T cells have an important role in dampening
anti-tumor T cell responses. For example, regulatory T cells accumulate in the tumors or
peripheral blood of patients with many different types of cancer, including lung, ovarian, breast,
pancreatic, skin, gastric, head and neck and liver cancers (124-132). The accumulation of
regulatory T cells in tumors is inversely correlated with survival in ovarian cancer patients,
linking regulatory T cells to the pathogenesis of the disease (28, 130).
In vivo depletion of regulatory T cells, by targeting surface-expressed CD4 or CD25, can
increase tumor rejection (133, 134). In mouse models, it has been shown that either transferring
splenocytes depleted of CD25-expressing cells or administering an anti-CD25 monoclonal
antibody induces autoimmunity and drives the recognition of self (100, 135). Administration of
an anti-CD25 monoclonal antibody also induces tumor rejection (136). Similar results have been
found by targeting CD4. Early studies demonstrated that depletion of all CD4* T cells, using a
depleting anti-CD4 antibody, leads to CTL mediated tumor regression (137). More recently, it
has been demonstrated that intratumoral depletion of local CD4* T cells induces tumor rejection
as well (138).
The major limitation of depleting CD4*CD25* regulatory T cells using anti-CD4 or anti-
CD25 antibodies is that the helper function of CD4* T cells is generally lost as well. With anti-
CD25 antibody treatments, recently activated CD8' T cells are also lost, as CD25 is upregulated
on these cells following activation. Thus, the identification of alternative approaches targeting
regulatory T cells function is still an active area of research. Targeting GITR may provide one
alternative. Treating mice with anti-GITR antibodies increases immunity to tumors, potentially
by attenuating regulatory T cell activity (139). Toll-like receptors (TLRs) may provide another
alternative, as engagement of TLRs has been shown to reverse regulatory T cell function (140,
141). Depletion or attenuation of regulatory T cells remains an attractive target to enhance
immunotherapeutic responses and minimize T cell tolerance.
1.3.4 Myeloid-derived suppressor cells
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature
myeloid cells, including macrophages, dendritic cells, granulocytes and other early stage myeloid
cells. In murine models, MDSCs are characterized as cells that express both the myeloid lineage
differentiation antigen Gr-1 and the integrin CD1 lb (28). While these cells can normally be
found in the spleens and bone marrow of healthy mice, they accumulate in the spleens, lymph
nodes and tumor tissue of many tumor-bearing mice (28, 142-146). In spleens, MDSC numbers
can increase 5- to 20-fold in tumor-bearing animals (147).
MDSCs have been shown to significantly inhibit anti-tumor T cell responses, most
notably inhibiting the effector functions of CD8' T cells (145). Their immunosuppressive
influence can be both antigen-specific and non-specific depending on the local environment in
which they are found. Numerous factors contribute to the suppression mediated by MDSCs,
including reactive oxygen and nitrogen species, arginase and inhibitory surface molecules. In
tumors, MDSC suppression is primarily antigen non-specific, and is mediated by nitric oxide
(NO) production and arginase activity (147). NO production can be induced by interferon (IFN)-
y and tumor necrosis factor (TNF) a within tumors (148), and can block the activation of
signaling molecules, such as JAK3 and STAT5, inhibit MHC II gene expression, and induce
apoptosis (147). Arginase activity is often induced by TGFp and/or IL-10 within tumors (148),
and depletes the local environment of L-arginine. This leads to a block in translation of the CD3
(-chain, and inhibits the ability of T cells to respond to activating stimuli (147). Increased
production of NO and elevated arginase activity also lead to increases in the production of
reactive oxygen species (ROS) by MDSCs. The suppressive influences of ROS are primarily
mediated by peroxynitrite, generated from the reaction of NO and superoxide. Peroxynitrite-
mediated nitrosylation of either TCRs or CD8 likely alters binding of TCR complexes to peptide-
MHC molecules, leading to T cell dysfunction (147). The multiple suppressive mechanisms
used by MDSCs within tumors induce T cell suppression independent of antigen recognition.
The suppressive functions of MDSCs in the peripheral lymphoid tissues can be quite
different from those in tumor tissues. For example, in peripheral lymphoid tissues, MDSCs
produce less NO and have lower arginase activity than in tumor tissues, but in contrast produce
higher levels of ROS (147). As ROS have short half-lives, T cell suppression requires direct
cell-cell contact in this environment. In vivo studies have shown that MDSCs can process
soluble proteins and present the resulting antigenic peptides on their surfaces to induce antigen-
specific T cell tolerance (149). Thus, the mechanisms used by MDSCs to dampen anti-tumor T
cell responses are influenced by the local environment.
In humans, MDSCs are characterized as CD33* cells that do not express either HLA-DR
or markers of mature lymphoid and myeloid cells, and they similarly inhibit CD8* T cell function
(150). They have been found in patients with non-small-cell lung cancer, head and neck cancer
and metastatic adenocarcinomas of the breast, colon and pancreas (150, 151). Peripheral blood
mononuclear cells (PBMCs) from patients with advanced cancers can be made up of a large
number of suppressive granuloctyes, and these cells mediate T cell tolerance through a
mechanism that requires hydrogen peroxide (H20 2) (151). Furthermore, high peroxynitrite
levels have been associated with tumor progression for head and neck cancer, pancreatic cancer,
breast cancer, malignant gliomas, melanoma and mesothelioma (152-156).
Tumor-derived factors can thus promote the generation and accumulation of MDSCs,
which subsequently tolerize tumor-reactive T cells using both antigen-specific and non-specific
mechanisms.
1.3.5 Dendritic cells
The suppressive microenvironment of a tumor can greatly alter the differentiation and
maturation of dendritic cells. The presence of tumor-derived factors can lead to a decreased
number of healthy, competent dendritic cells and an accumulation of both immature and
tolerogenic dendritic cells (28).
Data from both mice and humans suggests that the presence of tumors is correlated with a
decrease in the number of circulating dendritic cells. In tumor-bearing mice, there are decreased
numbers of dendritic cells in the spleen, lymph nodes and skin (157). Similarly, a decrease in
dendritic cell populations has been observed in human patients with head and neck cancer (158,
159). A more recent study in patients with prostate cancer, breast cancer or malignant glioma
demonstrated that these patients have a decrease in healthy, competent dendritic cell populations
and an increase in immature dendritic cell populations. Furthermore, these immature dendritic
cells have a reduced capacity to capture antigens and activate T cells (160). A decreased number
of healthy dendritic cells can make it more challenging to initiate anti-tumor immune responses.
Beyond decreases in dendritic cell numbers, the presence of tumors can significantly
impact dendritic cells maturation and differentiation. Two major dendritic cell subsets have been
identified in humans, myeloid dendritic cells (mDCs) and plasmacytoid dendritic cells (pDCs),
that differ in their hematological ancestry and functional properties (161). Myeloid dendritic
cells are potent antigen-presenting cells that can strongly activate T cells, and are critical to the
initiation and maintenance of adaptive immune responses. Plasmacytoid dendritic cells have less
potential to activate naive T cells, but have a critical role in orchestrating innate immune
responses (161). While functional mature mDCs can initiate robust anti-tumor T cell responses,
mDCs acted on by tumor-derived factors, including VEGF, TGFp, IL-6, prostaglandin E2
(PGE2) and IL-10, are generally suppressive (162-167). Tumor-derived factors block dendritic
cell maturation and differentiation, resulting in the accumulation of immature or partially
differentiated dendritic cells. These cells can induce both T cell anergy and the generation of
regulatory T cells. Thus, suppressive dendritic cells may not be a distinct subset, but rather
tumor-infiltrating dendritic cells can be educated by the tumor environment to take on regulatory
functions (168).
Tumor-derived factors can also modify the composition of dendritic cell subsets, leading
to a decrease in the ratio of mDCs to pDCs (169). In various human tumors, mature mDCs are
lacking (169-172), and pDCs infiltrate and/or persist (169, 173-175). As pDCs can be actively
tolerogenic, they augment the suppressive environment of a tumor (169, 176).
Tolerogenic dendritic cell populations exert diverse mechanisms of tolerance. Immature
dendritic cells induce regulatory T cells through the production of either TGF- (177) or IL-10
(178), while semi-mature dendritic cells induce regulatory T cells through antigen-specific
mechanisms (179). When acted on by tumor-derived factors, dendritic cells exhibit both altered
antigen presentation and an absence of appropriate costimulatory signals, inducing T cell anergy
(180, 181). Furthermore, expression of the immunosuppressive enzyme IDO has been detected
in both human and murine dendritic cell populations (182, 183). IDO is known to catalyze the
oxidative catabolism of the amino acid tryptophan, which is essential for T cell differentiation
and proliferation. As IDO-expressing dendritic cells reduce the availability of tryptophan, they
block T cell progression through the cell cycle and promote T cell apoptosis and anergy (183).
IDO-expressing dendritic cells can be induced by both membrane associated (GITR, CTLA-
4/CD28) and soluble (PGE2, TNFa, interferons, estrogens) factors in a tumor environment (184).
Myeloid and plasmacytoid dendritic cells that produce IDO have been identified in both mice
and humans (28, 183, 185), and pDCs that constitutively express IDO have also been identified
in mice (186). In particular, these cells comprise only 0.5% of cells in tumor-draining lymph
nodes, but they can significantly suppress T cell responses against antigens presented by either
the pDCs themselves or neighboring dendritic cells (186). IDO-expressing dendritic cells have
been found in breast tumors and also in the tumor-draining lymph nodes of patients with breast,
lung, colon and pancreatic cancers, as well as melanoma (183). These IDO-expressing dendritic
cells can be an important factor in dampening anti-tumor T cell responses (183).
Cancer is often associated with both decreases in dendritic cell numbers and
accumulations of immature and tolerogenic dendritic cells, suggesting dendritic cells can
significantly influence the suppressive environment of a tumor.
A major challenge to achieving significant clinical success with cancer immunotherapy
has been the generation of immunological tolerance. Each of the proposed mechanisms of tumor
immune evasion and tumor-induced T cell tolerance described here can significantly minimize
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anti-tumor immune responses in different local environments. Thus, each mechanism must be
analyzed for a particular model system or tumor type to determine which mechanisms are most
influential in that microenvironment. Therapeutic interventions can then be rationally designed
to break tolerance and overcome the immunosuppressive networks characteristic of tumors,
ideally creating more robust anti-tumor immune responses.
1.4 Strategies to Break Tolerance
1.4.1 Complications with systemic strategies
One of the limiting challenges facing systemic approaches to breaking tolerance is
persistent autoimmune complications. For example, extensive autoimmune complications have
resulted from regulatory T cell inactivation in a murine model (187). Many human autoimmune
diseases, including multiple sclerosis, type 1 diabetes and rheumatoid arthritis, are also
characterized by deficiencies in regulatory T cells (188). This suggests autoimmune
complications could arise from general regulatory T cell depletion in humans. Pervasive
autoimmunity has also been observed in both TGF- 1 null mice (189) and mice administered
neutralizing TGF-p antibodies (190). Similarly, systemic activation of CD40 to mature
tolerogenic dendritic cells, using either soluble CD40 ligand (CD40L) or anti-CD40 monoclonal
antibodies, is also likely to induce autoimmunity. Increased CD40 activation has been
implicated in the progression of various diseases, including systemic lupus erythemotosus (191),
rheumatoid arthritis (192), type 1 diabetes (193), neurodegenerative disorders (194, 195) and
allograft rejection (196, 197). Geldart, et al., recently reviewed the potential complications of
systemic CD40 activation (198).
The likelihood of extensive autoimmune complications from systemic treatments argues
strongly for the development of more localized approaches to break tolerance. Therapies
specifically targeting the tumor environment would minimize the risk of pervasive autoimmunity
(199). Current approaches being developed to target therapies to the tumor environment include
the generation of tumor-specific monoclonal antibodies, adoptive transfer of engineered tumor-
reactive T cells and direct intratumoral delivery of therapeutic agents.
1.4.2 Localized strategy 1: Monoclonal antibodies
Targeting monoclonal antibodies (mAbs) to tumors can initiate tumor cell death through
several different mechanisms. Unconjugated antibodies can mediate therapeutic effects through
antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC),
through elimination of surface antigens and through alterations in cell signaling (200). Beyond
direct therapeutic effects, mAbs can also provide a strategy for localization, as tumor-specific
antibodies can target agents directly to the tumor environment. Numerous cytokines, toxins,
cytotoxic drugs and radionuclides have been conjugated to mAbs for this approach (201).
Furthermore, antibody-directed enzyme prodrug therapy (ADEPT) attempts to expand the
antitumor impacts of antibody therapy to cells that do not express the tumor antigen. With
ADEPT, an enzyme used to activate a weakly toxic prodrug is localized to the tumor through
conjugation to a tumor-specific antibody, allowing activation of the drug only in the tumor
environment (202, 203).
Monoclonal antibodies have demonstrated clinical successes in the treatment of disease,
and the FDA has approved six unconjugated mAbs for the treatment of cancer (204). These
mAb therapies include Rituximab, a chimeric mAb which targets CD20 in lymphomas and other
malignancies (205, 206); Trastuzumab, a humanized antibody which targets HER2/neu in
metastatic breast cancer (207-209); Alemtuzumab, a humanized antibody which targets CD52 in
chronic lymphocytic leukemia (210); Bevacizumab, a humanized antibody which targets VEGF
in colorectal, lung, kidney and breast cancers (211-215); Cetuximab, a chimeric antibody which
targets epidermal growth factor receptors (EGFR) in a variety of human tumors (216-218); and
Panitumumab, a fully human antibody which also targets EGFR in colorectal cancer (219). In
addition to the unconjugated mAbs, the FDA has also approved one drug immunoconjugate and
two radioisotope conjugates (204). Gemtuzumab ozogamicin is a drug immunoconjugate
composed of a humanized mAb to CD33 and calicheamicin, a powerful enediyene antibiotic
(220, 221). The mAb to CD33 has been approved for acute myelogenous leukemia (204). The
radioisotope conjugates both target CD20 on lymphoma cells, and include ytrrium-90
ibritumomab tiuxetan and iodine-131 tositumomab (221). These approved mAb treatments are
an exciting step forward in the development and clinical use of targeted cancer therapies, and
suggest antibodies could potentially be used to deliver localized therapies to break tolerance.
1.4.3 Localized strategy 2: Engineered T cells
Since tumor-specific CD8' T cells naturally traffic to and accumulate in tumors, they
may be able to deliver therapeutic agents to the tumor environment as well. Although there are
currently no published reports of CD8* T cells being used to deliver active therapies to break
tolerance, there is significant data demonstrating genetic engineering of T cells to obtain other
augmented or non-natural functions to treat cancer. Genetic modifications have been used to
increase or alter T cell specificity, proliferative capacity, survival, localization and even effector
functions (222).
There are primarily two approaches being explored to reengineer T cells to recognize
tumor-associated or tumor-specific antigens. The first is to isolate TCR a- and P- chains from T
cells that recognize tumor-associated antigens. These defined TCR chains are then used to
transduce other T cell populations to alter their specificity using retroviral or lentiviral vectors
(223). In a mouse model, T cells engineered to recognize the model antigen influenza-virus
nucleoprotein exhibit anti-tumor activity against antigen-positive tumors in vivo (224). Human
T cells engineered with defined TCR chains recognize and react against tumor cells in vitro
(225), and have shown some success in the clinic in the treatment of melanoma patients (226).
The second approach to redirect T cells is to engineer the cells to express chimeric antigen
receptors (CARs) composed of single-chain variable fragments (scFvs) of antibodies recognizing
tumor antigens fused to signaling domains from either the TCR complex or the high-affinity IgE
receptor (227). Using this approach, antigen recognition is non-MHC-restricted. T cells directed
to recognize tumor-associated antigens using CARs lyse tumor cells in vitro (228) and also
induce anti-tumor effects in mouse models in vivo (229-232). Initial clinical trials using CAR-
modified T cells to treat patients with metastatic ovarian cancer, neuroblastoma or relapsed or
refractory B cell lymphoma have experienced challenges with T cell persistence following
transfer, but the results highlight the potential anti-tumor activity of the CAR approach (233-
235).
As tumors are poorly immunogenic, T cells undergo minimal proliferation in response to
tumor antigens, so novel strategies are being explored to engineer T cells for more robust
proliferative responses. One strategy has been to engineer T cells for dual specificity (227).
These T cells are engineered to recognize both a tumor-associated antigen as well as a strong
immunogen, such as alloantigen, influenza virus or Epstein-Barr virus (236-238), so the T cells
will expand following vaccination with the immunogen. In addition to the endogenous TCR, T
cells are programmed to have a second specificity using either defined TCR chains or CARs.
Alloreactive T cells engineered to express a CAR specific for the tumor-associated antigen
folate-binding protein respond to both allogeneic antigen and tumor-antigen expressing cells in
vitro, and expand significantly following administration of allogeneic cells in vivo (238). In
order to increase proliferative potential, T cells have also been engineered to present antigens
themselves, inducing the activation of other T cells. T cells engineered to express the model
viral antigen influenza A MP1 induce the expansion of MP1-specific T cells in vitro and
augment the anti-tumor activity of MPI and CD19 dual-specific T cells in vivo (239). Novel
engineering strategies will continue to be needed to increase T cell proliferative capacity in vivo.
Genetic engineering has also been used to alter the natural lifecycle of tumor-reactive T
cells. One approach that has been successful in vitro has been to engineer tumor-reactive T cells
to produce their own IL-2. Melanoma-specific T cells engineered to secrete IL-2 maintain their
antitumor function and demonstrate increased survival in vitro following cytokine withdrawal
(240), but have not demonstrated increased anti-tumor activity in melanoma patients (241).
Another important factor impacting T cell survival is telomere length, which has recently been
shown to correlate with the in vivo persistence of transferred T cells during adoptive
immunotherapy (242). Engineering human CD8* T cells to express human telomerase reverse
transcriptase increases their survival time in vitro (243). Expression of anti-apoptotic molecules
has also been used to increase T cell survival. Engineering T cells to express either Bcl-2 (244,
245) or Bcl-xL (246) increases survival in vitro, and engineering melanoma-specific T cells to
express Bcl-2 also increases anti-tumor activity in mouse models in vivo (245). T cell survival
has thus been effectively manipulated using genetic engineering strategies.
Initial studies have suggested that T cell localization can be altered to favor the tumor
environment by engineering T cells to express chemokine receptors recognizing chemokines
expressed by tumors. T cells transduced with a retroviral vector encoding CXC-chemokine
receptor 2 (CXCR2) migrate towards its chemokine ligand, CXCL1, in vitro (247). This data
suggests that the migration patterns of T cells could potentially be altered in vivo.
T cell function has similarly been improved using genetic engineering strategies (227).
One approach has been to engineer T cells to express members of the tumor necrosis factor
(TNF) superfamily, thereby allowing the cells to deliver apoptotic signals to tumor cells
expressing the appropriate death receptors. TILs transduced to express TNF or TNF-related
apoptosis-inducing ligand (TRAIL) show increased cytotoxicity against tumor cells in vitro (248,
249). Another approach has been to use T cells to deliver retroviruses encoding a suicide gene,
thereby increasing their cytotoxic potential. T cells specific for carcinoembryonic antigen (CEA)
have been engineered, using an inducible system, to generate and release retroviruses encoding
herpes simplex virus thymidine kinase (HSVtk). Mice with metastatic tumors show a significant
increase in survival following administration of retrovirus-producing T cells (250). The function
of T cells whose specificity has been redirected using CARs has been improved by coupling
antigen recognition to additional activation or costimulatory domains. T cells engineered with
CARs containing signaling domains from both CD3( and CD28 produce higher amounts of
cytokines than those with CARs containing either domain alone (251-254), and they also
maintain increased antitumor functions in mice (232, 253). Inclusion of domains from other
costimulatory molecules into CARs, including domains from CD137 (4-1BB), ICOS and CD134
(OX40), also increases T cell function in vitro and in vivo (255-258). Engineering T cell
function could thus augment the therapeutic impact of T cells in tumor environments.
Tumor-specific CD8* T cells provide an important strategy to localize therapies to
tumors, as they naturally traffic to and accumulate in tumor environments. Successful genetic
modification of T cells to enhance specificity, proliferative capacity, survival, localization and
effector functions, suggest it may be possible to engineer T cells to deliver active therapies to
break tumor-induced tolerance as well.
1.4.4 Localized strategy 3: Intratumoral delivery
Direct intratumoral administration of therapeutic agents is another attractive route of
delivery, because it targets the tumor-specific immune response directly to the tumor and could
potentially make use of undefined or unknown tumor antigens (261). Furthermore, antigen-
directed therapies often result in accumulation of antigen-specific cells at the site of vaccination
(261-264), emphasizing the potential importance of intratumoral delivery (261, 265, 266).
In order to mount an effective anti-tumor immune response in a tumor environment,
several critical components are required. These include the need for local provision of antigen, a
population of dendritic cells to present antigen, appropriate dendritic cell maturation signals, and
ultimately, infiltration of primed anti-tumor effector T cells. Thus, intratumoral delivery to date
has largely focused on augmenting these individual components (261).
One approach to ensure that both antigen and dendritic cells are present in tumors is
through intratumoral dendritic cell administration. Intratumoral delivery of either antigen-loaded
or unloaded dendritic cells has led to the generation of anti-tumor immunity in mouse and rat
models. In a transplanted colorectal tumor model, injection of dendritic cells into established
tumors increases immunity to tumor rechallenge following removal of the primary tumor (267).
Similarly, intratumoral administration of dendritic cells into transplanted gliomas increases CD4'
and CD8* T cell infiltration, increases immunity to tumor rechallenge and prolongs survival
(268). Furthermore, intratumoral dendritic cell therapy can promote antitumor immunity when
coupled with therapeutic approaches that promote tumor cell death, and thus provide dendritic
cells with additional sources of tumor antigens. Combination therapies have included such
approaches as chemotherapy, radiotherapy and/or localized tumor hyperthermia (269-271). In
order to further increase their therapeutic impact, dendritic cells have also been engineered to
express proinflammatory cytokines (272-276), pro-survival molecules (277), and TNF-related
ligands (278) prior to transfer. The potential of intratumoral dendritic cell delivery has been
demonstrated in human patients as well (279-284). An early study with metastatic dermal or
subcutaneous melanoma and breast cancer patients showed that intratumoral administration of
dendritic cells induces tumor regression and lymphocyte infiltration in the setting of injected
tumors (279). Thus, both animal and human studies have clearly highlighted the potential of
intratumoral dendritic cell delivery.
An alternative to directly injecting dendritic cells into tumors is to make use of the
natural homing properties of endogenous dendritic cells to increase their numbers in tumors
(261). Data on chemokine receptor expression has highlighted chemokines that would likely
attract immature dendritic cells to tumor tissues, including the inflammatory signals chemokine
(C-C motif) ligand 3 (CCL3), CCL5 and CCL20 (261). In four different tumor models,
intratumoral injection of an adenovirus encoding CCL20 decreases tumor cell growth (285).
Dendritic cell infiltration has been evaluated in one of those tumor models, B 16 melanoma, and
is significantly increased (285). Similarly, expression of either CCL3 or CCL20 in colorectal
tumor cells promotes increased dendritic cell infiltration and decreased tumor cell growth (286).
Intratumoral administration of recombinant CCL21 into lung tumors generates increased T cell
and dendritic cell infiltration and results in T cell dependent tumor eradication (287).
Intratumoral delivery of chemokines may therefore be a strategy to increase the presence of
endogenous dendritic cells in tumors.
The maturation status of either injected or infiltrating dendritic cells is critical in
determining their therapeutic potential, so strategies are also being explored to mature dendritic
cells in situ. Injecting or attracting dendritic cells into tumor environments pretreated with
agents to induce in situ dendritic cell maturation could further improve the outcome of
intratumoral delivery (261). For example, immature dendritic cells injected into adjuvant
(Imiquimod) pretreated sites are better able to generate anti-tumor immunity than mature
dendritic cells in mice (288). Imiquimod has been used as an immunomodulatory agent in the
treatment of melanoma and basal cell carcinoma in human patients as well (289, 290).
Effector T cells often do not traffic efficiently into tumors, due to a lack of inflammatory
signals and an abundance of immunosuppressive factors, including IL-10 and TGF-p (261).
Thus, intratumoral expression of chemokines or cytokines with the potential to specifically
attract effector T cells is another approach to augment T cell responses in tumors (261).
Intratumoral expression of either chemokine (C-X-C motif) ligand 10 (CXCL10) (291),
lymphoactin 1 (Lptn)/XCL1 (292) or CCL3 (293) enhances infiltration of activated T cells into
tumors and increases tumor rejection when coupled with adoptive cell transfer in murine models.
These results suggest that intratumoral expression of factors that attract activated T cells could
further augment immunotherapeutic responses.
Direct intratumoral administration is a promising strategy to localize activating and
inflammatory signals. The major limitation of this approach is the need for a tumor to be
accessible, so it may not be feasible for all tumors. Significant research has already been done to
use intratumoral administration and/or expression to localize antigen sources, dendritic cells and
effector T cells to tumor environments, and future research will likely uncover additional novel
strategies to use intratumoral delivery to interrupt immunosuppressive networks.
Targeting immunotherapies directly to tumor environments minimizes the risk of
autoimmune complications associated with systemic treatments. The successes already achieved
with such targeted approaches as monoclonal antibodies, adoptive transfer of engineered T cells
and intratumoral delivery of therapeutic agents provide both proof-of-principle and motivation
for the development of localized approaches to overcome tolerance.
1.5 Overall Thesis Objectives
In order to better understand the factors necessary to harness a productive CTL response
for cancer immunotherapy, the goal of this research has been to explore the interactions between
CD8' T cells and the immunosuppressive networks within tumors, using prostate cancer as a
model system. In particular, our objectives have been to demonstrate that tumor-specific CD8' T
cells are tolerized in the tumor environment of a spontaneous prostate cancer model, the
TRansgenic Adenocarcinoma of the Mouse Prostate (TRAMP) model, to elucidate potential
mechanisms of tolerance, and then to design novel mechanism-based immunotherapeutic
approaches to break tolerance locally within the tumor.
1.6 Our Experimental System
1.6.1 Prostate cancer as an immunotherapy target
Prostate cancer is currently the most common malignancy in American men.
Approximately I in 6 men will be diagnosed with the disease during their lifetime, and in 2009
alone, it is estimated that over 190,000 new cases of prostate cancer will be diagnosed in the
United States. Ultimately, 1 in 35 men will die of prostate cancer, comprising more than 10% of
cancer-associated deaths in American men (294).
Prostate cancer is a heterogeneous progressive disease characterized by an initial
prostatic intraepithelial neoplasia, followed by development of locally invasive disease, and
eventually by the emergence of hormone-refractory metastatic cancer (295). Androgens have a
critical influence in the pathogenesis of this disease. Most prostate tumors initially regress
following androgen removal, but begin to progress again due to the proliferation of androgen-
independent prostate tumor cells (296).
When prostate cancer is confined to the prostate tissue, radiotherapy and radical
prostatectomy are often effective treatments (295). However, if local control of prostate cancer
is unsuccessful, androgen ablation is considered the standard therapy. While most prostate
cancers respond to this treatment initially, disease recurs in the majority of patients (297, 298).
The invasive and often debilitating nature of current treatments, coupled with the lack of
effective treatments for late stage disease, emphasizes the critical need for new strategies to treat
prostate cancer (297).
Prostate cancer is considered an ideal candidate for immunotherapy for several reasons.
First, since the prostate is a nonessential organ, proteins expressed by either normal or neoplastic
cells could serve as T cell targets for immunotherapy. Second, there are already several known
proteins exhibiting specific or preferential expression in the human prostate, including prostate
specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phophatase
(PAP), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP), prostate
stem cell antigen (PSCA), kallikrein 4, prostein and trpp8 (298, 299). Third, immune responses
to these prostate-associated antigens can be considered tumor-specific in patients showing
disease recurrence or metastases following radical prostatectomy (298).
Immunotherapies to treat prostate cancer have been under investigation for more than 25
years. Strategies in development include the use of immunmodulatory cytokines and effectors,
peptide and tumor cell vaccines, viral vaccines, dendritic cell therapies and antibody therapies
(300). Recent strategies to use immunomodulatory effectors to augment antitumor immunity
have included the use of such agents as granulocyte macrophage colony-stimulating factor (GM-
CSF), FMS-like tyrosine kinase 3 (Flt3) ligand and IL-2. Peptide, tumor cell and viral vaccines
have largely focused on prostate or tumor-specific antigens to generate a specific response.
These antigens have included PSA, PAP, PSMA and PSCA. Dendritic cell therapies, most
notably Sipuleucel-T (APC8015; Provenge; Dendreon, Seattle, WA), have also recently achieved
success in the treatment of prostate cancer. With Sipuleucel-T, autologous dendritic cells are
harvested by luekapheresis, loaded ex vivo with a recombinant fusion protein comprised of PAP
and GM-CSF and reinjected back into patients. Antibody based therapies for prostate cancer
have relied on inducing cellular cytotoxicity (HER2/neu), delivering radioactive agents to induce
cell death (PSMA), and enhancing anti-tumor immune responses by blocking negative signaling
mechanisms (CTLA-4). The development of immunotherapies to treat prostate cancer continues
to be an exciting area of research. (300)
1.6.2 The TRAMP and TRP-SIY models
In order to evaluate cellular interactions that lead to CD8' T cell tolerance in tumors, and
to subsequently develop immunotherapeutic approaches to break tolerance, we have used
prostate cancer as a model system. TRAMP mice spontaneously develop prostate cancer
following the start of puberty (296). Cancer occurs in these mice due to expression of the
oncoprotein SV40 T antigen (TAg), which is under the control of a prostate-specific rat probasin
promoter (301). SV40 TAg can induce malignant transformation in vivo through interactions
with the tumor suppressors p53 and retinonblastoma (Rb). As loss of wild type p53 and Rb have
been associated with prostate cancer development and progression, this is a very relevant model
(301). Here, TAg expression is driven by androgens, and is thus developmentally regulated.
Tumors regress transiently following androgen ablation, but recur in the majority of mice.
Furthermore, disease progression in TRAMP mice is consistent with disease progression in
humans, which is characterized by an early intraepithelial hyperplasia, followed by progression
from a well differentiated to a poorly differentiated adenocarcinoma, and ultimately by the
development of fatal hormone-refractory prostate cancer (296).
In the Chen laboratory, we have also developed a transgenic mouse model, termed PB-
SlY, which expresses an artificial antigen in the prostate tissue that can be recognized by CD8' T
cells with a 2C TCR (302). The transgene encodes the octomer peptide SIYRYYGL (SlY) fused
to p-galactosidase, and is also under the control of a prostate-specific rat probasin promoter, as
above. We have crossed PB-SIY mice with TRAMP mice to generate double-transgenic TRP-
SlY mice, which spontaneously develop SLY-expressing prostate cancer (302). SLY-expression
in the tumor provides a convenient model tumor antigen to target for both characterizing the
CD8' T cell response and developing therapeutic interventions. The TRAMP and TRP-SIY
mice used for this research were generally 3.5 to 4.5 month old heterozygous males, which had
not yet formed palpable solid tumors.
1.6.3 The 2C TCR system
In order to evaluate the immune response to prostate cancer, we have coupled the
TRAMP and TRP-SIY mice with the 2C TCR system. The 2C TCR expressed on CD8' T cells
can specifically recognize SlY peptide in the context of Kb, consistent with antigen presentation
in the TRP-SIY model.
The 2C TCR system is based on a CTL clone isolated from a BALB.B (H-2b) mouse
injected with H-2d cells (303-305). A monoclonal antibody, 1B2, has also been generated that
specifically recognizes the 2C TCR (305), and the epitope recognized by this antibody has been
shown to map to all six of the TCR's complementarity determining regions (306). The 2C
transgenic mice have been crossed with recombinase activating gene-i (RAG1) knockout mice
on a C57BL/6 background, establishing the 2C/RAG mouse model. All CD8* T cells in this
model express the 2C TCR (307, 308).
The 2C TCR is known to react with L in the context of the overlapping peptides
QLSPFPFDL (QL9) and p2Ca from a-ketoglutarate dehydrogenase (303, 309, 310). It is also
alloreactive to Kbm3 in the context of the dEV8 peptide from NADH-ubiquinone oxoreductase
(311, 312). Furthermore, 2C T cells are known to be positively selected on Kb (313, 314). Kb
binds weakly to both p2Ca and dEV8, which are thus weak agonists (315). Using combinatorial
libraries, several strong agonists have also been identified that bind to K and activate 2C T cells
(316, 317). SIY peptide is one of the most well characterized of these (317).
We can thus transfer 2C T cells into TRAMP and TRP-SIY mice to evaluate the immune
response to SLY-expressing or non-expressing prostate cancers.
1.6.3 The WSN-SIY vaccination
In order to productively activate naive 2C T cells in vivo, the Chen laboratory, in
collaboration with Dr. Astrid Flandorfer (Mount Sinai School of Medicine), has developed an
influenza virus-based vaccine. The parental influenza strain, WSN, has been engineered to
express a SIY-neuraminidase fusion protein on its surface by using plasmid-based reverse
genetics (318) to insert SIY into the stem of neuraminidase. The resulting recombinant virus is
referred to as WSN-SIY.
TRAMP and TRP-SIY mice are intranasally infected with WSN-SIY at the time naYve 2C
cells are adoptively transferred. The virus infects the lung epithelilal cells, creating a significant
inflammatory environment in the lungs. Dendritic cells matured under these inflammatory
conditions then present SIY peptide to naive 2C cells in the lung draining lymph nodes, the
mediastenial lymph nodes (MLN). This provides a strong activating signal to 2C cells, which
proliferate extensively in the MLN. The activated 2C cells then exit into the peripheral tissues,
including the prostate tumor environment, where their function can be evaluated. (302)
The TRAMP and TRP-SIY mice, the 2C TCR system and the WSN-SIY influenza
vaccination comprise the experimental system we have used to both explore tumor-induced T
cell tolerance and to design, develop and evaluate novel immunotherapuetic approaches to break
tolerance locally.
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Chapter 2
Rapid Tolerization of Virus-Activated Tumor-Specific CD8* T cells
in Prostate Tumors of TRAMP Mice'
2.1 Abstract
In order to evaluate T cell responses to tumors in a spontaneous model, we expressed a
nominal CD8* T cell epitope, SIYRYYGL (SLY), in the prostate tissue of Transgenic
Adenocarcinoma of the Mouse Prostate (TRAMP) mice. These double transgenic mice
spontaneously develop prostate adenocarcinomas that express SIY, and are referred to as TRP-
SLY mice. Following adoptive transfer into TRP-SIY mice, naYve SIY-specific CD8* T cells
were rapidly tolerized in the prostate draining lymph nodes (PDLN). Intranasal vaccination with
a recombinant influenza virus expressing SLY, led to the activation of SIY-specific T cells in the
lung draining lymph nodes. Activated T cells expressed such effector cytokines as IFN-y and
TNFa, destroyed SIY-loaded targeted cells in vivo, and infiltrated extensively into prostate
tumors, where they rapidly lost their effector functions. A population of tolerized T cells
persisted long term in the prostate tissue, but not in lymphoid tissues, and could reacquire
effector functions following ex vivo cytokine treatment. These results suggest that antigen-
specific T cells can be activated or tolerized simultaneously in different microenvironments of
the same host, and that effector T cells can be rapidly tolerized in tumors. Our TRP-SIY model
provides a new system to study critical T cell-tumor interactions and to evaluate the efficacy of
cancer immunotherapies.
Contributions:
Dr. Ailin Bai engineered the novel PB-SIY and TRP-SIY models. We both then contributed to
characterizing the 2C T cell response to cross-presented SLY antigen from the prostate. Fig. 2.3
B, C and D, Fig. 2.5 D and Fig. 2.7 are data I generated. The remaining data was generated by
Dr. Ailin Bai. We jointly contributed to the intellectual direction and writing of the original
manuscript. Sections of the manuscript I did not write, I have rewritten here for the purposes of
this thesis.
'Significant sections of this chapter have been previously published in:
Bai, A., E. Higham, H. N. Eisen, K. D. Wittrup, and J. Chen. 2008. Rapid tolerization of virus-
activated tumor-specific CD8+ T cells in prostate tumors of TRAMP mice. Proc. Nati. Acad Sci.
U. S. A. 105: 13003-13008.
2.2 Introduction
CD8* cytotoxic T lymphocytes (CTLs) are the primary immune cells responsible for
killing antigen-displaying target cells. Directing CTL activity towards cancer cells to achieve
tumor eradication is thus an important objective of cancer immunotherapy (1, 2). Antigens
recognized by CTLs are peptide-MHC complexes, which are short peptides bound to class I
major histocompatibility (MHC) proteins. Tumor cells often display peptide-MHC complexes
that are either unique or tissue-restricted (3, 4), so CTL activity can be directed against them to
yield therapeutic benefits without significant damage to surrounding normal tissues.
Tumor-specific T cells have been found in cancer patients (5), but tumor regression or
rejection as a result of endogenous anti-tumor T cell responses is rare. The lack of responses is
most often due to either T cells not recognizing or encountering tumor-specific antigens
(ignorance) or not fully responding to them (tolerance) (6, 7). Like other tissue peptide-MHC
antigen complexes, tumor antigens can be cross-presented by specialized antigen-presenting
cells, including dendritic cells. However, presentation of tumor antigens does not generally
induce productive activation of naYve T cells, due to suboptimal costimulatory signals (8-10).
Current immunotherapeutic approaches are focused primarily on enhancing in vivo T cell
priming through vaccination strategies or adoptively transferring ex vivo activated T cells.
While promising results have been achieved in various animal models using such approaches,
objective and durable anti-tumor responses have rarely been achieved in cancer patients (11-14).
Most animal studies have used transplanted tumors, which differ in important ways from
spontaneously developed (autochthonous) tumors in cancer patients (13-15). Recently, though,
an increasing number of spontaneous tumor models have been engineered through direct genetic
modifications of the mouse germline (16-18). In contrast to transplanted tumors, spontaneous
tumors are generally refractory to immune-mediated rejection using current immunotherapeutic
strategies (19), as is true for tumors in human patients. This lack of response is generally a
product of T cell tolerance resulting from the interactions between antigen-specific T cells and
tumor cells.
In order to better understand T cell-tumor cell interactions, and thus identify potential
intervention points to augment CTL-mediated immunotherapies, we developed a model for CTL
recognition of prostate cancer in spontaneous tumors. Prostate cancer is an ideal target for
immunotherapy, because of the expression of known tissue-restricted antigens and the
nonessential nature of normal tissue that shares antigen expression (20). We have engineered a
nominal CD8* T cell epitope into a murine spontaneous prostate cancer model, and have
evaluated CTL responses to this defined tumor antigen at different stages of T cell function. Our
results demonstrate that naive antigen-specific T cells can be either activated or tolerized
simultaneously in the same host, depending on the microenvironment in which the epitope is
presented. Activated T cells generated in lymph nodes are rapidly tolerized when they infiltrate
tumors expressing antigen. Interestingly, these tolerized T cells only persist in tumors, and are
comparable to tumor-infiltrating lymphocytes (TILs) identified in human cancer patients (21).
2.3 Materials and Methods
2.3.1 Mice and virus
The transgenic construct was assembled by ligating a composite rat probasin promoter
fragment ARR 2PB (a gift from Dr. R. J. Matusik of Vanderbilt University) (22), a p-
galactosidase-SIY fusion gene, and the bovine growth hormone poly-adenylation sequence. The
founder mice were generated on a C57BL/6 background in the Rippel Transgenic Facility at the
Massachusetts Institute of Technology. TRAMP mice were purchased from the Jackson
Laboratory (Bar Harbor, ME) and bred to homozygosity. Littermates from the cross of
heterozygous PB-SIY and homozygous TRAMP mice were used for all experiments. The
RAG 1- 2C TCR transgenic mice (2C/RAG) were maintained on C57BL/6, C57BL/6 Thy 1.1, or
C57BL/6 GFP* backgrounds. All mice were housed in a specific pathogen free facility, and
studies were carried out in accordance with the institutional guidelines on animal care.
Recombinant influenza A/WSN-SIY virus was constructed by inserting the SIY epitope
into the stem of neuraminidase using plasmid-based reverse genetics (23). 100 pfu and 1x10 5 pfu
were used for intranasal and intraperitoneal infections, respectively.
2.3.2 Adoptive transfer and influenza infection
NaYve 2C cells were isolated from the lymph nodes and spleens of 2C/RAG mice. Red
blood cells (RBC) were lysed from the splenocytes. Lymph node and spleen cells were pooled,
and 1-1.5x10 6 cells in 100pL PBS or HBSS were injected retroorbitally into C57BL/6, PB-SIY,
TRAMP or TRP-SIY mice. Where indicated, mice were also intranasally infected with 100 pfu
WSN-SIY in 50pL PBS immediately following adoptive transfer. For adoptive transfer of
effector T cells, naYve 2C GFP cells were transferred into C57BL/6 recipients, which were
infected with WSN-SIY, as above. Five days post infection, mediastenial lymph nodes (MLN)
were harvested and 20x106 cells in 100pL PBS (containing ~1x10 6 2C cells) were injected
retroorbitally into TRP-SIY mice, which had been infected intranasally with 100 pfu WSN-SIY 5
days earlier. Five days after effector cell transfer, lymphoid and non-lymphoid tissues were
harvested for analysis.
2.3.3 Cells, antibodies and flow cytometry
Lymphoid tissues were minced between frosted glass slides to prepare single cell
suspensions. Prostate tissues were microdissected and digested with 2pig/mL collagenase A
(Roche) in RPMI 1640 plus 10% FCS for lhr at 370C. Samples were then minced between
frosted glass slides and filtered through a 70im nylon mesh. For the lungs and liver, perfusion
was performed with cold PBS. Lung samples were ground through a metal cell strainer, RBCs
were lysed, and cells were filtered through a nylon mesh. Ground liver samples were digested
with collagenase A and DNase I (0.2mg/mL, Sigma), and separated on 35% and 65%
discontinuous percoll gradients before RBC lysis and filtration through a nylon mesh.
Antibodies to CD8 (BD Bioscences), Thy 1.1 (BD Biosciences), CD25 (BD Biosciences),
CD62L (BD Biosciences), IFN-y (XMGl.2, BD Biosciences), TNFa (MP6-XT22, BD
Bioscences), Foxp3 (FJK-16a, eBioscience), perforin (eBioOMAK-D, eBioscience) and
granzyme B (16G6, eBioscience) were conjugated to FITC, PE, APC or PerCP-Cy5.5. 2C TCR
was detected using clonotypic antibody 1B2 conjugated to biotin. 2C cells were identified with
an anti-CD8 antibody plus 1 B2, anti-Thy 1.1 or GFP. Stained cell samples were evaluated using
a FACSCaliburTM (BD Biosciences) and data were analyzed using FlowJoTM software (Tree
Star).
For intracellular IFN-y and TNFa cytokine staining, cells were restimulated with IpM
SlY peptide for 4hr in the presence of 10tg/mL brefeldin A (Sigma). Surface staining was
followed by cell fixation with Cytofix/Cytoperm buffer (BD Biosciences), and staining with
antibodies specific for IFN-y and TNFa. IFN-y recapture assay was carried out using the mouse
IFN-y Secretion Assay Detection Kit (Miltenyi Biotech). Cells from lymphoid organs were
stimulated directly with lpg/mL SlY peptide for 3hrs at 37*C in RPMI 1640 plus 10% FCS.
Cells from non-lymphoid tissues were mixed at a 1:1 ratio with syngeneic splenocytes and were
then restimulated. Following restimulation, cells were incubated with the IFN-y "catch" reagent
for 45min at 370C. Cells were then stained and analyzed by flow cytometry.
Intracellular Foxp3, perforin or granzyme B staining was performed using a BD
Cytofix/Cytoperm Kit (BD Biosciences). Briefly, cells were stained for 2C TCR and CD8, and
dead cells were or were not marked using a LIVE/DEAD@ Fixable Red Dead Cell Stain Kit
(Invitrogen). Following fixation and permeabilization, cells were stained intracellularly with a
PE-conjugated Foxp3, perforin or granzyme B antibody. For Foxp3 staining, a 1:50 dilution of
rat serum (BD Pharmingen) was added during the intracellular staining step.
2.3.4 In vivo cytotoxicity assay
Syngeneic C57BL/6 splenocytes were labeled for 10min at room temperature with either 5pLM
CFSE (CFSEHi) or 0.5ptM CFSE (CFSELO) in PBS with 0.1% BSA. After washing, CFSEHi cells
were pulsed with 1ptg/mL SlY peptide for lhr at 37*C, while the CFSELO cells were left
unpulsed. CFSE i and CFSELO cells were mixed at a 1:1 ratio and injected retroorbitally into
mice (5x10 6 cells/mouse). Twelve hrs later, the ratio of CFSEHi to CFSELo cells in lymphoid
organs was evaluated by flow cytometry.
2.4 Results
2.4.1 Naive CD8* T cells are tolerized by cross-presented antigen from the prostate
In order to evaluate CD8* T cell responses to prostate cancer, we engineered transgenic
mice that express a nominal antigen in the prostate tissue which can be recognized by CD8* T
cells with a 2C T cell receptor (TCR) (24). The transgene encodes SIYRYYGL (SIY) peptide
fused to p-galactosidase, and is under the control of a composite minimum probasin (PB)
promoter, which drives prostate-specific expression of the transgene (Fig. 2.1 A) (22). In the
transgenic line, termed PB-SIY, transgene expression could be detected at the transcript level in
the prostate lobes, testis and seminal vesicles using RT-PCR (Fig. 2.1 B), and at the protein level
in the prostate lobes using X-gal staining (Fig. 2.1 C, D). Although transcript was abundantly
detected in the testis, the protein product could not be detected.
PB-SIY mice were also crossed with TRAMP mice (17) to engineer double transgenic
TRP-SIY mice. The CD8' T cell response to SLY-expressing cells in the prostate was evaluated
by adoptively transferring CFSE-labeled naYve 2C cells into both PB-SIY and TRP-SIY mice.
2C cells proliferated in the prostate draining lymph nodes (PDLN) of both groups of mice, but
did not proliferate in the non-draining lymph nodes (Fig. 2.2 A), supporting that SLY-expression
is restricted to the prostate tissue. 2C cells proliferated more extensively and rapidly in the
PDLN of TRP-SIY mice than PB-SIY mice, most likely a result of more abundant SIY epitope
in the prostate tissue of the former due to neoplasia. Despite a strong proliferative response, the
majority of proliferating 2C cells did not acquire the ability to produce IFN-y (Fig. 2.2 B). Four
weeks after adoptive transfer, 2C cells could be detected in the PDLN, but not in other peripheral
lymph nodes (data not shown). These results suggest that when naYve 2C cells encounter cross-
presented SLY in the PDLN, they become partially activated, but are rapidly tolerized.
2.4.2 Virus infection activates naive CD8' T cells in TRP-SIY mice
As CD8* T cells are strongly activated by virus infection, we challenged TRP-SIY mice
with an influenza virus engineered to express SLY (WSN-SIY) (23) at the time of 2C cell
adoptive transfer. In the mediastenial lymph nodes (MLN) that drain the lung, 2C cells
upregulated CD25 and downregulated CD62L (Fig. 2.3 A). These cells also proliferated
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Figure 2.1 Engineering of PB-SIY transgenic mice. A, Transgene construct. The SIY
epitope (underlined) fusion sequence and flanking residues are shown in single-letter amino acid
code. ARR2PB, a composite rat probasin promoter; BGHpA, bovine growth hormone poly(A)
signal. B, RT-PCR analysis of fkgal-SIY transcript levels from total RNA isolated from
different tissues of a PB-SIY mouse. RNA was extracted from tissues using TRIZOL Reagent.
cDNA was synthesized using an Omniscript RT kit, following the manufacturer's instructions.
PCR amplification was performed using the primers 5'-TAC CGT TGA TGT TGA AGT GGC
GAG-3' and 5'-AAC AGA TGG CTG GCA ACT AGA AGG-3'. HPRT was used as control.
LP, DP, VP and AP are lateral, dorsal, ventral and anterior lobes of prostate, respectively. SV,
seminal vesicle. C, X-gal staining of prostate and testis. Prostate tissue and testis from both
C57BL/6 and PB-SIY mice were fixed and then subjected to whole mount X-gal staining. D,
Prostate lobe cryosections from age-matched 6 month old TRAMP and TRP-SIY mice following
X-gal staining. Experiments performed by Ailin Bai.
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Figure 2.2 Naive CD8* T cell response to cross-presented SIY antigen from the prostate.
Naive CFSE-labeled 2C cells were adoptively transferred into PB-SIY and TRP-SIY mice
(3x106 cells/mouse). A, Cells were harvested at the indicated days post transfer and were
evaluated for 2C TCR, CD8 and CFSE. CFSE content of 2C TCR*CD8* cells is shown. B,
Cells harvested from the lymph nodes at 5 dpi were stimulated with SIY peptide for 4 hrs and
were analyzed for 2C TCR, CD8 and intracellular IFN-y expression. CFSE versus IFN-y profiles
are shown for 2C TCR*CD8* cells. Non-PDLN cells contain pooled samples from inguinal,
cervical, maxillary and mesenteric lymph nodes. Numbers indicate percentage cells in gated
region. Representative data from one of at least three similar experiments are shown.
Experiments performed by Ailin Bai.
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Figure 2.3 Activation of 2C T cells in TRP-SIY mice by WSN-SIY vaccination. TRAMP
and TRP-SIY mice received adoptive transfer of naive or CFSErlabeled naYve 2C cells (1-
1.5x10 6 cells/mouse) and intranasal infection with WSN-SIY. A, On the indicated dpi, harvested
cells from MLN and PDLN were evaluated for 2C TCR, CD8 and CD25 or CD62L expression.
CFSE versus CD25 or CD62L profiles are shown for 2C TCR*CD8* cells. B, Cells harvested
from MLN and PDLN at 5 dpi were stimulated with SIY peptide for 4hrs and were analyzed for
2C TCR, CD8 and IFN-y expression. Histograms show IFN-y expression by 2C TCR*CD8*
cells. C, 4.5 days after 2C cell transfer and WSN-SIY infection, mice were injected with target
cells (a mixture of SIY peptide-pulsed CFSEm and unpulsed CFSE"" C57BL/6 splenocytes,
5x10 6 cells/mouse). Twelve hrs later, the frequency of 2C cells, CFSEm and CFSE"' cells were
measured in MLN and PDLN by flow cytometery. Dot plots show 2C TCR versus CD8 staining
profiles and histograms show CFSE intensities of transferred target cells. D, Cells harvested
from MLN and PDLN at 7 dpi were analyzed for 2C TCR, CD8 and intracellular granzyme B or
perforin expression. Histograms show granzyme B or perforin expression by 2C TCR*CD8*
cells. E-G, Prostate lobes were harvested at 1Odpi. E, Hematoxylin and eosin staining of
prostate tissue sections. F, 2C TCR versus CD8 staining profiles of live cells in prostates. G,
Cells were stimulated with or without SIY peptide for 4hrs and were analyzed for Thy 1.1, CD8
and intracellular IFN-y expression. Histograms show IFN-y expression by Thyl.1*CD8* cells.
Numbers indicate percentage cells in gated region. Representative data from one of two to five
independent experiments are shown. Experiments in panels A, E, F and G performed by Ailin
Bai.
extensively. By 6 days post infection (dpi), the 2C cells had proliferated so vigorously that they
almost completely diluted out their CFSE stain. In contrast, 2C cells in the PDLN of the same
mice showed only limited proliferation. Although they had proliferated by 3 dpi, they did not
upregulate CD25 or downregulate CD62L. There were also dramatic differences in the IFN-y
response. While all 2C cells from the MLN of virus infected TRAMP and TRP-SIY mice could
produce high levels of IFN-y, only ~-20% of 2C cells from the PDLN of TRP-SIY mice could
produce IFN-y, and at much lower levels (Fig. 2.3 B). Consistently, 2C cells lysed SIY-pulsed
CFSE target cells in the MLN of both TRAMP and TRP-SIY mice, but not in the PDLN of
TRP-SIY mice (Fig. 2.3 C). There were no significant differences in intracellular granzyme B
expression between 2C cells from the PDLN or MLN of TRAMP or TRP-SIY mice, but 2C cells
from the PDLN of TRP-SIY mice did express lower levels of intracellular perforin (Fig 2.3 D).
This data suggests that in the same mice, 2C cells become strongly activated in the MLN by
influenza infection, but tolerized in the PDLN by prostate antigen.
2.4.3 Virus-activated CD8' T cells infiltrate prostates
In the absence of influenza challenge, 2C cells could not be detected by flow cytometry
in the prostate tissue of either TRAMP or TRP-SIY mice, but with influenza infection, these
cells could be detected by 7dpi (data not shown). By 1Odpi, large numbers of lymphocytes
infiltrated the prostate tissue (Fig. 2.3 E), and the majority of these cells were 2C cells (Fig. 2.3
F). There were ~80x more 2C cells present in the prostate tissue of TRP-SIY mice (4.3x10 5
2.6x10 5/prostate) relative to TRAMP mice (5.3x10 3 ± 4.2x103/prostate), although the TRAMP
prostate tissue was comparably neoplastic. Effector 2C cells activated in the MLN through
intranasal influenza infection could maintain their effector functions for at least 2-3 days
following infiltration into SlY-expressing prostate tumors. Thus, following a short SlY
encounter, ~70% of 2C cells from the prostates of either TRAMP or TRP-SIY mice could
produce IFN-y (Fig. 2.3 G). Interestingly, ~40% of 2C cells from the prostates of TRP-SIY mice
could produce IFN-y ex vivo, even in the absence of exogenous SIY peptide. This was likely a
result of recent exposure to SlY epitope in TRP-SIY prostates.
2.4.4 Virus-activated CD8' T cells are tolerized in TRP-SIY mice
Although effector 2C cells infiltrate the prostate tissue, vaccinated TRP-SIY mice exhibit
no difference in survival relative to non-vaccinated TRAMP or TRP-SIY mice (data not shown).
As p-gal expression could be detected in TRP-SIY prostates, and 2C cell infiltration was
significantly increased, it is unlikely that antigen loss could account for the lack of significant
long-term anti-tumor effects. Rather, effector 2C cells were likely rendered tolerant by either
immunosuppressive mechanisms or persistent SlY expression in tumors. Consistently, distinct
populations of memory 2C cells could be detected in the spleens and lymph nodes of TRAMP
mice by 4 months post infection, but virtually no 2C cells could be detected in the same tissues
of TRP-SIY mice at this timepoint (Fig. 2.4 A). In order to demonstrate that memory T cell
populations in TRP-SIY mice were not simply quantitatively smaller but functionally equivalent,
we rechallenged vaccinated TRAMP and TRP-SIY mice with SlY peptide in complete Freund's
adjuvant (CFA). By 5 days post challenge, 2C cells had expanded significantly in TRAMP mice,
with the most extensive expansion (~30 fold) in the inguinal lymph nodes (ILN), which drain the
challenge site (Fig. 2.4 B). In contrast, 2C cells in rechallenged TRP-SIY mice were barely
detectable in most lymphoid organs. Small numbers of 2C cells could be detected in the PDLN
of some mice (Fig. 2.4 B).
Interestingly, despite their absence from lymphoid organs, significant 2C cell populations
could be detected in the prostate tissue of vaccinated TRP-SIY mice for the remainder of their
lives (Fig. 2.4 C). Four months post infection, approximately lOx more 2C cells could be
detected in TRP-SIY prostates relative to TRAMP prostates [(2.4±1.3)x10 4 versus (2.9±1.5)x103,
p<0.05]. Small populations of 2C cells could also be detected in the lungs. Upon in vitro
restimulation, ~60% of 2C cells from the lungs of TRP-SIY mice could produce both IFN-y and
TNFa, but only ~3% of 2C cells from the prostates could produce both cytokines. In contrast,
~20% of 2C cells from the lungs and ~25% from the prostates of TRAMP mice could produce
IFN-y and TNFa (Fig. 2.4 D). Although -25% of 2C cells from the prostates of TRP-SIY mice
could produce IFN-y alone, the expression level was significantly lower than that for 2C cells
from the lungs. 2C cells from TRP-SIY prostates also had elevated PD-I expression levels (Fig.
2.4 E), and did not expand in number when mice were challenged with SlY peptide in CFA (data
not shown). 2C cells from TRAMP prostates exhibited a gradual loss in the ability to produce
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Figure 2.4 Induction of 2C cell tolerance in TRP-SIY mice following WSN-SIY
vaccination. TRAMP and TRP-SIY mice received adoptive transfer of naYve 2C cells and
intranasal infection with WSN-SIY and were evaluated 4 months post infection. A, 2C TCR
versus CD8 staining profiles of live cells from select lymphoid tissues. NonPDLN cells
contained pooled samples, as in Fig. 2.2. B, Mice received subcutaneous injection of 50pg SIY
peptide emulsified in CFA, and were evaluated 5 days later. 2C TCR versus CD8 staining
profiles of live cells are shown. C, 2C TCR versus CD8 staining profiles of live cells from
prostates and lungs. D, Cells were stimulated with SIY peptide for 4hrs and were analyzed foi
2C TCR, CD8 and intracellular IFN-y and TNFa expression. TNFa versus IFN-y staining
profiles are shown for 2C TCR*CD8+ cells. E, Harvested cells from prostates and lungs were
analyzed for 2C TCR, CD8 and PD-1. Histograms show PD-1 expression on 2C TCR+CD8*
cells. Numbers indicate percentage cells in gated region. Representative data from one of three
experiments are shown (A-D). Experiments performed by Ailin Bai.
effector cytokines as well, most likely due to tumor-mediated immune suppression independent
of antigen. Together, this data suggests that 2C cells persist in the prostates but not the lymphoid
tissues of TRP-SIY mice following WSN-SIY vaccination, and those cells that persist are
tolerized.
In order to evaluate how rapidly effector 2C cells are tolerized in TRP-SIY prostates, we
evaluated the ability of 2C cells from different organs to produce effector cytokines at 14 dpi. In
TRAMP mice, ~75% of 2C cells from either the lungs or spleens and ~45% of 2C cells from the
prostates could produce both IFN-y and TNFa (Fig. 2.5 A). In TRP-SIY mice, -70% of 2C cells
from the lungs could produce both cytokines, but this percentage dropped to ~40% in the spleens
and ~4% in the prostates. 2C cells from TRP-SIY prostates lost the ability to produce TNFa by
14dpi and the ability to produce IFN-y between 7-28 dpi (Fig. 2.5 B, C). As effector 2C cells do
not start to infiltrate the prostate tissue until approximately 7dpi, these results suggest that
effector cell tolerization is very rapid.
NaYve 2C cells are tolerized in the PDLN during the course of virus-induced activation of
2C cells in the MLN of TRP-SIY mice. Although tolerized 2C cells in the PDLN do not
infiltrate the prostate tissue extensively, they complicate our interpretation of effector 2C cell
tolerance in tumors. To address this issue, we directly examined the fate of effector 2C cells
transferred into TRP-SIY mice. For this purpose, the effector cells were generated by injecting
naYve 2C cells into C57BL/6 mice and infecting the mice with WSN-SIY; then, 5 dpi, 20x10 6
MLN cells (containing ~1x10 6 2C cells) were transferred into TRP-SIY mice, which had been
infected with WSN-SIY intranasally 5 days earlier (but without transfer of naYve 2C cells). Five
days after effector cell transfer, 2C cells from various organs were assayed for IFN-y expression
following SIY restimulation. While -45-80% of 2C cells from the spleens, lungs and various
lymph nodes expressed IFN-y, only -15% of 2C cells from the prostates expressed IFN-y, and at
low levels (Fig. 2.5 D), further supporting the rapid tolerization of effector 2C cells in the
prostates of TRP-SIY mice.
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Figure 2.5 Rapid tolerization of activated effector 2C cells in TRP-SIY prostates A,
TRAMP and TRP-SIY mice received adoptive transfer of naive 2C cells and intranasal infetion
with WSN-SIY, as in Fig. 2.2. Cells harvested from various tissues at 14pdi were stimulated
with SLY peptide for 4hrs and were analyzed for cytokine expressin. TNFa versus IFN-y
staining profiles are shown for Thyl.1*CD8* cells. B and C, TRAMP and TRP-SlY mice
received adoptive transfer of naive 2C cells (1-1.5x106 cells/mouse) and intranasal infection with
WSN-SIY. At various timepoints, harvested cells from prostates were stimulated with SIY
peptide for 4hrs and were analyzed for 2C TCR, CD8 and intracellular IFN-y and/or TNFa. The
percentage of 2C TCR*CD8* cells expressing (B) IFN-y or (C) TNFa are shown over a 120 day
timecourse following infection. Dda shown is pooled from several experiments, with 3-5 mice
per timepoint. D, 1.5x106 naive GFP* 2C cells were transferred into C57BL/6 mice, which were
immediately infected with WSN-SIY. Five days later, 20x10 6 MLN cells were transferred into
recipient TRP-SIY mice, which had been infected with WSN-SIY 5 days earlier. Five days after
WNW
effector cell transfer, lymphoid and non-lymphoid tissues were harvested, and recovered cells
were analyzed for IFN-y expression after SIY restimulation. Dot plots show GFP versus CD8
profiles to identify 2C cells. Histograms show IFN-y expression by 2C cells pooled from 3 TRP-
SlY mice. Numbers indicate percentage cells in gated region. Experiments in panels A, B and C
performed by Ailin Bai.
2.4.5 Tumor-tolerized T cells can regain the ability to produce cytokines in vitro
In order to determine whether 2C cell tolerance could be reversed, persisting 2C cells
were purified from TRP-SIY prostates by cell sorting, labeled with CFSE and transferred into
untreated C57BL/6 mice. As controls, 2C cells isolated from livers of TRAMP mice were
similarly transferred. Donor 2C cells from prostate and liver tissues underwent comparable
homeostatic proliferation in the livers of C57BL/6 recipients (Fig. 2.6 A). Seven days post
transfer, C57BL/6 recipients were then challenged intraperitoneally with WSN-SIY.
Approximately 30-50 fold more 2C cells were recovered from the livers and spleens of mice that
received 2C cells from TRAMP livers, but only ~2 fold and 10 fold more 2C cells were
recovered from the livers and spleens, respectively, of mice that received 2C cells from TRP-SIY
prostates (Fig. 2.6 B).
Purified 2C cells labeled with CFSE were cultured in vitro in the presence of either IL-2,
IL-7 or IL- 15 for 4 days. During that time, 2C cells from TRAMP livers expanded
approximately 5 fold in the presence of exogenous IL-2 (Fig. 2.6 C). Although the cells diluted
CFSE in the presence of IL-15, there was minimal increase in the total cell numbers (data not
shown). In the presence of IL-7, 2C cells survived, but did not undergo significant proliferation.
2C cells from TRP-SIY prostates also proliferated in the presence of IL-2, but not in the presence
of either IL-15 or IL-7. Interestingly, tolerized 2C cells from TRP-SIY prostates regained their
ability to produce both IFN-y and TNFa in the presence of either IL-2, IL-15 or IL-7 (compare
Fig. 2.6 D with 2.4 D and 2.5 A). However, the percentages were not as high as those for 2C
cells from TRAMP livers. This data suggests that tolerized 2C cells can be refunctionalized to
proliferate and secrete effector cytokines under certain conditions.
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Figure 2.6 Response of tolerized 2C cells in vivo and in vitro. TRAMP and TRP-SIY mice
(Thyl.2) received adoptive transfer of naive 2C cells (Thyl.1*) and intranasal infection with
WSN-SIY. Twenty-eight dpi, Thyl.1*CD8* 2C cells were purified from TRP-SIY prostates or
TRAMP livers by cell sorting and were labeled with CFSE. A and B, Purified, CFSE-labeled 2C
cells were transferred into naive recipient C57BL/6 mice (Thy1.2*, 1x10 5 cells/mouse). Seven
days after transfer, half of the recipients were intraperitoneally infected with WSNSIY or were
mock injected with PBS. Six dpi (13 days after transfer to secondary hosts), spleens and livers
were evaluated for cell number, Thyl.1, CD8 and CFSE. A, CFSE content of Thyl.1*CD8* 2C
cells from the livers of non-infected recipient C57BL/6 mice. B, Total number of Thyl.l*CD8*
2C cells in spleens and livers of recipient C57BL/6 mice, either with or without intraperitoneal
WSN-SIY infection. C and D, Purified, CFSE-labeled 2C cells were cultured ex vivo for 4 days
in the presence of either IL-2, IL-7 or IL- 15. Some cells were then stimulated with SIY for 4 hrs
and assayed for intracellular IFN-y and TNFa. C, Cell numbers after ex vivo culture normalized
to the input cell numbers. D, Percentages of IFN-y and TNFa expressing 2C cells in various ex
vivo cultures. *p<0.05. Representative data from one of two independent experiments are
shown. Experiments performed by Ailin Bai.
2.5 Discussion
Current immunotherapies induce limited clinical responses, so there is a widely accepted
need for better models to study T cell-mediated approaches to treating cancer. Here, we
engineered a transgenic mouse line that when coupled with the TRAMP model enables detailed
characterization of the functional response of antigen-specific and tumor-specific CTLs. In our
TRP-SIY model, expression of the SlY epitope is restricted to the prostate tissue. Consistent
with data from other transgenic studies, the transgenic antigen in the prostate tissue (Kb-SIY) is
comparable to a self-antigen, as it induces a sub-optimal response from adoptively transferred
naive 2C cells (25-27). Cross-presentation of tumor-derived antigen in TRP-SIY mice initiated
more robust 2C cell proliferation than that of non-tumor tissue antigen in PB-SIY mice, likely a
result of increased amounts of antigenic epitope due to prostate neoplasia. Despite this increased
proliferative response, 2C cells did not express activation markers, acquire the ability to produce
effector cytokines or infiltrate the prostate tissue significantly (Fig. 2.2). Other than a small
number of 2C cells in the PDLN, the majority of cells eventually disappeared from recipient
mice, suggesting systemic tolerance had been induced. In our model, adoptively transferred
naYve 2C cells were robustly activated in the MLN following intranasal infection with WSN-SIY.
The effector 2C cells infiltrated the prostate tissue extensively, were rapidly tolerized, and then
persisted long-term. This result is consistent with previous findings that TAg-specific T cells
persist long-term in TRAMP prostates (28). Coupling TRAMP and TRP-SIY mice with the 2C
TCR system and WSN-SIY vaccination has created a new and promising model for studying T
cell function, tolerance and reactivation to prostate cancer, and for evaluating novel
immunotherapeutic approaches.
Adoptive immunotherapies generally use effector T cells that have been activated ex
vivo. The effectiveness of this approach can often be limited by poor persistence or rapid
tolerization following T cell transfer into recipients (29). T cells activated ex vivo may not be
efficiently programmed to respond or adapt to an in vivo environment with different cytokines
and helper cell populations. In contrast, T cells activated directly in vivo, particularly in the
setting of viral infection, become potent effector cells, a fraction of which can persist long-term
as memory T cells. Our results clearly establish that following WSN-SIY vaccination in TRP-
SLY mice, naYve 2C cells become simultaneously activated in the MLN and tolerized in the
PDLN. The initial activation phenotype of 2C cells in the MLN of TRP-SIY mice infected with
WSN-SIY is identical to that in hosts that do not express the SLY transgene. The virus-activated
2C cells rapidly acquire effector functions, including the ability to produce cytokines and kill
target cells. Furthermore, they are able to infiltrate SLY-expressing prostate tumors and express
IFN-y in the tumor environment for a minimum of 2-3 days (Fig. 2.3).
Despite robust activation of tumor-specific T cells by WSN-SIY vaccination, a dramatic
tolerant state minimizes the long-term response in vaccinated TRP-SIY mice. Tumor-specific T
cells are deleted in the peripheral lymphoid organs, and T cells that persist in the antigen-
expressing tumors are non-functional (Fig. 2.4). Adoptively transferred effector T cells are
similarly tolerized in antigen-expressing prostate tumors (Fig. 2.5). While tolerization of naive T
cells has been extensively studied, much less is known about the tolerization of effector T cells.
Our data suggests that tolerized 2C cells exhibit a significant defect in TNFa production, but a
fraction of cells maintain the ability to produce low levels of IFN-y, similar to exhausted CTLs
induced during chronic viral infections (30). Tolerized 2C cells also display increased PD-1
expression levels, reminiscent of exhausted T cells (31). Deleting the PD-I ligand, PD-L 1, had
no impact on tolerization, though (data not shown). The tolerization of fully-activated antigen-
specific T cells in the tumor environment is one of the major challenges that must be overcome
to eventually achieve long-tenn immunotherapeutic responses in the clinic.
TILs have been identified in various solid tumors from cancer patients (1, 21), and their
presence has often been associated with a favorable prognosis (32). However, these TILs are
generally non-functional (21). In certain tumor environments, suppressive cell populations,
including CD4* and CD8' regulatory T cells and immature myeloid cells, as well as suppressive
cytokines, such as TGF-3, have been implicated in T cell tolerance. In other environments, the T
cells themselves are inherently defective (33, 34). The molecular mechanisms driving both the
tolerization of TILs and their long-term persistence in tumors are not well understood. These
cells are inherently difficult to study due to their heterogeneity in patients and the lack of
knowledge about their antigen specificity. In our TRP-SIY mice, effector T cells rapidly lose
their function in antigen-expressing tumors, but persist long-term without undergoing deletion.
Kiniwa, et al., recently demonstrated the importance of CD8*Foxp3* suppressor cells in human
prostate tumors (35). However, both intracellular staining and transcriptional profiling show that
tolerized 2C cells in the prostates of TRP-SIY mice are not converted into Foxp3+ suppressor
cells (Fig. 2.7 and Fig. 3.4). Preliminary data suggests that tolerized 2C cells do not express
elevated IL-7R or IL-15R (data not shown), so increased survival cytokine signaling cannot
account for their persistence either.
TILs posses significant therapeutic potential. Previous studies have demonstrated that ex
vivo culture of TILs with cytokines can induce strong proliferative responses and potent effector
functions (21). Our experiments with secondary transfer of tolerized 2C cells show that simply
removing T cells from the influence of persistent antigen is not enough to fully reverse tolerance,
suggesting that effector cell inactivation is not induced by a dominant extrinsic suppressor.
Interestingly, the yc cytokines could all partially recover IFN-y and TNFa production by tolerized
T cells (Fig. 2.6). As we better understand the mechanisms by which yc cytokines can reverse a
tolerant state, we may be better equipped to restore the function of TILs ex vivo, leading to novel
T cell based immunotherapeutic approaches.
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Figure 2.7 Tolerized 2C cells in TRP-SIY prostates are not converted into Foxp3*
suppressor cells. TRAMP and TRP-SIY mice received adoptive transfer of naive 2C cells and
intranasal infection with WSN-SIY. 30 days later, harvested cells from prostates, PDLN and
lungs were analyzed for 2C TCR, CD8 and intracellular Foxp3 expression. Histograms show
Foxp3 expression by 2C TCR*CD8* cells. Top number indicates percentage 2C TCR*CD8* cells
and bottom number indicates percentage 2C TCR-CD8* cells.
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Chapter 3
Survey of Potential Mechanisms of Immune Evasion and Tumor-
Induced Tolerance in the TRAMP Model
3.1 Introduction
Once we had demonstrated that naYve and effector 2C T cells are rapidly tolerized in the
tumor environment of TRP-SIY mice (Chapter 2), we wanted to develop novel approaches to
overcome tolerance. In order to rationally design immunotherapeutic interventions, we needed
to better understand which mechanisms of immune evasion and/or tumor-induced tolerance
likely exert a dominant influence in TRP-SIY mice. This chapter will highlight initial data used
to rule out unlikely mechanisms. Chapters 4 and 5 will focus on data establishing dendritic cells
as primary mediators of tolerance in this model, and our novel approaches to overcome their
influence.
3.2 Materials and Methods
3.2.1 Mice, influenza virus, and adoptive transfer
TRAMP and TRP-SIY mice used for all experiments were heterozygous males. The
RAGIl1' 2C TCR transgenic (2C/RAG) mice were maintained on C57BL/6 or C57BL/6 Thy1.1
backgrounds. Mice were maintained in a specific pathogen-free facility, and all animal
experiments were performed in compliance with the institutional guidelines on animal care.
For adoptive transfer, naive 2C cells were isolated from the spleens and lymph nodes of
2C/RAG mice. The red blood cells were lysed from the splenocytes, and pooled cells from the
lymph nodes and spleens were resuspended in PBS. TRAMP and TRP-SIY mice then received
retroorbital injection of 1-1.5x 106 cells in1O0pL PBS.
Recombinant WSN-SIY influenza virus expressing a SIY-neuraminidase fusion protein
was described previously (1). Where indicated, mice were infected with WSN-SIY at the time of
2C cell transfer, and received intranasal administration of 100pfu WSN-SIY in 50ptL PBS.
3.2.2 Antibodies and flow cytometry
Single cell suspensions were prepared from lymphoid tissues by grinding them between
frosted glass slides and filtering the suspensions through 70pm nylon mesh. Prostate tissues were
microdissected and digested with 2pig/mL collagenase A (Roche) and 170U/mL DNase I
(Sigma) in RPMI 1640 plus 10% FBS for 1lhr at 370C. Digested samples were then ground
between frosted glass slides and filtered through nylon mesh. Lung samples were processed
through a metal cell strainer and digested with collagenase, as above. The red blood cells were
lysed, and the samples were filtered through nylon mesh.
Antibodies to CD8 (53-6.7, BioLegend), Thyl.1 (Ox-7, BioLegend), CD4 (RM4-5, BD
Pharmingen), CD25 (PC61.5, BD Biosciences), Foxp3 (FJK-16a, eBioscience), CD1 lb (MI/70,
eBioscience), Gr-l (RB6-8C5, BD Pharmingen), CD115 (AFS98, eBioscience) and IFN-y
(XMGl.2, BD Pharmingen) were conjugated to either FITC, PE or APC. The 2C TCR was
identified using a biotin-conjugated 1B2 clonotypic antibody, detected with streptavidin-APC
(BioLegend). Retrovirally-transduced 2C T cells were identified using 1B2 plus an antibody to
CD8. Antibody-stained cells were analyzed using a FACSCaliburTM instrument (BD
Biosciences), and the data was processed using FlowJoTM software (Tree Star).
Intracellular Foxp3 staining was performed using a BD Cytofix/Cytoperm Kit (BD
Biosciences). Briefly, cells were stained for CD4 and CD25, and dead cells were marked using a
LIVE/DEAD@ Fixable Red Dead Cell Stain Kit (Invitrogen). Following fixation and
permeabilization, cells were stained intracellularly with a 1:25 dilution of a PE-conjugated
Foxp3 antibody plus a 1:50 dilution of rat serum (BD Pharmingen).
Intracellular IFN-y staining was also performed using a BD Cytofix/Cytoperm Kit (BD
Biosciences). 2C T cells were stimulated in vitro with 1 lpg/mL SlY peptide for 4hr at 37'C in
the presence of BD GolgiPlug TM containing brefeldin A. Cells were stained for 2C TCR, plus
CD8 or Thy 1.1, and dead cells were marked using a LIVE/DEAD@ Fixable Red Dead Cell Stain
Kit (Invitrogen). Following fixation and permeabilization, cells were stained intracellularly with
a 1:50 dilution of a PE-conjugated anti-IFN-y antibody (BD Pharmingen).
3.2.3 Retrovirus infection and generation of in vitro memory T cells
The MSCV-IRES-GFP (MIG) retroviral vector encoding a dominant negative TGFp type
1I receptor (dn TGFpRII) was a gift from Dr. Chung Lee (Northwestern University) (2).
Retroviruses were produced in 293FT cells via co-transfection with pCL-Eco (Imgenex), which
encodes the retroviral packing components, using TransIT-LTI (Mirus).
In order to generate TGFs-insensitive T cells, naYve 2C cells were pooled from the
spleens and lymph nodes of 2C/RAG mice, following lysis of red blood cells. 2C cells were
stimulated for 36hrs with I g/mL SlY peptide in RPMI plus 10% FBS, 50 M 2-
mercaptoethanol, 10mM HEPES, 4mM L-glutamine, 100U/mL penicillin, 100pig/mL
streptomycin, and 50U/mL IL-2. Activated 2C cells were then transduced by spin infection with
retroviral supernatant plus 4Rg/mL polybrene (American Bioanalytical), and cultured for another
48hrs at 5x10 5 cells/mL in the above medium. Cells were then rinsed and cultured in the same
medium, except that IL-2 was substituted with recombinant murine IL-7 (Peprotech), for 6 days
to generate in vitro memory T cells.
For adoptive transfer, TRP-SIY mice received retroorbital injection of Ix 106 in vitro
memory 2C cells in 100 L PBS.
3.2.4 Mouse T Cell Anergy and Immune Tolerance PCR Array
TRAMP and TRP-SIY mice received adoptive transfer of naYve 2C cells and infection
with WSN-SIY. Thirty days later, cells were harvested from the prostates and lungs, as above,
and 2C cells were purified by cell sorting. Gene expression was then analyzed using a Mouse T
Cell Anergy and Immune Tolerance PCR Array (SABiosciences). Briefly, RNA was isolated
from purified 2C cells using an RNeasy Micro Kit (Qiagen), and approximately 25ng RNA per
sample was then converted into cDNA using an RT2 First Strand Kit (SABiosciences). CDNA
was added to the RT2 qPCR Master Mix and was aliquoted across the array. Thermal cycling
was then performed using an ABI Prism 7000 Sequence Detection System (Applied
Biosciences). Fold changes in gene expression were calculated and compared.
3.3 Results
3.3.1 Deletion
Following adoptive transfer of naive 2C cells and intranasal infection with WSN-SIY, 2C
cells can be detected in the prostates of both TRAMP and TRP-SIY mice for the remainder of
the lives of the animals (Fig. 2.4), suggesting direct deletion of tumor-reactive T cells is an
unlikely mechanism of evasion in this model.
3.3.2 Decreased antigen presentation
By 10 days after adoptive transfer of naive 2C cells and intranasal infection with WSN-
SlY, up to 80x more 2C cells can be detected in the prostates of TRP-SIY mice than in the
prostates of TRAMP mice (Section 2.4.3, Fig. 2.3 E and F). Even at late timepoints, day 30 and
beyond, up to 1Ox more 2C cells can be detected in the prostates of TRP-SIY mice than in
TRAMP mice (Section 2.4.4, Fig. 2.4 C). This data suggests that 2C cells are aware of the
presence of antigen in the TRP-SIY prostate tissue, and that decreased antigen processing and
presentation is not likely a dominant mechanism of evasion.
3.3.3 Ignorance
Activated 2C cells infiltrate extensively into the prostates of both TRAMP and TRP-SIY
mice. Thus, ignorance is unlikely to be a critical strategy of evasion (Section 2.4.3, Fig. 2.3 E
and F).
3.3.4 Immunosuppressive cytokines: TGF-p
As the TRAMP-C2 cell line derived from TRAMP mice can produce up to lOx more
TGF-pl than other prostate cancer cells lines (2), we wanted to evaluate whether TGF-
production has a significant immunosuppressive effect in TRAMP tumors in vivo. In particular,
we generated TGF-p insensitive 2C cells and evaluated their function within TRP-SIY prostates.
We activated naYve 2C cells, transduced them with a retrovirus encoding a dominant negative
TGF-P type II receptor (dnTGFRII) (2), and then transitioned the cells into a memory
phenotype in vitro to ensure they could respond productively to a second antigen encounter in
vivo. We then adoptively transferred control or TGF-P insensitive in vitro memory 2C cells into
TRP-SIY mice and intranasally infected the mice with WSN-SIY. Eleven days later, we
harvested various tissues, and evaluated the ability of recovered 2C cells to produce IFN-y
following in vitro restimulation. There were no significant differences in the function of control
or TGF- insensitive 2C cells in the prostates of TRP-SIY mice (Fig. 3.1). Both groups of cells
were less than 30% IFN-y* at this timepoint, suggesting that TGF-p does not suppress 2C cells
directly in TRP-SIY tumors. However, TGF-p may still have an indirect suppressive effect on
2C cells by modulating other critical cell populations, such as dendritic cells.
3.3.5 Regulatory T cell
In order to assess the potential influence of CD4*CD25*Foxp3+ regulatory T cells in the
tumor environments of TRAMP and TRP-SIY mice, we analyzed differences in the
accumulation of regulatory T cells in age-matched mice. Cells were collected from the prostates,
PDLN, spleens, PLN and lungs of 4 month old C57BL/6, TRAMP and TRP-SIY mice, and the
composition of CD4*CD25*Foxp3+ regulatory T cells was evaluated by flow cytometry. There
were no significant differences in the accumulation of regulatory T cells in age-matched tumor-
free (C57BL/6) or tumor-bearing (TRAMP or TRP-SIY) mice (Fig. 3.2), suggesting that
CD4*CD25*Foxp3* regulatory T cells are not likely exerting a dominant influence during the
early stages of tumor development. We have also demonstrated at both the protein and transcript
level that tolerized persisting 2C cells are not converted into Foxp3* suppressor cells in TRAMP
or TRP-SIY prostates (Fig. 2.7 and 3.4). Although lack of accumulation does not definitively
exclude a role for regulatory T cells, our data is consistent with recently published work
establishing that regulatory T cells are not the dominant mechanism of tolerance in the TRAMP
model (3).
3.3.6 Myeloid-derived suppressor cells
We assessed the potential influence of myeloid-derived suppressor cells (MDSCs) in
TRAMP and TRP-SIY mice by similarly evaluating differences in the accumulation of MDSCs
in age-matched mice. Cells were harvested from the prostates, spleens and PDLN of 4 month
old C57BL/6, TRAMP and TRAMP-SIY mice, and the composition of CDl lb'Gr-l* cells was
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Figure 3.1 TGF-p insensitive 2C cells are tolerized in TRP-SIY prostates. Naive 2C cells
were activated with SIY peptide plus IL-2 for 36hrs, and were or were not transduced with a
retrovirus expressing GFP and a dominant negative TGF-p type II receptor (dn TGFpRII). Cells
were cultured for 2 additional days in IL-2 and then transitioned into a memory phenotype by
culturing them for 6 days in IL-7. TRP-SIY mice then received adoptive transfer of control ox
TGF-p insensitive in vitro memory 2C cells and intranasal infection with WSN-SIY. Eleven
days later, cells were harvested from various tissues, restimulated with SIY peptide for 4hrs and
evaluated for 2C TCR, CD8 and intracellular IFN-y expression. Dot plots show IFN-y versus
CD8 staining profiles for 2C TCR*CD8* live cells. Numbers indicate percentage IFN-y* cells.
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Figure 3.2 CD4*CD25*Foxp3* regulatory T cells do not accumulate in the tumor
environments of TRAMP or TRP-SIY mice. Prostates, PDLN, spleens, PLN and lungs were
harvested from age-matched 4 month old C57BL/6, TRAMP and TRP-SIY mice, and tissues
were pooled from 3 mice for each group. Samples were evaluated for CD4, CD25 and
intracellular Foxp3 expression. Dot plots show CD25 versus CD4 expression for Foxp3* cells.
Top number indicates percentage of total cells that are CD4*CD25* Foxp3* and bottom number
indicates percentage of CD4* cells that are CD4*CD25* Foxp3*.
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evaluated by flow cytometry. As observed for regulatory T cells, there were no significant
differences in the composition of CD 11 b'Gr- I + cells between tissue samples from age-matched
mice (Fig. 3.3). We also evaluated differences in the accumulation of CD115* MDSCs, which
are known to convert T cells into suppressor cells (4). While, there were no significant
differences in the accumulation of these cells in the prostates or spleens, there was some
enrichment for CD1 15* MDSCs in the PDLN of TRAMP and TRP-SIY mice relative to
C57BL/6 mice (Fig. 3.3). Based on this data, MDSCs do not likely have a dominant influence
during the early stages of tumor development. Again, minimal differences in accumulation do
not provide a definitive answer on the importance of MDSCs, as their suppressive influence can
be antigen-specific (5), but it does suggest that other tolerizing mechanisms may be of more
importance during tumor initiation. As the tumor environment changes with disease progression,
the dominant suppressive mechanisms may be altered as well.
3.3.7 Mouse T Cell Anergy and Immune Tolerance PCR Array
We also analyzed gene expression profiles for targeted pathways in tolerized 2C cells, to
explore potential molecular mechanisms of T cell dysfunction in the tumor environments of
TRAMP and TRP-SIY mice. In particular, we used a Mouse T Cell Anergy and Immune
Tolerance PCR Array (SABiosciences) that measures the relative expression of 84 genes known
to be involved in T cell tolerance or anergy, including genes that encode T and B cell regulators,
cytokines, cytokine receptors, TNF superfamily members, TNF receptors and various
transcription factors. In order to generate the cells for this analysis, we transferred naYve 2C cells
into TRAMP and TRP-SIY mice, intranasally infected the mice with WSN-SIY, and harvested
cells from the prostates and lungs 30 days later. We purified the 2C cells by cell sorting, isolated
total RNA, converted the RNA into cDNA and evaluated gene expression using RT-PCR.
We normalized the gene expression data for 2C cells from TRP-SIY prostates to that for
2C cells from either TRP-SIY lungs (Fig 3.4 A) or TRAMP prostates (Fig 3.4 B). This allowed
us to look for differences in gene expression between 2C cells in tumor or non-tumor tissue as
well as between 2C cells in antigen-expressing and non-expressing tumors, respectively. In
normalizing the data to 2C cells from TRP-SIY lungs, candidates that showed significant
upregulation (fold change greater than 1) included: BTLA, which is an inhibitory receptor on
101
Prostate
CD11b - CD11b -
Figure 3.3 CD11b*Gr-1* cells do not accumulate in the tumor environments of TRAMP or
TRP-SIY mice. Prostates, spleens and PDLN were harvested from age-matched 4 month old
C57BL/6, TRAMP and TRP-SIY mice, and tissues were pooled from 3 mice for each group.
Samples were evaluated for CDllb, Gr-1 and CD 115 expression. Dot plots show Gr-I versus
CDI lb staining profiles for live cells or CD1 15 versus CD1 lb staining profiles for CDI 1bGr-l
live cells. Numbers indicate percentage of double positive cells.
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Figure 3.4 Gene expression profiles for targeted pathways in tolerized 2C cells. TRAMP
and TRP-SIY mice received adoptive transfer of naive 2C cells and intranasal infection wit-
WSN-SIY. Thirty days later, 2C cells were purified from the prostates and lungs by cell sorting,
total RNA was isolated and converted into cDNA, and gene expression was evaluated through
RT-PCR using a Mouse T Cell Anergy and Immune Tolerance PCR Array (SABiosciences).
Gene expression data for 2C cells from TRP-SIY prostates was normalized to that for 2C cells
from either TRP-SIY lungs (A) or TRAMP prostates (B). Data reported is fold change. Boxed
genes had a fold change greater than 1 or less than -1.
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lymphocytes; CD40L; GM-CSF (Csf2); Egr2, which is a transcription factor whose
overexpression is associated with inhibited T cell activation; and several members of the TNF
superfamily. Upregulation of BTLA (6) or Egr2 (7) could contribute to 2C cell tolerance in
TRP-SIY prostates, as they both have previously established immunosuppressive functions.
Candidates that showed significant downregulation included IL-1ORa and IL-4. In normalizing
the data to 2C cells from TRAMP prostates, candidates that showed significant upregulation
included Fas; Nhlh2, which encodes a basic helix-loop-helix transcription factor (8); and another
TNF superfamily member. The only candidate that exhibited significant downregulation was
Cmal, which encodes a serine proteinase known to be expressed in mast cells (9). Its role in T
cell tolerance has not been well characterized. As Fas, a TNF family member, is upregulated on
2C cells in TRP-SIY prostates relative to those in TRAMP prostates, a more significant fraction
of cells could be undergoing cell death. The most interesting information to come out of this
analysis is that several TNF superfamily members are upregulated on 2C cells in TRP-SIY
prostates, when normalized to cells from either TRP-SIY lungs or TRAMP prostates, so this
would be an interesting family of proteins to explore further. Thus, gene expression analysis of
tolerized 2C cells from TRP-SIY prostates has identified some interesting candidates to evaluate
further to better characterize the molecular mechanisms driving T cell dysregulation in this
model.
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3.4 Discussion
In order to design novel mechanism-based immunotherapeutic interventions, we surveyed
potential strategies of immune evasion and tumor-induced tolerance in the TRP-SIY model to
rationally identify probable suppressive mechanisms. Using this survey approach, we identified
several mechanisms as being unlikely to exert a dominant influence during the early stages of
tumor development. These mechanisms included direct deletion of tumor-reactive T cells,
decreased antigen processing and presentation, ignorance, immununosuppressive cytokines
(TGF-p), regulatory T cells and myeloid-derived suppressor cells. The next two chapters will
now present data establishing dendritic cells as primary mediators of tolerance in this model, and
our novel approaches to overcome their influence.
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Chapter 4
Activation of Tolerogenic Dendritic Cells in the Tumor Draining
Lymph Nodes by CD8* T Cells Engineered to Express CD40
Ligand 2
4.1 Abstract
Tolerogenic dendritic cells in the tumor microenvironment can inhibit the generation and
maintenance of robust anti-tumor T cell responses. Here, we investigated the effects of local
delivery of CD40 ligand (CD40L) by tumor-reactive CD8* T cells on dendritic cell activation
and anti-tumor T cell responses in the TRAMP model. To increase the immunostimulatory
signal, CD40L was engineered, by deleting the majority of the cytoplasmic domain, to increase
both its level of expression and duration on the surface of CD8' T cells. Tumor-reactive CD8' T
cells expressing the truncated form of CD40L stimulated maturation of dendritic cells in vitro
and in the prostate draining lymph nodes (PDLN) in vivo. Following dendritic cell maturation, a
significantly higher fraction of adoptively transferred, tumor-reactive (reporter) CD8* T cells
was stimulated to express IFN-y and infiltrate the prostate tissue. The anti-tumor CD8' T cell
response was further enhanced if TRAMP mice were also immunized with a tumor-specific
antigen. These findings demonstrate that augmented T cell responses can be achieved by
engineering tumor-reactive T cells to deliver stimulatory signals to dendritic cells in the tumor
microenvironment.
2Significant sections of this chapter have been submitted for publication in:
Higham, E., K.D. Wittrup, and J. Chen. 2009. Activation of Tolerogenic Dendritic Cells in the
Tumor Draining Lymph Nodes by CD8* T Cells Engineered to Express CD40 Ligand. J.
Immunol.
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4.2 Introduction
Harnessing the power of the immune system to destroy cancer has been a long-standing
objective of cancer immunotherapy. One widely investigated approach has been adoptive cell
transfer (ACT), in which tumor-specific T cells are isolated from patients, expanded ex vivo and
reinjected back into the patients to destroy tumor cells. Significant success has been achieved
with ACT in treating metastatic melanoma patients, reaching over 50% response rates when
ACT is coupled with lymphodepleting preconditioning strategies (1-3). Despite this significant
progress, transferred T cells can still be inactivated (tolerized) or deleted, limiting their
therapeutic effect. Developing strategies to maximize the function of tumor-reactive T cells in
vivo may further increase the clinical impact of T cell-based immunotherapies.
Like most tissue antigens, tumor antigens are cross-presented by specialized antigen-
presenting cells, such as dendritic cells (DCs). Mature dendritic cells displaying tumor antigens
can initiate productive anti-tumor T cell responses. However, DCs that have been exposed to
tumor-derived factors, including VEGF, TGFP, IL-6, PGE2 and IL-10, tend to anergize T cells
(4-9). Such tolerogenic DCs have been found in both tumors and tumor draining lymph nodes
(TDLNs). Regardless of their tissue origin, they generally share the ability to induce CD4* and
CD8* regulatory T cells and anergize antigen-specific T cells (10). Thus, to increase the
therapeutic efficacy of adoptively transferred T cells, it is critical to activate tolerogenic DCs in
the tumor environment.
CD40 and CD40 ligand (CD40L) are members of the TNF family, and their interaction
provides a potent signal for DC activation (11). CD40L expression is tightly regulated, being
transiently expressed on the surface of activated CD4* T cells for less than 24hrs (11). To
explore CD40 ligation as a strategy to activate tolerogenic DCs, systemic administration of
agonist anti-CD40 antibodies has been investigated. In mice, such treatment has been shown to
mature DCs and replace the need for CD4* T cell help (12-14). Based on these observations,
CD40 ligation has been used to boost the CD8* T cell response to tumors and to break peripheral
self-tolerance (15-17). The consequences of these treatments have proven to be system
dependent in murine models, though, as significant immune suppression has been observed as
well (18-21). In humans, anti-CD40 monoclonal antibodies (22-26), recombinant soluble
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CD40L protein (27), and CD40L-expressing autologous tumor cells (28, 29) have been evaluated
clinically to treat cancer patients. Although the initial phase I clinical results have shown
significant objective anti-tumor responses (30), and no major systemic toxicity has been
observed, transient cytokine release syndrome has been a side-effect with several of the agonist
anti-CD40 monoclonal antibodies (30). Because elevated CD40 activation has also been
implicated in the progression of systemic lupus erythematosus (31), rheumatoid arthritis (32),
type 1 diabetes (33), neurodegenerative disorders (34, 35), and allograft rejection (36-38),
systemic activation of CD40 could potentially induce autoimmunity. To overcome the variable
outcomes and circumvent potential side-effects associated with systemic CD40 ligation, CD40L
or anti-CD40 could be delivered locally in the TDLNs and/or tumor tissue.
In this study, we report a new strategy to locally deliver stimulatory CD40L signals using
tumor-reactive CD8* T cells, which naturally traffic to TDLNs. To increase the stimulatory
signal, we designed a mutant murine CD40L, which lacks the majority of its cytoplasmic
domain, to increase both the expression level and duration on the surface of CD8' T cells. Using
an antigen-specific TRAMP model, we show that transferred CD40L-expressing tumor-specific
CD8* T cells can stimulate the maturation of dendritic cells in the PDLN and augment anti-
tumor responses of adoptively transferred, tumor-specific reporter CD8' T cells. These findings
demonstrate that augmented anti-tumor T cell responses can be induced by engineering T cells to
deliver CD40L-mediated stimulatory signals to dendritic cells in the tumor environment.
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4.3 Materials and Methods
4.3.1 Mice, influenza virus, antibodies and flow cytometry
TRAMP and TRP-SIY mice used for all experiments were 3.5 to 4.5 month old
heterozygous males. The RAG1' 2C TCR transgenic (2C/RAG) mice were maintained on
C57BL/6 or C57BL/6 Thy 1.1 backgrounds. Recombinant WSN-SIY influenza virus expressing
a SIY-neuraminidase fusion protein was described previously (40). For infection, TRP-SIY mice
were infected intranasally with 100pfu WSN-SIY virus in 50p.L PBS. Mice were maintained in a
specific pathogen-free facility, and all animal experiments were performed in compliance with
the institutional guidelines on animal care.
Agonist anti-CD40 antibody (FGK45.5) was a gift from Dr. A. Rolink of the Basal
Institute for Immunology, Basel, Switzerland (41). Antibodies to CD40L (MR1, eBioscience),
CD8 (53-6.7, BioLegend), Thy1.1 (Ox-7, BioLegend), CD1 Ic (N418, BioLegend), CD80 (16-
1OA1, BD Pharmingen) and CD86 (GL1, BD Pharmingen) were conjugated to either FITC, PE
or APC. The 2C TCR was identified using a biotin-conjugated 1B2 clonotypic antibody,
detected with streptavidin-APC (BioLegend). Retrovirally-transduced 2C T cells were identified
using 1B2 plus an antibody to either Thyl.1 or CD8. Antibody-stained cells were analyzed
using a FACSCaliburT M instrument (BD Biosciences), and the data was processed and evaluated
using FlowJoTM software (Tree Star).
Intracellular IFN-y staining was performed using a BD Cytofix/Cytoperm Kit (BD
Biosciences). Briefly, 2C T cells were stimulated in vitro with 1 Jtg/mL SlY peptide for 4hr at
37'C in the presence of BD GolgiPlugT M containing brefeldin A. Cells were stained for 2C
TCR, plus CD8 or Thyl.1, and dead cells were marked using a LIVE/DEAD@ Fixable Red
Dead Cell Stain Kit (Invitrogen). Following fixation and permeabilization, cells were stained
intracellularly with a PE-conjugated anti-IFN-y antibody (XMG1.2, BD Pharmingen).
4.3.2 Anti-CD40 treatment
TRP-SIY mice were injected intraperitoneally with 500[LL of either PBS or 200[tg anti-
CD40 antibody in PBS daily for 3 days. One day after the first anti-CD40 injection, the treated
mice were injected retroorbitally with 100 L PBS containing 1-1.5x 106 naYve 2C cells from the
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spleens and lymph nodes of 2C/RAG mice. Immediately following T cell transfer, mice were
infected intranasally with WSN-SIY virus (39). Five and 10 days post infection (dpi), 2C T cells
from the PDLN, spleens and peripheral lymph nodes (PLN) were analyzed for IFN-y expression,
as above.
4.3.3 Construction of retroviral vectors expressing wildtype and mutant CD40L
pMemCD40L, which contains full-length murine CD40L (GenBank accession no.
X65453.2) (42), was obtained from Dr. Richard Kombluth of the University of California at San
Diego. A BglII/SalI generated full-length CD40L fragment (wild type) was then subcloned into
a retroviral vector that expresses Thyl.1 (MSCV-IRES-Thyl.1). Mutation of the tyrosine at
amino acid residue 5 of CD40L to alanine (TAC-+GCC, CD40L Y5A) was performed through
site-directed mutagenesis, using a QuikChange II Site-Directed Mutagenesis Kit (Stratagene).
To delete the first thirteen amino acid residues of the N-terminal cytoplasmic domain of CD40L
(CD40L Al-13), amino acid residue 12 was first mutated from TCC to TCT through site-directed
mutagenesis to generate a BgllI site. The deletion was then completed by BglII digestion and
subcloning into the retroviral vector above. Following ligation, a start codon was reintroduced at
amino acid 13 (GTG->ATG). Retroviruses expressing wildtype and mutant CD40L were
produced in 293FT cells via co-transfection with pCL-Eco (Imgenex), which encodes the
retroviral packing components, using TransIT-LT 1 (Mirus).
4.3.4 Retrovirus infection and generation of in vitro memory T cells
NaYve 2C cells were pooled from the spleens and lymph nodes of 2C/RAG mice,
following lysis of red blood cells. 2C cells were stimulated for 36hrs with 1 [g/mL SlY peptide
in RPMI plus 10% FBS, 50 [M 2-mercaptoethanol, 10mM HEPES, 4mM L-glutamine, 1OOU/mL
penicillin, 100pg/mL streptomycin and 50U/mL IL-2. Activated 2C cells were then transduced
by spin infection with the indicated retroviral supernatant plus 4 tg/mL polybrene (American
Bioanalytical), and cultured for another 48hrs at 5x1 05 cells/mL in the above medium. Cells
were then rinsed and cultured in the same medium, except that IL-2 was substituted with
recombinant murine IL-7 (Peprotech), for 6 days to generate in vitro memory T cells.
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4.3.5 In vitro BMDC maturation assay
Retrovirally-transduced in vitro memory 2C cells were restimulated by mixing the cells
1:1 with C57BL/6 splenocytes in the presence of I [tg/mL SlY peptide for 48hrs. CD40L-
expressing 2C cells were purified by sorting for Thy .L + cells. The sorted T cells were then co-
cultured at a 10:1 ratio with day 6 immature bone marrow-derived dendritic cells (BMDCs). To
generate immature BMDCs, bone marrow was harvested from the femurs of C57BL/6 mice.
After lysis of red blood cells, the cells were resuspended at 2x1 05 cells/mL and cultured for 6
days in RPMI plus 10% FBS, 50pM 2-mercaptoethanol, 4mM L-glutamine, 1 OOU/mL penicillin,
100pg/mL streptomycin and a 1:30 dilution of J5 cell supernatant containing GM-CSF. As
controls, BMDCs were cultured alone, either in the presence or absence of 1 [tg/mL
lipopolysaccharide (LPS). In the absence of LPS, control BMDCs were either left
unmanipulated or were taken off the tissue culture plate and concentrated (107 cells/mL), to
simulate the other co-culture conditions. Following a 24hr coculture, maturation of BMDCs was
evaluated by flow cytometry by measuring CD1 Ic, CD86 and CD80 expression.
4.3.6 In vivo dendritic cell activation and reporter T cell response
In vitro memory 2C cells either expressing or not expressing CD40L were transferred
into TRP-SIY mice (1-5 x10 6 cells/mouse). A subset of mice was also infected with WSN-SIY.
Six days later, the maturation status of the dendritic cells in the PDLN, PLN, mediastenial lymph
nodes (MLN) and/or spleens was evaluated by assaying for CD Ilc, CD Ilb, CD86 and CD80
expression. Alternatively, 6 days following the transfer of in vitro memory 2C cells, naYve
Thy 1. High reporter 2C cells were transferred into the TRP-SIY mice. Five and 10 days post
transfer, reporter 2C cells from the PDLN, PLN and spleens were evaluated for IFN-y
expression, as above.
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4.4 Results
4.4.1 Systemic anti-CD40 treatment breaks tolerance transiently in TRAMP mice
We have previously developed transgenic mice that express a nominal antigen
SIYRYYGL (SIY) in the prostate tissue that can be recognized by CD8' T cells displaying the
2C TCR (39). Introduction of the transgene into TRansgenic Adenocarcimona of the Mouse
Prostate (TRAMP) mice results in the generation of double transgenic TRP-SIY mice, which
develop SlY-expressing prostate cancer. When TRP-SIY mice are infected intranasally with a
SIY-expressing influenza virus (WSN-SIY), adoptively transferred 2C cells become fully
activated, infiltrate the prostate tissue, but rapidly lose their function (39).
To determine the effects of anti-CD40 treatment on T cell activation and function, TRP-
SlY mice were injected with either PBS or an agonist anti-CD40 antibody one day before, on the
same day and one day after 2C cell transfer and WSN-SIY infection. Five days post infection
(dpi), ~67% of 2C cells from the prostate draining lymph nodes (PDLN) of anti-CD40 treated
mice were stimulated to produce IFN-y, whereas less than 40% of 2C cells from the PDLN of
PBS-treated mice produced IFN-y (Fig. 4.1 A). However, by 10 dpi, only ~10% of 2C cells from
the PDLN of anti-CD40-treated mice still expressed IFN-y, whereas 77% of 2C cells from the
PDLN of PBS-treated mice expressed IFN-y (Fig. 4.1 B). Although anti-CD40 treatment also
resulted in an earlier appearance of 2C T cells in the spleens and peripheral lymph nodes (PLN),
most of these cells were incapable of producing IFN-y. In contrast, in PBS-treated mice, almost
all 2C cells from the spleens and PLN were able to produce IFN-y. These results suggest that
while systemic anti-CD40 treatment can stimulate a tumor-specific CD8* T cell response
transiently in the PDLN of TRP-SIY mice, it can lead to severe immune suppression in the long-
term.
4.4.2 Truncation of the cytoplasmic domain of CD40L leads to increased levels and
duration of surface expression
One approach to deliver localized CD40 stimulation is to express CD40L on tumor-
reactive CD8* T cells, which naturally traffic to TDLNs and tumor tissues. Thus, we constructed
a retrovirus expressing CD40L and the surface marker Thy 1.1. To test CD40L expression on
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Figure 4.1 Effect of systemic anti-CD40 treatment on a tumor-reactive CD8* T cell
response in TRP-SIY mice. TRP-SIY mice were injected with PBS or anti-CD40 antibody on
days -1, 0 and +1. On day 0, mice were injected with naive 2C cells and infected with WSN-SIY
virus. Five (A) and 10 (B) days post infection, single cell suspensions were prepared from the
PDLN, spleens and PLN, and cells were restimulated in vitro with SIY peptide for 4hr. Samples
were stained for 2C TCR, CD8 and intracellular IFN-y. Dot plots show 2C TCR versus CD8
staining profiles of live cells. Histograms show IFN-y expression by 2C TCR*CD8* cells.
Numbers indicate percentage of positive cells. Representative data from one of two simila
experiments are shown.
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CD8* T cells, 2C T cells were activated with SlY peptide for 36 hrs, spin-infected with retroviral
supernatant, and were monitored for CD40L and Thy1.1 expression. Twenty-four hrs post
retroviral transduction, 12% of Thy1.1+ cells were also CD40L* (Fig. 4.2). However, by 48 hrs
post transduction, only 2% of Thyl.l+ cells were still CD40L*. Because both CD40L and
Thyl.1 expression were driven by the same viral LTR, these results suggest that CD40L
expression is tightly regulated post-translationally on the surface of CD8' T cells, as observed
for CD4' T cells (11).
To achieve a more sustained and higher level of CD40L expression, we constructed
CD40L mutants with potentially reduced susceptibility for receptor-mediated endocytosis (43).
In one mutant, referred to as CD40L Y5A, a tyrosine at position 5 was mutated to an alanine, as
this residue was thought to be critical for the maintenance of a conserved endocytosis domain
(43). However, the mutant displayed expression kinetics and levels comparable to the wild type
CD40L (Fig. 4.2), suggesting this mutation has no significant impact on CD40L expression on
CD8' T cells. In the second mutant, referred to as CD40L Al-13, the terminal 13 amino acid
residues were deleted from the 22 amino-acid intracellular domain. With this mutant, 41% of
Thy1.l+ 2C cells expressed CD40L by 24 hrs post retroviral transduction, and 10% of Thy1.1+
2C cells still expressed CD40L by 48 hrs post transduction (Fig. 4.2). In addition, the level of
CD40L Al-13 expression was substantially higher than wildtype CD40L expression at 24 hrs
post transduction. Therefore, deletion of the terminal 13 amino acid residues significantly
increases the level and duration of CD40L expression on activated CD8' T cells. CD40L Al -13
was used for all subsequent experiments.
4.4.3 CD40L-expressing 2C cells stimulate maturation of dendritic cells in vitro and in
vivo
Our strategy for localized CD40 ligation was to engineer tumor-reactive 2C T cells to
express CD40L Al- 13. Because even the truncated form of CD40L is only transiently expressed
following T cell activation, an important requirement for the success of this approach is that the
retrovirally-transduced CD8' T cells express CD40L again when they encounter antigen a
second time. Thus, retrovirally-transduced 2C cells were transitioned into a memory phenotype
in vitro (Fig. 4.3 A) to ensure they could respond to a second antigen encounter in TRP-SIY
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Figure 4.2 Surface expression of wildtype and mutant CD40L. Naive 2C cells were
activated with SIY peptide plus IL-2 for 36hrs. Cells were then transduced with a retrovirus
expressing Thy 1.1 alone (control) or Thy 1.1 plus the wild type CD40L, CD40L Y5A or CD40L
A1-13, and were analyzed for CD40L expression 24hrs and 48hrs later. The time in parentheses
corresponds to days post stimulation. Dot plots show CD40L versus Thy1.1 staining profiles of
live cells. Numbers indicate the percentage of Thy1.1+ cells that are CD40L*. Transduction
efficiencies were 20-25% in all cases, and representative data from one of at least two similar
experiments are shown.
117
CD44
B. Oday
11
CD62L
m In vitro memory 2C cells
Naive 2C cells
2 days
Thyl.1 *cells
- Thy1.1 - cells
CD40L
Figure 4.3 Kinetics of CD40L A1-13 re-expression on retrovirally-transduced in vitro
memory 2C cells. Naive 2C cells were activated with SIY peptide plus IL-2 for 36hrs, and were
then transduced with a retrovirus expressing Thy 1.1 and CD40L Al -13. Cells were cultured for
2 additional days in IL-2 and then transitioned into a memory phenotype by culturing them for 6
days in IL-7. A, Histograms show CD44 or CD62L expression on naive 2C cells and in vitro
memory 2C cells. B, In vitro memory cells were restimulated with SIY peptide plus IL-2 in the
presence of a 1:1 mix of C57BL/6 splenocytes, and were stained for Thyl.1, 2C TCR, and
CD40L on days 2, 3 and 4. Histograms show CD40L expression on 2C TCR*Thy1.1*
transduced cells or 2C TCR*Thyl.1~ non-transduced cells. Representative data from one of al
least two similar experiments are shown.
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mice. In order to demonstrate the ability of these retrovirally-transduced in vitro memory 2C
cells to re-express CD40L, the cells were stimulated with SIY peptide 10 days after transduction,
long after CD40L had ceased expression. The restimulated 2C cells began to upregulate CD40L
two days after restimulation, reached maximal levels of expression three days after restimulation,
and began to downregulate expression by four days after restimulation (Fig. 4.3 B). Therefore,
the retrovirally-transduced in vitro memory CD8' T cells are capable of re-expressing CD40L
when they encounter antigen again.
To demonstrate the functionality of CD40L expression on CD8* T cells, we determined
whether CD40L-expressing 2C cells could mature bone marrow-derived dendritic cells
(BMDCs) in vitro. 2C T cells were transduced with the CD40L Al-13 retrovirus, transitioned in
vitro into memory cells, restimulated with SIY peptide for 48hrs, and then co-cultured with
immature BMDCs (Fig. 4.4 A). Twenty-four hrs later, the maturation status of the BMDCs was
evaluated by assaying for CD80 and CD86 expression. As controls, BMDCs were cultured
alone, with control retrovirally-transduced in vitro memory 2C cells that do not express CD40L,
or with lipopolysaccharide (LPS). Approximately 15% of BMDCs expressed both CD80 and
CD86 when cultured alone, whereas -55% BMDCs expressed both markers following
stimulation with LPS. Although ~34% of BMDCs expressed both CD80 and CD86 when
cultured with 2C cells that did not express CD40L, a significantly higher percentage (-45%) of
BMDCs expressed both markers when cultured with CD40L-expressing 2C T cells (Fig. 4.4 B).
Thus, CD40L-expressing 2C cells can stimulate BMDC maturation in vitro.
We also determined if CD40L-expressing (therapeutic) 2C cells could stimulate
maturation of dendritic cells in the PDLN of TRP-SIY mice. Retrovirally-transduced in vitro
memory 2C cells begin to reexpress CD40L in the PDLN approximately 5 days after transfer
(Fig. 4.5). We therefore evaluated the maturation status of CD Il*cCDl l b* dendritic cells in the
PDLN and spleens 6 days after transferring in vitro memory 2C cells either expressing or not
expressing CD40L (Fig. 4.4 C). A comparable fraction of dendritic cells from the PDLN of mice
that received either no cells or control 2C cells expressed CD80 and/or CD86, whereas a higher
fraction of dendritic cells from the PDLN of mice that received CD40L-expressing 2C cells
expressed CD80 and/or CD86 (Fig. 4.4 C). Minimal difference was seen in the maturation of
dendritic cells in the spleens of these mice (Fig. 4.4 C). These results suggest that CD40L-
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Figure 4.4 CD40L A1-13-expressing 2C cells simulate maturation of dendritic cells in vitro
and in vivo. Schematic diagram (A) and results (B) of in vitro BMDC maturation assay.
Retrovirally-transduced in vitro memory 2C cells were generated as in Fig. 4.3 and restimulated
with SIY peptide for 48hrs. Thyl.1* transduced 2C cells were purified by cell sorting and
cultured with immature BMDCs for 24 hrs. Cells were stained for CD 11c, CD80 and CD86.
Dot plots show CD80 and CD86 expression on CD1 1c* BMDCs under the indicated conditions.
Numbers in graphs indicate the percentage of CD80*CD86* cells. Numbers below graphs
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indicate the average percentage of CD80*CD86* cells ± standard deviation (SD). Representative
data from one of at least two similar experiments are shown. P value is <0.05 when percentages
of CD80*CD86* BMDCs were compared between samples stimulated with either control 2C
cells or CD40L Al-13 2C cells. C, In vivo dendritic cell maturation. In vitro memory 2C cells
either expressing or not expressing CD40L were transferred into TRP-SIY mice. Six days later,
cells from the PDLN and spleens were pooled from 5 mice and stained for CDI Ic, CD 11b.
CD80 and CD86. Dot plots show CD80 and CD86 expression of CD11c*CD1lb* cells.
Numbers indicate the percentage of positive cells. Representative data from one of at least twc
similar experiments are shown.
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Figure 4.5 Kinetics of CD40L A1-13 re-expression by transduced 2C cells in the PDLN of
TRP-SIY mice. In vitro memory 2C cells transduced with a retrovirus expressing CD40L Al-13
were transferred into TRP-SIY mice. Three, 4 and 5 days later, cells from the PDLN were
stained for 2C TCR, CD8 and CD40L. Dot plots show CD40L versus CD8 staining profiles
gating on 2C TCR*CD8* cells.
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expressing 2C cells can stimulate dendritic cell maturation in the PDLN of TRP-SIY mice,
where they encounter tumor-derived antigen.
4.4.4 CD40L-expressing 2C cells stimulate a more robust anti-tumor T cell response
The ability of CD40L-expressing 2C cells to stimulate local DC maturation is expected to
stimulate a more robust T cell response in TRP-SIY mice. Thus, TRP-SIY mice were injected
with in vitro memory 2C cells either expressing or not expressing CD40L. or were given no
cells. Some of the TRP-SIY mice were also infected with WSN-SIY at the time of 2C cell
transfer (Fig. 4.6 A). When dendritic cells had matured locally in the PDLN, approximately 6
days after transfer (Fig. 4.4 C)., naYve Thy 1.1 High reporter 2C cells were transferred into the mice.
Since Thy L.1 expression on the reporter cells is at least a log higher than on the retrovirally-
transduced therapeutic 2C cells, the populations could be clearly differentiated. Five days later,
reporter 2C cells from the PDLN and spleens were evaluated for their ability to express IFN-y
following in vitro restimulation (Fig. 4.6 A). Without transfer of therapeutic 2C cells, only ~10%
of the reporter 2C cells from the PDLN of TRP-SIY mice were able to express IFN-y (Fig. 4.6
B). This baseline level increased to ~20% if mice were transferred with control in vitro memory
2C cells, either with or without a WSN-SIY infection. In contrast, the fraction of reporter 2C
cells that could express IFN-y increased to -40% if the mice were transferred with CD40L-
expressing 2C cells. If the mice received a WSN-SIY infection at the time the CD40L-
expressing 2C cells were transferred, up to 75% of the reporter 2C cells in the PDLN could
express IFN-y (Fig. 4.6 B). A smaller difference was observed in the percentages of reporter 2C
cells that could express IFN-y in the spleens at this timepoint, consistent with minimal effects of
CD40L-expressing 2C cells on the maturation of the dendritic cells in the spleens (Fig. 4.4 C).
No significant or consistent trends were observed in the total reporter cell numbers in the PDLN
or spleens between the different treatment groups.
By 10 days after reporter 2C cell transfer, the effector 2C cells had exited the PDLN, and
the immune response had begun to contract. Even at this timepoint, more reporter 2C cells were
able to produce IFN-y in the periphery of mice that received CD40L-expressing 2C cells than in
those that received control 2C cells (Fig. 4.7). Furthermore, 4-6 times as many reporter 2C cells
infiltrated the prostates of TRP-SIY mice that received CD40L-expressing 2C cells than those
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Figure 4.6 CD40L A1-13-expressing 2C cells stimulate a more functional anti-tumor T cell
response in TRP-SIY mice. A, Schematic diagram of experimental protocol. In vitro memory
2C cells either expressing or not expressing CD40L Al-13 were transferred into TRP-SIY mice.
As a control, some TRP-SIY mice were not injected with any in vitro memory 2C cells. The
mice were divided into two groups. One group was infected intranasally with WSN-SIY and the
other group was not infected. Six days later, naYve Thyl.lH'gh reporter 2C cells were transferred
into all mice. Five days after transfer, reporter 2C cells were analyzed for IFN.y expression. B,
Reporter 2C T cell responses. Cells from the PDLN and spleens of above treated mice were
restimulated with SIY peptide for 4hr, and then stained for Thy 1.1, CD8 and intracellular IFN-y.
Dot plots show IFN-y versus Thyl.1 staining profiles gating on Thyl.lHigh CD8* reporter 2C
cells. Numbers in graphs indicate the percentage of IFN-y* cells. Numbers below graphs
indicate the average percentage of IFN-y* cells + SD of the analyzed tissues. Representative data
from two similar experiments are shown.
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Figure 4.7 Transfer of CD40L A1-13-expressing 2C cells leads to increased infiltration of
reporter 2C cells into TRP-SIY prostates. The experimental protocol is the same as outlined
in Fig. 4.6 A, but the reporter 2C cells were analyzed 10 days after transfer. Dot plots show 2C
TCR versus Thyl.1 staining profiles gated on live cells. IFN-y versus Thyl.1 staining profiles
are gated on 2C TCR+Thyl.lHigh reporter 2C cells. Numbers in graphs indicate percentage of
positive cells in the gated region. Numbers below graphs indicate the average percentage of
positive cells in the prostate tissue 4 SD. Increased reporter cell infiltration into the prostate is
indicated by percentages of 2C TCR*Thyl .High cells.
125
0.3
4 Thy 1.1
27.6
24.51
31.21
Thy 1. 1
0.6 283
that received control 2C cells (Fig. 4.7). However, there was no difference in the ability of the
reporter 2C cells from the prostate tissue to express IFN-y.
Together, these results suggest that the transfer of CD40L-expressing therapeutic 2C cells
conditions TRP-SIY mice for more robust anti-tumor T cell responses, which can be further
enhanced by active immunization.
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4.5 Discussion
One problem that limits the efficacy of adoptive T cell therapies is rapid tolerization or
deletion of transferred tumor-reactive T cells in cancer patients. Although recent studies have
shown that younger or central memory-like CD8* T cells are more potent and persist longer than
effector memory-like T cells in the setting of ACT (44, 45), their increased requirement for
costimulatory support may heighten the influence of tolerogenic DCs on these transferred cells.
Because of its critical and natural role in DC activation, CD40 ligation has been explored to
activate tolerogenic DCs in the tumor environment. Although systemic administration of agonist
anti-CD40 antibodies has been shown to replace the need for CD4* T cell help (12-14), boost
CD8' T cell responses to tumors and break peripheral self-tolerance (15-17), there is also
evidence that it can induce immune suppression (18-21). Similarly, we found that systemic
administration of an agonist anti-CD40 antibody in TRP-SIY mice initially stimulated an anti-
tumor CD8' T cell response, but eventually led to severe immune suppression, in the context of
an influenza infection (Fig. 4.1). In addition, systemic anti-CD40 administration is associated
with significant side effects (wasting, lethargy, swelling along the abdominal aorta). The
complicated and variable outcomes of systemic CD40 ligation in immune responses emphasize
the need to induce CD40 ligation locally in the tumor tissue.
Here, we report a novel strategy to activate tolerogenic DCs by using tumor-reactive
CD8* T cells to deliver an activating CD40L signal in the tumor environment. This strategy
allows us to localize the immunostimulatory signal in both time and space. CD40L is normally
expressed on activated CD4* T cells for less than 24hrs (11), and its expression on activated
CD8' T cells is similarly transient. Because CD40L transcription is driven by a retroviral LTR
in our study, the tight regulation of CD40L expression on the surface of CD8* T cells is likely
regulated at the post-translational level. Supporting this notion, deletion of the terminal 13
amino acid residues of the cytoplasmic domain led to a higher level and extended duration of
CD40L expression on the surface of CD8' T cells. This deletion mutant is designed to minimize
receptor-mediated endocytosis, but does not likely impact other regulatory mechanisms that also
control CD40L expression, such as down regulation of CD40L transcription, proteolytic
cleavage, and release of soluble CD40 (11), and thus surface CD40L expression is still transient.
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We used in vitro memory 2C T cells to deliver CD40L to the correct location, because they
recognize a tumor-derived epitope (SIY) and naturally traffic to the TDLNs and tumor tissue.
Following adoptive transfer, only those retrovirally-transduced 2C cells that traffic to the PDLN
have the opportunity to encounter SlY and re-express CD40L. Even with truncation of the
majority of the cytoplasmic domain, CD40L is only expressed on the surface of 2C T cells for 48
to 72 hrs after activation (Fig. 4.2). Consequently, delivery of the immunostimulatory CD40L
signal is limited both spatially and temporally. This should minimize the potential autoimmune
complications and immune suppression associated with systemic CD40 ligation.
Like CD40L expressed on activated CD4* T cells, CD40L expressed on the surface of
activated CD8* T cells also stimulates maturation of DCs both in vitro and in vivo (Fig. 4.4).
Co-culture of BMDCs with CD40L-expressing 2C cells for 24hrs is sufficient to stimulate up-
regulation of CD80 and CD86 on DCs, to a similar extent as observed with LPS stimulation (Fig.
4.4 B). Similarly, transfer of CD40L-expressing 2C cells into TRP-SIY mice stimulated up-
regulation of CD80 and CD86 on some DCs in the PDLN. Despite the modest observable effect
on DC maturation in vivo, the anti-tumor CD8* T cell response was significantly enhanced, as
indicated by the increased percentage of reporter 2C cells that could produce IFN-y in the PDLN
and infiltrate the prostate tissue. The enhanced anti-tumor response was even more dramatic
when the CD40L-expressing 2C cells were activated by an influenza infection, as opposed to by
the tolerizing environment of the tumor (Fig. 4.6). Following influenza infection, a higher
fraction of retrovirally-transduced 2C T cells likely re-expressed CD40L, which simulated
maturation of more DCs in the PDLN (Fig 4.8). Thus, augmented anti-tumor T cell responses
can be induced by engineering T cells to deliver CD40L-mediated stimulatory signals to
dendritic cells in TDLNs.
There are two critical environments in which tolerance needs to be prevented or broken
for adoptive T cell transfer to be most effective: the TDLNs and the tumor itself. If tolerance is
broken in the tumor, but not in the TDLNs, adoptively transferred T cells may be tolerized upon
initial transfer. This is particularly true for central memory-like T cells that traffic through the
secondary lymphoid tissues prior to entering the tumor. If tolerance is broken in the TDLNs, but
not in the tumor, adoptively transferred T cells may be tolerized upon entering the tumor tissue.
Our approach breaks tolerance in the lymphoid tissues, but not in the tumor itself. As the
128
PDLN
CD40L A 1-13
2C cells
Control
2C cells
C CO
FSC FSC
Figure 4.8 CD40L A1-13-expressing 2C cells induce an increased number of mature
dendritic cells in the PDLN of TRP-SIY mice following administration of WSN-SIY virus.
TRP-SIY mice were injected with in vitro memory 2C cells expressing or not expressing CD40L
Al-13, followed immediately with an intranasal WSN-SIY infection. Six days later, cells from
the spleens, MLN and PDLN were pooled from 5 mice and stained for CD 11c, CD1 1b, CD80
and CD86. Dot plots show CD80 and CD86 expression of CD 11c*CD11b+ cells, and numbers
indicate percentage of positive cells in the gated region. Representative data from one of at leasi
two similar experiments are shown. Compared to non-infected mice (Fig. 4.4 C), the percentage
of DCs that expressed CD86 in the PDLN was increased if TRP-SIY mice were infected with
WSN-SIY virus.
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retrovirus-mediated CD40L expression is transient, the engineered 2C cells no longer express
CD40L when they infiltrate the tumor, approximately 7 days post transfer (39). As a result,
neither dendritic cells nor CD40-expressing tumor cells in the prostate tissue are impacted.
Thus, following transfer of CD40L-expressing therapeutic 2C cells, adoptively transferred
reporter 2C cells become productively primed in the PDLN, maintain their function in the
periphery, infiltrate the tumor tissue extensively, but become rapidly tolerized in the tumor (Fig.
4.7). Since the tumor-infiltrating T cells become tolerized, we did not evaluate alterations in
disease progression or overall survival of treated mice. To overcome tolerance in both the
TDLNs and tumor tissue, our approach needs to be combined with other approaches that break
tolerance in the tumor tissue. Alternatively, CD40L could be further engineered to achieve more
prolonged surface expression.
Recent pre-clinical and clinical studies have made significant progress in advancing the
success of adoptive cell therapy in the clinic. T cell engineering strategies may further augment
the promise of such approaches. Our study demonstrates that adoptively transferred T cells can
be engineered to deliver functional signals to dendritic cells in the tumor environment, and that
those dendritic cells can then stimulate more robust T cell responses. As we better understand
the critical role that dendritic cells play in the activation, maintenance and tolerization of T cells
in the tumor environment, similar approaches can be explored to engineer tumor-reactive CD8'
T cells to deliver important functional signals to dendritic cells to overcome tumor tolerance.
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Chapter 5
Intratumoral Injections of Antigen-Loaded Dendritic Cells Can
Refunctionalize Persisting Tumor-Infiltrating Lymphocytes in a
Spontaneous Prostate Cancer Model
5.1 Abstract
Dendritic cells play a critical role in priming, maintaining, dampening and potentially
reinvigorating anti-tumor T cell responses. Using systemic dendritic cell depletion, we
demonstrate that resident dendritic cells in the tumor are an important factor driving the
tolerization of tumor-reactive T cells in the Transgenic Adenocarcinoma of the Mouse Prostate
(TRAMP) model. In order to minimize their suppressive influence, we injected ex vivo matured,
antigen-loaded dendritic cells directly into the tumor For the first time, we show that this
mechanism-based immunotherapy can significantly delay the tolerization of tumor-infiltrating
effector T cells and reverse the tolerization of resident tumor-infiltrating lymphoyctes (TILs),
generating new potential therapeutic applications for TILs. These findings demonstrate that
dendritic cells can critically influence the immunosuppressive networks in tumors.
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5.2 Introduction
The primary objective of cancer immunotherapy is to empower the immune system to
directly destroy cancer cells. CD8* cytotoxic T lymphyocytes (CTLs) are the primary immune
cells that kill antigen-displaying target cells, so finding strategies to direct CTL activity towards
cancer cells is essential to meeting this objective (1, 2). Tumor-infiltrating lymphocytes (TILs)
have been identified in many human cancer patients, but the tumor-reactive CD8* T cell
populations are generally non-functional (tolerized) (3). One approach to use TILs for cancer
immunotherapy has been adoptive cell transfer (ACT), in which TILs are isolated from patients,
expanded ex vivo and reintroduced into patients to kill cancer cells. ACT has been successful in
treating metastatic melanoma patients, as response rates of over 50% have been achieved when
ACT is combined with patient preconditioning strategies (4-6). However, one challenge to ACT
approaches is that activated T cells can lose their function through tumor-induced tolerance, so
additional strategies are needed to help maintain the function of activated TILs as they enter
tumor environments.
Given the critical influence dendritic cells (DCs) have in determining the outcome of
anti-tumor T cell responses, they continue to be an important focus in the development of
immunotherapies. DCs are professional antigen-presenting cells (APCs) that capture, process
and present antigens and migrate to the lymphoid tissues to educate naYve T cells (7). They
detect and respond to signals from their environment, such as the local cytokine milieu, to
determine their maturation status and subsequently direct T cell function. The suppressive
microenvironment in tumors can significantly alter the maturation and differentiation of DCs.
While functional mature DCs can initiate robust anti-tumor T cell responses, DCs educated by
tumor-derived factors, such as VEGF, TGFp, IL-6, PGE2 and IL-10, are generally suppressive
(8-13). Furthermore, these tumor-derived factors can also modify the composition of distinct DC
subsets, leading to a decrease in the ratio of myeloid dendritic cells (mDCs) to plasmacytoid
dendritic cells (pDCs), the two major DC subsets found in humans (14). As pDCs can be
actively tolerogenic, they further augment the suppressive environment in tumors (14, 15).
While endogenous DCs can dampen T cell responses in tumors, DC therapy has the
potential to reinvigorate anti-tumor immune responses and challenge immunosuppressive
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networks. Intratumoral administration of DCs is one attractive route of delivery, because it
targets the tumor-specific immune response directly to the tumor and could potentially make use
of undefined or unknown tumor antigens (16). Furthermore, data suggests that few DCs
administered at distant locations ever reach the draining lymph nodes, emphasizing the
importance of intratumoral delivery (16-18). Intratumoral administration of either antigen-
loaded or unloaded DCs has led to the generation of anti-tumor immunity in mouse and rat
models. In a transplanted colorectal tumor model, injection of DCs into established tumors led
to increased immunity to tumor rechallenge following removal of the primary tumor (19).
Similarly, intratumoral administration of DCs into transplanted gliomas increased CD4* and
CD8* T cell infiltration, increased immunity to tumor rechallenge and prolonged survival (20).
The potential of intratumoral DC delivery has been demonstrated in human patients as well (21-
26). An early study with metastatic dermal or subcutaneous melanoma and breast cancer
patients showed that intratumoral administration of DCs induced tumor regression and
lymphocyte infiltration in the setting of injected tumors (21). Thus, both animal and human
studies have established the therapeutic potential of this approach.
Intratumoral administration of DCs has also been coupled with therapeutic interventions
that promote tumor cell death or increase the immunogenicity of tumor cells, thus providing DCs
with additional sources of tumor antigens. These combination therapies have included such
approaches as chemotherapy, radiotherapy and localized tumor hyperthermia (27-29). In a
transplanted colon cancer model, intratumoral DC administration alone induced partial tumor
eradication, but induced complete eradication when coupled with systemic chemotherapy (27).
Similarly, in transplated melanoma and sarcoma models, intratumoral DC delivery could inhibit
tumor growth in an additive and/or synergistic way when coupled with tumor irradiation (28),
and systemic anti-tumor immune responses could be detected. Thus, combination therapies
combining intratumoral DC administration with approaches to increase antigen availability have
broadened the potential uses of DCs.
In order to further increase their therapeutic impact, DCs have also been genetically
engineered to augment their function prior to intratumoral transfer. They have been engineered
to express proinflammatory cytokines, such as IL-12 (30, 31), IL-7 (32), IL-2 (31) and IFN-a
(33); anti-apoptotic molecules, such as Bcl-xL (34); and TNF-related ligands, such as CD40L,
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RANKL or 4-IBBL (35). These modifications have increased systemic anti-tumor immunity,
inhibited tumor cell growth and increased DC survival or function. Genetic engineering has thus
been used to augment the therapeutic impact of DCs.
There have been several important limitations to the animal studies evaluating
intratumoral delivery. First, these studies have focused on transplanted or metastatic tumor
models, which do not provide direct insight into T cell populations found in spontaneous primary
tumors; either resident tolerized TILs or tumor-reactive effector T cells that infiltrate tumors
during ACT. While intratumoral DC delivery has recently been shown to enhance the
therapeutic efficacy of ACT when coupled with radiotherapy (36), it is not clear how the kinetics
of T cell tolerance were altered in the tumor through this approach. Second, anti-tumor
immunity has generally been established through gross measurements of tumor growth, with
minimal focus on cellular mechanisms within tumors. Third, the generation of functional anti-
tumor CD4* or CD8* T cell immunity has primarily been evaluated by measuring antigen-
specific responses or effector cytokine production by T cells from the spleens or lymph nodes of
tumor-bearing animals. However, the function of T cells in the periphery can be significantly
different than the function of T cells in the inimunosuppressive environment of a tumor (37). In
order to further harness the immunostimulatory potential of intratumoral DC therapy, a better
understanding is needed of the influence DCs have on the functional state of therapeutic T cell
populations within tumors themselves.
Using a spontaneous prostate cancer model, we demonstrate that endogenous DCs in the
tumor environment are a critical factor in tolerizing tumor-infiltrating T cells. In order to
outcompete their influence, we inject ex vivo matured, antigen-loaded DCs directly into the
tumor tissue, and demonstrate that these cells can prime a robust anti-tumor T cell response in
the prostate draining lymph nodes (PDLN). However, productive initial priming is not enough to
maintain a long-term response in the tumor. Using therapeutic intraprostatic injections of ex
vivo matured, antigen-loaded DCs at timepoints following initial priming, we are able to both
delay the tolerization of tumor-infiltrating effector T cells and reverse the tolerization of
persisting tumor-resident T cells. As both of these populations are representative of TILs found
in human cancer patients, this approach has therapeutic implications to both enhance ACT and
mobilize resident TILs in situ.
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5.3 Materials and Methods
5.3.1 Mice and influenza virus
TRP-SIY mice were generated as previously reported (37). TRAMP and TRP-SIY mice
used for experiments were ~4mo old progeny of homozygous TRAMP mice crossed with
heterozygous PB-SIY mice. The 2C RAG 1-/- TCR transgenic mice (2C/RAG) were maintained
on C57BL/6 and C57BL/6 Thy 1.1 backgrounds. CD 1l c-DTR/GFP mice were maintained on a
C57BL/6 Thyl.1 background. Mice were housed in a specific pathogen-free facility, and all
experiments were performed in compliance with the guidelines outlined by MIT's Committee on
Animal Care.
As previously reported, the recombinant WSN-SIY influenza virus expressing a SIY-
neuraminidase fusion protein was generated using plasmid-based reverse genetics (38).
5.3.2 Cells, antibodies and flow cytometry
Single cell suspensions were prepared from lymphoid tissues by grinding them between
frosted glass slides and filtering the suspensions through 70gm nylon mesh. Prostate tissues
were microdissected and digested with 2gg/mL collagenase A (Roche) and 170U/mL DNase I
(Sigma-Aldrich) in RPMI 1640 plus 10% FBS for lhr at 37*C. Digested samples were then
ground between frosted glass slides and filtered through 70gm nylon mesh.
Antibodies to CD8 (53-6.7, BioLegend), Thyl.1 (Ox-7, BioLegend), Thyl.2 (53-2.1,
eBioscience), CD1I c (N418, BioLegend), PDCA-1 (eBio927, eBioscience), Gr-1 (RB6-8C5, BD
Biosciences) and B220 (RA3-6B2, BioLegend) were conjugated to FITC, PE or APC. The 2C
TCR was stained using a biotin-conjugated clonotypic 1B2 antibody detected with streptavidin-
APC (BioLegend). Stained cells were analyzed using a FACSCaliburTM instrument (BD
Biosciences), and the data was processed using FlowJoTM software (Tree Star).
Intracellular IFN-y and TNFa staining was performed using a BD Cytofix/Cytoperm Kit
(BD Biosciences). Recovered cells were restimulated with 1 pg/mL SIY peptide for 4hr at 370 C
in the presence of BD GolgiPlugT M containing brefeldin A. Surface antigens were stained, dead
cells were identified using a LIVE/DEAD@ Fixable Red Dead Cell Stain Kit (Invitrogen), and
all cells were fixed and permeabilized. Samples were then stained with a PE-conjugated anti-
IFN-y antibody (XMG1.2, BD Pharmingen) and or APC-conjugated anti-TNFa antibody (MP6-
XT22, BioLegend).
5.3.3 Adoptive transfer and influenza infection
NaYve 2C cells were isolated from the spleens and lymph nodes of 2C/RAG mice. The
red blood cells were lysed from the splenocytes, and pooled cells from the lymph nodes and
spleens were resuspended at 1-1.5x 106 cells / 100pL PBS. TRAMP and TRP-SIY mice then
received retroorbital injection of 1 00 L of 2C cell suspension.
Where indicated, mice were infected with WSN-SIY at the time of 2C cell transfer, and
received intranasal administration of I O0pfu WSN-SIY in 50ptL PBS.
5.3.4 Generation of CD1lc-DTR/GFP bone marrow chimeras and depletion of dendritic
cells
Approximately 2mo old TRP-SIY mice were lethally irradiated with 2 doses of 500rad
administered 3.5hrs apart. Mice were then reconstituted through retroorbital injection of 12x10 6
bone marrow cells from CD Il c-diphtheria toxic receptor/green fluorescent protein (CD 1l c-
DTR/GFP) mice.
Eight weeks after reconstitution, mice received retroorbital adoptive transfer of 1.5x106
naYve 2C cells and intranasal infection with 1 O0pfu WSN-SIY, as above. Six days later, mice
were or were not injected i.p. with 20ng/g diphtheria toxin (Sigma-Aldrich) in PBS. After 4
days, mice were sacrificed, and the function of 2C cells from various tissues was evaluated
through intracellular IFN-y staining, as above.
5.3.5 Generation of bone marrow-derived dendritic cells
Bone marrow was collected from the femurs of C57BL/6 mice. The red blood cells were
lysed, and the remaining cells were resuspended at 2x10 5 cells/mL in RPMI plus 10% FBS,
50ptM 2-mercaptoethanol, 4mM L-glutamine and 1OOU/mL / 100ptg/mL penicillin-streptomycin
supplemented 1:30 with the supernatant from J5 cells secreting GM-CSF. Half the media was
changed out on days 3 and 5, 1 pg/mL LPS was added on day 6, and cells were harvested on day
7. Where indicated, BMDCs were loaded with Ip g/mL SlY peptide for lhr at 37'C and/or were
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labeled for 10 min at 370 C with 5pM CFSE (Invitrogen) in PBS plus 0.1% BSA on the day of
harvest. BMDCs were rinsed and resuspended at lx106 cells / 40IL PBS for intraprostatic
injection or 1x10 6 cells / 250pL PBS for subcutaneous injection.
5.3.6 Intraprostatic and subcutaneous injections
For surgical intraprostatic injections, all supplies were sterilized prior to use. Mice were
anesthetized using Avertin. The abdominal area was shaved and then disinfected with 10% PVP
Iodine (Fisher Scientific) and ethanol. A 1cm longitudinal incision was made through the layers
of the abdomen, and the seminal vesicles, prostate tissue and bladder were exposed using sterile
cotton tipped applicators (VWR). Approximately 5x 2[tL injections of PBS, BMDCs in PBS or
1pig/mL SlY peptide in PBS were made into each lobe of the prostate. The abdominal layers
were then sutured and/or stapled closed.
For subcutaneous injections, BMDCs in PBS were injected into the loose skin below the
neck.
5.3.7 In vivo cytotoxicity assay
Syngeneic C57BL/6 Thy 1.1 splenocytes were activated on anti-CD3 coated plates in the
presence of 50U/mL IL-2 for 3 days. Activated splenocytes were then labeled for 10min at 37'C
with either 5ptM CFSE (CFSEOS) or no CFSE (CFSENeg) in PBS plus 0.1% BSA. After
washing, the CFSEP" cells were pulsed with 1p g/mL SlY peptide for 1hr at 370C. CFSEP"* and
CFSENeg cells were then mixed at a 1:1 ratio and retroorbitally injected into mice (20x 106
cells/mouse). Approximately 24hrs later, the ratio of CFSEO* to CFSE Ne cells in recovered
tissue samples was evaluated by flow cytometry.
5.3.8 Statistics
The statistical significance of data generated was analyzed using a two-tailed Student's t-
test, and P values less than 0.05 were considered significant.
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5.4 Results
5.4.1 Endogenous dendritic cells in TRP-SIY prostates are suppressive
We previously reported the generation and characterization of transgenic mice that
express the artificial antigen SIYRYYGL (SIY) in the prostate tissue, PB-SIY mice. We also
generated double transgenic TRP-SIY mice that develop spontaneous prostate cancer expressing
SlY by crossing PB-SIY mice with TRansgenic Adenocarcinoma of the Mouse Prostate
(TRAMP) mice (37). Furthermore, we have demonstrated that adoptively transferred SIY-
specific 2C T cells are rapidly tolerized in the tumor environment of TRP-SIY mice (37), and
that tolerogenic DCs in the PDLN partially mediate this tolerance (Higham, et al., 2009,
submitted).
We also wanted to investigate whether DCs in the prostate tissue itself are suppressive.
In particular, we investigated whether DCs from tumor-bearing mice express markers consistent
with a pDC phenotype. We isolated CD 11 c cells from the spleens and prostates of non-tumor-
bearing C57BL/6 mice and tumor-bearing TRAMP and TRP-SIY mice and compared the
expression of PDCA- 1, Gr- 1 and B220 on CD 1 clx" cells. There were no significant differences
in the phenotype of DCs isolated from the spleens of these mice (Fig. 5.1 A), but consistent
differences were seen in the phenotype of DCs from the prostates. There were increases in the
percentage of CD 1I ow cells expressing PDCA- 1, Gr- I and/or B220 in the prostates of TRAMP
and TRP-SIY mice relative to C57BL/6 mice (Fig. 5.1 A), suggesting that DCs from the prostates
of the tumor-bearing mice have a more suppressive phenotype.
In order to evaluate whether CD 11 c+ cells critically influence 2C cell tolerance in the
tumor tissue, we engineered chimeric CD 1 c-diphtheria toxic receptor/green fluorescent protein
(CDl lc-DTR/GFP) mice by reconstituting lethally-irradiated TRP-SIY recipients with bone
marrow from CD1 lc-DTR/GFP donors. Eight weeks after reconstitution, we dosed the CD1I1c-
DTR/GFP bone marrow transfer (BMT) mice with diphtheria toxin (DT), and demonstrated that
over 90% of the CD 11 c cells could be depleted from the spleens and prostates (Fig. 5.1 B and
C). We then used the remaining CD 1l c-DTR/GFP BMT mice for functional analyses. On day
0, we infected the mice intranasally with WSN-SIY and retro-orbitally transferred naYve 2C cells.
Six days later, we dosed half the mice with DT. On day 10, we then harvested various tissues,
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Figure 5.1 Endogenous dendritic cells in TRP-SIY prostates are suppressive. A, CD11 c'
cells were isolated from the spleens and prostates of C57BL/6, TRAMP and TRP-SIY mice by
cell sorting. Sorted cells were then stained for B220, Gr-i or PDCA-1. Dot plots are gated on
live cells. Data shown is from 5 pooled mice in each group, and is representative of at least 2
similar experiments. B, Experimental protocol for DC depletion in CD 11c-DTR/GFP BMT
mice. C, DC depletion efficiency. CD 11c-DTR/GFP BMT (spleens) or CD1 1c-DTR/GFP
(prostates) mice were or were not injected i.p. with diphtheria toxin. Two days later, mice were
sacrificed, and the composition of CD1 1cGFP* cells in the spleens and prostates was evaluated.
Dot plots show CD 11c versus GFP profiles gated on live cells. D, Results of DC depletion.
Samples were stained for 2C TCR, Thyl.1 and intracellular IFN-y. Dot plots show 2C TCR
versus Thyl.1 staining profiles gated on live cells or IFN-y versus Thyl.1 staining profiles gated
on 2C TCR*Thyl.l cells. Numbers in the upper right corner indicate percentage of positive
cells, and numbers in parentheses indicate the average percentage of positive cells ± one standard
deviation.
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and evaluated the ability of recovered 2C cells to produce IFN-y following in vitro restimulation
(Fig. 5.1 B). Depleting DCs generated no significant differences in the function of 2C cells from
the spleens, as ~55% of the cells were IFN-y< in all mice (Fig. 5.1 D). Similarly, no significant
differences were seen in the function of 2C cells from the PDLN. Following DC depletion, there
was an increase in the percentage of 2C cells that were IFN-y* in the prostates (Fig. 5.1 D).
While only 30-35% of 2C cells were IFN-y* in control mice, 45-50% of 2C cells were IFN-y*
following DC depletion (Fig. 5.1 D). Thus, DCs likely influence 2C cell tolerance in the
prostates of TRP-SIY mice.
Both the phenotypic and functional data suggest that endogenous DCs in the prostates of
TRP-SIY mice are suppressive.
5.4.2 Intraprostatic injections of antigen-loaded dendritic cells can prime a tumor-
reactive T cell response
Here, we wanted to evaluate whether intraprostatic injections of ex vivo matured,
antigen-loaded DCs could overcome the influence of dysfunctional DCs in TRP-SIY mice. We
generated and matured DCs in vitro, loaded them with SlY peptide, and surgically injected Ix106
cells directly into the prostate tissue. A control group of mice received intranasal WSN-SIY
infections for priming in place of surgery, and all mice received adoptive transfer of naive 2C
cells. Ten days later, various tissues were harvested, and the ability of recovered 2C cells to
produce IFN-y was evaluated.
Intraprostatic injections of SIY-loaded DCs led to effective priming in the PDLN, as over
70% of 2C cells were IFN-y* (Fig. 5.2). These activated 2C cells were able to exit the PDLN and
maintain their function in the periphery, and over 70% of 2C cells were IFN-y* in the spleens at
this time point. For 2C cells primed in the mediastinal lymph nodes (MLN) with a WSN-SIY
infection, over 65% of 2C cells were IFN-y* in the spleens, but the cells had already begun to be
tolerized in the PDLN. Only ~37% of 2C cells were IFN-y* in the PDLN of these control mice
(Fig. 5.2). There were no significant differences in the functionality of 2C cells in the prostates
of mice that received intranasal WSN-SIY infection versus those that received intraprostatic
injections of SIY-loaded DCs. In both cases, only -27% of the cells were IFN-y* (Fig. 5.2).
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Figure 5.2 Intraprostatic injections of antigen-loaded dendritic cells can prime a tumor-
reactive T cell response when administered as a vaccine, but do not break tolerance in the
tumor. On day 0, TRP-SIY mice received adoptive transfer of naYve 2C cells and either
intranasal infection with WSN-SIY or intraprostatic injections of ex vivo matured, SIY-loaded
DCs. On day 10, mice were sacrificed, and 2C cells were evaluated for IFN-y expression
following in vitro restimulation. Samples were stained for 2C TCR, Thyl.1 and intracellular
IFN-y. Dot plots show 2C TCR versus Thyl.1 staining profiles gated on live cells or IFN-y
versus Thy 1.1 staining profiles gated on 2C TCR*Thy1.1+ cells. Numbers indicate percentage of
positive cells. Data is representative of at least 2 similar experiments.
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Despite the fact that SIY-loaded DCs were injected directly into the prostates, tumor-infiltrating
2C cells were still rapidly tolerized.
Thus, intraprostatic injections of SIY-loaded DCs could prime a productive anti-tumor
response, but could not break tolerance in the tumor tissue when administered as a priming
vaccine.
5.4.3 Intraprostatic injections of antigen-loaded dendritic cells can delay the tolerization
of tumor-infiltrating T cells
More importantly than priming a tumor-specific T cell response, we wanted to
demonstrate that SIY-loaded DCs could delay the tolerization of tumor-infiltrating effector 2C
cells. For these experiments, on day 0, we adoptively transferred naYve 2C cells and infected
TRP-SIY mice with WSN-SIY. Seven days later, as the 2C cells infiltrated the prostate tissue
(37), we surgically injected either PBS or 1x106 ex vivo matured, SIY-loaded DCs into the
prostates. On days 11, 13, 15, and 20, we then harvested various tissues and evaluated the ability
of recovered 2C cells to produce IFN-y (Fig. 5.3 A).
For TRP-SIY mice that received intraprostatic injections of PBS, the 2C cells in the
prostate tissue were tolerized at all timepoints evaluated, as only 25-30% of cells were IFN-y*
(Fig. 5.3 B). Tolerization was significantly delayed in mice that received intraprostatic injections
of SIY-loaded DCs, though. On days I1 and 13, between 50-60% of 2C cells in the prostate
tissue were IFN-y*, and on day 15, still over 45% of 2C cells were IFN-y*. By day 20, the
function of 2C cells in the prostate tissue was significantly decreased, and less than 25% of 2C
cells were IFN-y* (Fig. 5.3 B).
In order to better understand the parameters necessary to break tolerance, we evaluated
whether intraprostatic injections of either SLY peptide alone or ex vivo matured, unloaded DCs
alone would be sufficient to delay the tolerization of tumor-infiltrating 2C cells. On day 0, we
adoptively transferred naYve 2C cells into TRAMP and TRP-SIY mice and infected them
intranasally with WSN-SIY. Seven days later, we surgically injected either PBS, SLY peptide in
PBS or ex vivo matured, unloaded DCs into the prostate tissue. On day 11, we then harvested
the prostates and evaluated the ability of recovered 2C cells to produce IFN-y. We have
previously shown that the baseline tolerization of 2C cells in the prostates of TRAMP mice is
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Figure 5.3 Intraprostatic injections of antigen-loaded dendritic cells can delay the
tolerization of tumor-infiltrating T cells when administered as a therapeutic. A,
Experimental protocol and B, results for therapeutic intraprostatic injections during a primary
response. 2C cells were evaluated as in Fig. 5.2. Data shown is from prostate tissue, and is from
at least 3 similar experiments. C, SIY peptide and unloaded DC controls. On day 0, TRAMP
and TRP-SIY mice were given adoptive transfer of naive 2C cells and intranasal infection wit'
WSN-SIY. On day 7, mice received intraprostatic injections of either PBS, SIY peptide in PBS
or ex vivo matured, unloaded (empty) DCs. On day 11, mice were sacrificed, and 2C cells were
evaluated as in Fig. 5.2. Data shown is from prostate tissue, and is from at least 2 similar
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experiments. D, DC localization. On day 0, DCs were labeled with CFSE, loaded with SlY and
injected into the prostates of TRAMP mice. On days 3 and 8, mice were sacrificed, and the
composition of CFSE-positive cells was evaluated in various tissues. Dot plots show CD11c
versus CFSE profiles gated on live cells. Representative data from 2-3 mice per group is shown.
Numbers in the upper right corner indicate percentage of positive cells, and numbers in
parentheses indicate the average percentage of positive cells ± one standard deviation. *P values
<0.05 when compared to control.
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less than in TRP-SIY mice (37). Here, ~ 45% and -29% of 2C cells in the prostates of TRAMP
and TRP-SIY mice respectively were IFN-y* following the injection of PBS (Fig. 5.3 C).
Injecting SlY peptide into the prostates of TRAMP mice drove further tolerization of 2C cells in
-60% of mice, resulting in only ~30% of 2C cells being IFN-y* (Fig. 5.3 C, Fig. 5.4). Injecting
SlY peptide into the prostates of TRP-SIY mice had no significant impact (Fig. 5.3 C).
Interestingly, injecting ex vivo matured, unloaded DCs into the prostates of TRAMP mice had no
significant impact, while the same treatment helped to partially maintain the function of 2C cells
in the prostates of TRP-SIY mice (Fig. 5.3 C). Approximately 35% of 2C cells were IFN-y* in
the prostates of TRP-SIY mice following injection of ex vivo matured, unloaded DCs (Fig. 5.3
C).
We also evaluated the localization, migration and survival of injected DCs over time. In
particular, we injected ex vivo matured, CFSE-labeled DCs into the prostates of TRAMP mice,
and monitored their localization over time. Three days after injection, the majority of DCs were
in the prostate tissue, a fraction of DCs had drained to the PDLN, but no DCs were detected in
the peripheral lymph nodes (PLN) or spleens (Fig. 5.3 D). By 8 days after injection, few DCs
could be detected. The majority of surviving DCs were still in the prostate tissue, with a small
number of DCs in the PDLN (Fig. 5.3 D). The localization and survival of the DCs is therefore
consistent with the localization and kinetics of the therapeutic impact.
Our data suggests that intraprostatic injections of ex vivo matured, SIY-loaded DCs can
significantly delay the tolerization of tumor-infiltrating 2C cells during a primary response.
5.4.4 Intraprostatic injections of antigen-loaded dendritic cells can reverse the
tolerization of tumor-infiltrating and persisting T cells
We previously demonstrated that a significant population of tolerized 2C cells persists
long-term in the prostates of TRP-SIY mice, but had been unable to generate a robust recall
response (37). Here, we wanted to determine if intraprostatic injections of SIY-loaded DCs
could refunctionalize persisting tolerized 2C cells to generate a recall response. On day 0, we
transferred naYve 2C cells into TRAMP and TRP-SIY mice and infected them with WSN-SIY.
Thirty days later, we then injected PBS or ex vivo matured, SIY-loaded DCs into the prostate
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Figure 5.4 Injection of SIY peptide in PBS further tolerizes 2C cells in some TRAMP
prostates. Same experimental protocol as Fig. 5.3 C for injection of SIY peptide in PBS. Data
shown is from prostate tissue, and samples with IFN-y production comparable to and below the
average for PBS control mice are as marked. Numbers in the upper right corner indicate
percentage of positive cells. Data is from 2 similar experiments.
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tissue. On days 35, 37 and 40, we harvested various tissues and evaluated the ability of
recovered 2C cells to produce IFN-y (Fig. 5.5 A).
By day 35, there had been approximately a 3-fold expansion of 2C cells in the prostates
of TRP-SIY mice that received intraprostatic injections of SIY-loaded DCs, and a significant
recovery in their ability to produce IFN-y (Fig. 5.5 B). While only ~20% of 2C cells were IFN-y*
in the prostates of mice that received intraprostatic injections of PBS, ~45% of 2C cells were
IFN-y* in mice that received intraprostatic injections of DCs (Fig. 5.5 B). These cells showed a
similar increase in their ability to produce TNFa (Fig. 5.5 C). By 5 days after surgery, there was
also a dramatic increase in inflammatory infiltrates into the tissue (Fig. 5.5 D). In order to
refunctionalize the tumor-infiltrating lymphocytes on day 30, the SIY-loaded DCs had to be
injected directly into the prostate tissue. Injecting the same cells subcutaneously generated no
significant recall response or recovery in the ability of persisting 2C cells to produce IFN-y (Fig.
5.5 E). The recall response was even more dramatic in the prostates of TRAMP mice. By day
35, intraprostatic injections of SIY-loaded DCs generated approximately a 20-fold expansion of
2C cells in the prostate tissue, and -60% of those cells were IFN-y* (Fig. 5.5 F)
Not only had persisting 2C cells reacquired the ability to produce effector cytokines, but
they also reacquired the ability to kill antigen-displaying target cells in the tumor, as
demonstrated through an in vivo CTL assay. On day 35, 2C cells killed minimal target cells in
the prostates of TRP-SIY mice that received intraprostatic injections of PBS, while 2C cells
killed over 60% of target cells in the prostates of mice that received intraprostatic injections of
SIY-loaded DCs (Fig. 5.5 G).
On day 37, over 50% of 2C cells were still IFN-y* in the prostates of TRP-SIY mice that
received intraprostatic injections of SIY-loaded DCs. The therapeutic effect decreased
significantly by day 40, when the function of 2C cells had returned to the baseline level of
tolerance (Fig. 5.5 B).
This data demonstrates that intraprostatic injections of SIY-loaded DCs can reverse the
tolerization of tumor-infiltrating and persisting 2C cells in both TRAMP and TRP-SIY mice,
generating a recall response with no ex vivo manipulation of the T cells.
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Figure 5.5 Intraprostatic injections of antigen-loaded dendritic cells can reverse the
tolerization of persisting tumor-infiltrating lymphocytes. A, Experimental protocol and B,
results for therapeutic intraprostatic injections to generate a recall response. 2C cells were
evaluated as in Fig. 5.2. Data shown is from prostate tissue, and is from at least 2 similar
experiments. C, Similar protocol as A, but samples were stained for Thyl.1 plus intracellular
IFN-y and TNFa. Dot plots show IFN-y versus TNFa staining profiles gated on Thy1.1* cells.
Data shown is from prostate tissue on day 35. Numbers indicate percentage of positive cells. D,
Hematoxylin and eosin stained prostate tissue samples from 5 days after surgery. Scale bar
represents 100m. E, Subcutaneous injection of DCs. On day 0, TRP-SIY mice received
adoptive transfer of naYve 2C cells and intranasal infection with WSNSIY. On day 30, mice
were injected subcutaneously with ex vivo matured, SIY-loaded DCs. On day 35, 2C cells were
evaluated as in Fig. 5.2. Data shown is from prostate tissue. F, Same experiment as A, but
performed with TRAMP mice. Data shown is from prostate tissue on day 35. G, In vivo CTL
assay. In vitro activated C57BL/6 Thyl.1 splenocytes were labeled with CFSE (CFSEPO') or not
(CFSNeg). CFSEOs cells were pulsed with SIY peptide, and CFSE's and CFSEe cells were
then mixed at a 1:1 ratio and retroorbitally injected into TRP-SIY mice. The following day, mice
were sacrificed, and the composition of CFSEF's and CFSNeg cells was evaluated. CFSE
histograms are gated on live Thyl.1* cells. Data is representative of at least 2 similar
experiments. Numbers in the upper right corner indicate percentage of positive cells. Numbers
below the panels indicate the total number of 2C cells ± one standard deviation (x10 4) or the
average percentage of positive cells ± one standard deviation. *P values <0.05 when compared
to control.
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5.5 Discussion
Our data highlights the critical role DCs play in priming, maintaining and reinvigorating
anti-tumor T cell responses. Immature or abnormally differentiated DCs can induce regulatory T
cells (39) and lead to the tolerization of naYve (40-42) and effector T cells (43). Our data
demonstrates that endogenous DCs in the tumor environment of TRP-SIY mice can tolerize both
naYve and effector T cells as well. We have previously shown that DCs in the PDLN can tolerize
naYve 2C cells ((37) and Higham, et al., 2009, submitted). Here, we use CDt lc-DTR/GFP BMT
mice to demonstrate that DCs in the prostate tissue can also tolerize productively-primed effector
2C cells (Fig. 5.1 D). Systemic depletion of DCs augmented the effector functions of 2C cells in
the prostate tissue (Fig. 5.1 D), suggesting that endogenous DCs exert a critical influence in
inducting effector T cell tolerance. Shafer-Weaver, et al., also recently demonstrated that tumor-
resident DCs are important to the immunosuppressive environment of TRAMP tumors (44).
Based on the suppressive influence of endogenous DCs, we designed a mechanism-based
therapeutic intervention to break T cell tolerance by injecting ex vivo matured, SIY-loaded DCs
directly into the tumor tissue. Our results have overcome several important limitations of
previous animal studies evaluating intratumoral DC administration. First, since TRAMP and
TRP-SIY mice develop spontaneous prostate tumors, we were able to evaluate T cell populations
representative of those found in spontaneous primary tumors in human cancer patients. These
include activated effector T cells that infiltrate tumors during ACT, as well as persisting,
tolerized TILs. Second, we directly explored the cellular mechanisms mediated by intratumoral
DC delivery, in the tumor itself rather than in the peripheral tissues. Our results demonstrate that
intratumoral DC delivery can delay the tolerization of effector T cells infiltrating the prostates of
TRP-SIY mice (Fig. 5.3 B), suggesting this approach could increase the function of effector T
cells infiltrating tumors during ACT. Importantly, intratumoral DC delivery could also
refunctionalize a fraction of persisting, tolerized 2C cells in TRP-SIY tumors, leading to a 3-fold
expansion of the cells and a recovery in their ability to produce effector cytokines and kill
antigen-displaying target cells (Fig. 5.5). Thus, intratumoral DC delivery could reverse the
tolerization of TILs directly in the tumor and surrounding healthy tissue. Such refunctionalized
TILs could potentially be used to help address residual disease following surgical excision of a
solid tumor, providing another therapeutic application for TILs. The augmented T cell function
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observed within the tumor tissue was likely due to healthy DCs providing antigen in the presence
of appropriate costimulatory and cytokine support. To our knowledge, this is the first time
intratumoral DC administration has been directly demonstrated to both overcome the influence
of endogenous suppressive DCs and to delay and reverse T cell tolerance.
The kinetics of the therapeutic response following intratumoral DC delivery are
consistent with the localization and lifetime of the injected DCs. The DCs are localized to the
prostate tissue and PDLN, and by day 8, the majority of these have died (Fig. 5.3 D), leading to a
decrease in the therapeutic impact. The T cell response was thus maintained as long as the
healthy injected DCs survived in the tissue (Fig. 5.3 and 5.5). These results suggest that
engineering DCs for prolonged survival, such as through expression of Bcl-xL (34), might
further increase their therapeutic impact.
We and others have previously reported that effective initial priming is not enough to
maintain a long-term anti-tumor T cell response in this model (37, 45). Here, we show that
intraprostatic injections of SIY-loaded DCs can generate robust priming in the previously
tolerizing PDLN. The effector 2C cells can exit into the periphery, but are rapidly tolerized in
the prostate tissue (Fig. 5.2). These 2C cells enter the prostate 5-7 days after activation (37), and
since the lifetime of mature DCs is also on the order of days (46), infiltrating 2C cells receive
minimal therapeutic impact from the injected DCs. These results emphasize how critical it is to
evaluate T cell function directly in the tumor tissue. While 2C cells in the PDLN and spleens
were highly functional at 10 days post transfer, those in the tumor tissue itself where tolerized
(Fig. 5.2).
Our experiments evaluating the ability of either inflammation, SlY peptide or ex vivo
matured, unloaded DCs alone to delay the tolerization of tumor-infiltrating 2C cells further
highlight the important influence DCs have in determining the balance between function and
tolerance for effector T cells. By injecting SIY peptide directly into prostates, it can theoretically
be presented by endogenous DCs. Our data shows that in TRAMP mice, where no other source
of SIY antigen is available, this can drive further tolerization of infiltrating 2C cells (Fig. 5.3 C
and 5.4). Conversely, in TRP-SIY mice, injecting SIY peptide alone has no additional effect, as
antigen is already being presented by endogenous DCs. Injecting healthy, ex vivo matured,
unloaded DCs has no impact on the tolerization of 2C cells in TRAMP prostates. In TRP-SIY
159
prostates, where the DCs can potentially acquire local antigen, ex vivo matured, unloaded DCs
partially maintain the function of infiltrating 2C cells (Fig. 5.3 C). This data suggests that even
in the absence of previously identified tumor antigens, unloaded DCs could acquire relevant
antigens in tumors to help maintain the function of infiltrating T cells. Thus, the nature of DCs
presenting antigen can determine the balance between maintaining function or driving tolerance
for tumor-reactive effector T cells in tumor tissue.
Significant work still needs to be done to identify the optimal signals delivered by DCs to
either delay tolerization of effector T cells or refunctionalize persisting tolerized T cells.
Different DC subsets offer unique cytokine and costimulatory support that can significantly
impact T cell function and differentiation (47). For example, Mailliard, et al., have shown that a-
type-I polarized DCs are highly effective at generating anti-tumor CTLs in vitro (48), adding to
previous research on the importance of proinflammatory mediators in producing strongly
activating DCs (47). Thus, optimal DC culture conditions need to be identified to generate the
most potent therapeutic DC populations for previously tolerized T cells. As the critical
costimulatory and cytokine signals continue to be identified, DCs engineered using lentiviral or
retroviral systems may provide a source of consistently effective cells. Furthermore, using
engineered DCs, costimulatory and cytokine systems could be established that surpass natural
DC support, such as combinations of CD40, CD80, CD86, CD137L (4-lBBL), CD252 (Ox4OL),
IL-2, IL-7 and/or IL-15. Engineered DCs could therefore be optimized to stimulate TILs in situ.
As the tolerized, persisting tumor-infiltrating T cells refunctionalized here are representative of
TILs found in human cancer patients, such approaches may have significant clinical impact.
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Chapter 6
Conclusions and Future Directions
In order to elucidate factors necessary to induce, maintain and promote a productive CTL
response against cancer, this research has focused on exploring the interactions between CD8* T
cells and the immunosuppressive networks within tumors. In particular, we have demonstrated
that tumor-reactive CD8* T cells are tolerized in the tumor environment of a spontaneous
prostate cancer model, the TRAMP model, demonstrated that tumor-resident dendritic cells are
an important factor in inducing tolerance, and designed two novel immunotherapeutic
approaches to minimize the suppressive influence of those dendritic cells.
In the first part of this research, Dr. Ailin Bai developed a model for CTL recognition of
prostate cancer in spontaneous tumors. In this model, called TRP-SIY, TRAMP mice have been
engineered to express the nominal CD8* T cell epitope SLY in the prostate tissue, allowing
characterization of the functional response of SIY-specific 2C T cells in the tumor environment.
In the absence of vaccination, we demonstrated that adoptively transferred naYve 2C cells
proliferated in the PDLN, but did not acquire the ability to produce effector cytokines or
infiltrate the prostate tissue, suggesting the cells had not been productively activated. Following
intranasal vaccination with WSN-SIY, 2C cells were robustly activated in the MLN. They
proliferated rapidly, acquired the ability to produce effector cytokines and kill antigen-displaying
target cells, and infiltrated the prostate tissue extensively. Interestingly, naYve 2C cells were
simultaneously tolerized in the PDLN of the same animals, highlighting the critical influence the
local environment can have in determining the functional state of T cells following antigen
recognition. Despite robust initial priming in the MLN, effector 2C cells that infiltrated the
prostates of TRP-SIY mice were rapidly tolerized, losing their ability to produce effector
cytokines. These tolerized 2C cells then persisted long-term in tumors. This data demonstrates
that both naive and effector 2C cells are rapidly tolerized in the tumor environment of TRP-SIY
mice.
The tolerized antigen-specific T cells that persist in TRP-SIY prostates are consistent
with TILs identified in solid tumors from cancer patients (1, 2). As observed in our model, these
TILs are generally non-functional (2). The molecular mechanisms inducing the tolerization of
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TILs and driving their long-term persistence in tumors have not been well characterized. In the
second part of this research, we used the TRP-SIY system to explore potential mechanisms
leading to the tolerization of TILs and to rationally design immunotherapeutic interventions to
break tolerance, in an effort to help address one of the major challenges facing cancer
immunotherapy.
Through a survey analysis, we identified several mechanisms of tolerance as being
unlikely to exert a dominant influence during the early stages of tumor development in the TRP-
SlY model. These mechanisms included direct deletion of tumor-reactive T cells, decreased
antigen processing and presentation, ignorance, immunosuppressive cytokines (TGF-p),
regulatory T cells and myeloid-derived suppressor cells. Importantly, our data established that
dendritic cells are primary mediators of 2C cell tolerance in the PDLN and prostates of TRP-SIY
mice. Dosing mice systemically with anti-CD40, to mature dendritic cells non-specifically,
enabled 2C cells to acquire and maintain the ability to produce IFN-y in the PDLN for a period
of time. Furthermore, depleting endogenous dendritic cells from TRP-SIY mice, following
productive initial priming, promoted the function of effector 2C cells in the prostate tissue. A
more significant fraction of those 2C cells maintained the ability to produce IFN-y following
dendritic cell depletion. Endogenous dendritic cells in the prostates of tumor-bearing TRAMP
and TRP-SIY mice also had a more suppressive phenotype than those from non-tumor-bearing
C57BL/6 mice. This data all suggests that dendritic cells are critical factors in tolerizing both
naYve and effector 2C cells in the tumor environment of TRP-SIY mice.
After establishing dendritic cells as important mediators of tolerance, we developed two
localized approaches to interrupt their suppressive influence. Our first strategy was to engineer
2C cells to express CD40L to mature dendritic cells in the PDLN. As tumor-reactive CD8' T
cells naturally traffic to and accumulate in the tumor environment, they were used to deliver
functional signals to local dendritic cells. Our second approach was to directly inject ex vivo
matured, SIY-loaded dendritic cells into the prostate tissue to overcome the influence of
endogenous suppressive dendritic cells. This was used to both delay the tolerization of effector
T cells and reverse the tolerization of persisting T cells.
We demonstrated that systemic CD40 ligation can lead to significant immune
suppression under certain conditions, motivating our efforts to localize this signal. In the natural
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course of CD4* T cell activation, CD40L is transiently expressed and tightly regulated. In order
to increase the immunostimulatory potential of CD40L, we therefore engineered a mutant
CD40L protein that displayed higher expression levels and longer expression kinetics on the
surface of CD8' T cells. This mutant lacks the majority of its cytoplasmic domain, which likely
minimizes receptor-mediated endocytosis, enabling altered expression characteristics. We
demonstrated that adoptive transfer of 2C cells engineered to express the mutant CD40L induced
maturation of dendritic cells in the PDLN and augmented the function of adoptively transferred
naYve 2C cells. These findings establish for the first time that enhanced T cell responses can be
achieved by engineering tumor-reactive T cells to deliver stimulatory signals to dendritic cells in
the tumor environment. Thus, prior to adoptive transfer, TILs could potentially be engineered to
carry and deliver signals to interrupt tolerizing mechanisms.
The influence of endogenous dendritic cells could also be overcome by outcompeting
them with healthy dendritic cells. Injecting ex vivo matured, SIY-loaded dendritic cells directly
into TRP-SIY prostates enabled us to evaluate the influence of dendritic cells on T cell
populations that are representative of those found in human primary tumors. These include
activated T cells that infiltrate tumors during ACT, as well as long-term, persisting, tolerized
TILs. We demonstrated that intratumoral dendritic cell delivery could delay the tolerization of
effector T cells infiltrating TRP-SIY prostates, suggesting this approach could increase the
function of effector T cells infiltrating tumors during ACT, and thus potentially increase their
therapeutic efficacy. Furthennore, intratumoral dendritic cell delivery could refunctionalize a
fraction of persisting, tolerized 2C cells in TRP-SIY tumors, leading to a significant expansion of
the cells and a recovery in their ability to produce effector cytokines and kill antigen-displaying
target cells within tumors. Thus, intratumoral dendritic cell delivery could reverse the
tolerization of TILs in situ, providing another strategy to increase the therapeutic impact of TILs.
The augmented T cell function within tumors was most likely a result of healthy dendritic cells
providing antigen in the presence of effective costimulatory and cytokine support. To our
knowledge, this is the first time intratumoral dendritic cell administration has been directly
demonstrated to both overcome the influence of endogenous suppressive dendritic cells and to
delay and reverse the tolerization of T cells in the tumor tissue.
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Most animal studies evaluating immunotherapeutic approaches have used transplanted
tumors, which differ in important ways from the spontaneously developed tumors in cancer
patients (3-5). Therefore, in recent years, an increasing number of transgenic mouse models
have been engineered to spontaneously develop cancer. These models have largely been
developed using one of three strategies: 1) expression of either a tissue-specific oncogene or
SV40 T antigen controlled by a tissue-specific promoter, 2) targeted deletion of tumor suppressor
genes, or 3) conditional activation of oncogenes or deletion of tumor suppressor genes through
Cre-lox regulation (5).
TRAMP mice were engineered through tissue-specific expression of SV40 T antigens
(6). Models for breast cancer, ovarian cancer, pancreatic cancer and melanoma have also been
developed using similar approaches (strategy 1) (5). The tumor-specific immune responses
observed in these mice have varied greatly depending on the tissue in which the tumor forms, the
type of tumor and the antigen expressed. In an SV40 T antigen-driven pancreatic tumor model
expressing HA, naYve tumor-reactive T cells rapidly lose the ability to produce IFN-y, kill
antigen displaying target cells and respond to rechallenge (7). In a TGF-a/Trp53---driven
pancreatic tumor model, in vitro stimulated, tumor-reactive T cells exhibit an impaired ability to
infiltrate spontaneous tumors (8). While the first observation is consistent with our results in the
TRP-SIY model, the second is not. Interestingly, in a cNeu-driven mammary tumor model
expressing tERK, naive tumor-reactive T cells activated in vivo using an antigen-specific
vaccination survive long-term and can delay the development of spontaneous tumors. This
suggests that the tumor-specific T cells maintain their function in vivo for a significant period of
time (9), also in contrast to our observations.
Conditional activation of oncogenes or deletion of tumor suppressor genes through Cre-
lox regulation (strategy 3) has increased the potential for using mouse models to evaluate
immunotherapeutic approaches. In these inducible models, antigen expression is tightly
controlled, and the responses of both endogenous and transferred T cells can be more thoroughly
evaluated. In a Kras-induced lung tumor model expressing SIY, naYve 2C cells recognize SlY in
the tumor draining lymph nodes, infiltrate lung tissue, but do not infiltrate SIY-expressing
tumors or persist (10). Activated 2C cells also exhibit reduced cytotoxic potential. The findings
with both naYve and effector 2C cells are consistent with our findings in the TRP-SIY model.
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Similarly, in a c-myc-induced liver tumor model expressing OVA, naYve OT I cells infiltrate the
liver, but do not express IFN- 7 or exhibit cytotoxic killing (11). Observations made from these
recent spontaneous tumor models suggest that tumor-specific immune responses must be
evaluated in the context of the tissue, tumor and antigen environment, as the responses induced
can vary significantly.
Our research has helped to understand the influence of tumor-resident dendritic cells on
TILs, and has outlined novel strategies to minimize their influence. However, there are still
many outstanding questions to explore through future work with this system to continue
optimizing the design of immunotherapeutic interventions. First, additional research should
evaluate how the immunosuppressive network within TRP-SIY tumors changes with disease
progression. Our research has focused on tolerizing mechanisms during the early stages of
tumor development, but as tumors continue to evolve, the dominant suppressive mechanisms
may change as well (12). Research exploring the temporal relationship between
immunosuppressive mechanisms should continue to inform therapy development.
As our work has established that dendritic cells are important mediators of T cell
tolerance in TRP-SIY tumors, it would now be interesting to assess the suppressive mechanisms
used by those dendritic cells. Tolerization is antigen-specific in our model, as 2C cells are not
tolerized to the same extent in TRAMP prostates as in TRP-SIY prostates (Fig. 2.4), despite the
fact that the dendritic cells display a comparable suppressive phenotype in the two models (Fig.
5.1 A). It is possible that chronic SLY presentation on dendritic cells in TRP-SIY tumors simply
drives proliferation to the point of 2C cell exhaustion. Although, data demonstrating that
intratumoral injections of ex vivo matured, SIY-loaded dendritic cells helps to maintain the
function of effector 2C cells (Fig. 5.3 B) refutes this possibility. It is more likely that antigen
recognition in the context of a second suppressive signal drives tolerization. This second signal
could be a soluble factor, such as TGF-p, IL- 10 or nitric oxide, or an inhibitory surface molecule,
and it could be delivered by the dendritic cells themselves, tumor cells or other cell populations
within the tumor environment (12). However, our data suggests that TGF-p is not acting directly
on 2C cells (Fig. 3.1). Additional research should elucidate the molecular mechanisms by which
dendritic cells in TRP-SIY tumors are suppressive.
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One limitation to our strategy of engineering tumor-reactive CD8' T cells to express
CD40L to mature dendritic cells in the tumor environment is that it only addresses tolerization in
the TDLN. Since CD40L expression is transient, the tumor-reactive CD8' T cells no longer
express CD40L when they infiltrate tumors. Further engineering of CD40L could potentially
generate mutants with even longer expression kinetics, ensuring the protein is still expressed as
CD8' T cells enter tumors. It would be interesting to explore how local expression of CD40L in
tumors would impact both tumor-resident dendritic cells and CD40-expressing tumor cells. This
could also be evaluated by surgically injected CD40L-expressing T cells into tumors. Thus,
research to engineer CD40L-expressing tumor-reactive T cells could be expanded to explore the
impact of such therapeutic cells in tumor tissue.
Our data confirms that intratumoral injections of dendritic cells have significant potential
to augment immunotherapeutic responses. In order to fully realize this potential, a more
comprehensive understanding is needed of the costimulatory and cytokine signals required to
delay or reverse T cell tolerance. The costimulatory requirements for dendritic cells to activate
or tolerize naYve T cells have been well characterized. Less is known about the costimulatory
requirements to maintain function or tolerance for effector T cells (13), but virtually nothing is
known about the costimulatory requirements for previously tolerized T cells. Dendritic cells
could be engineered, using lentiviral or retroviral systems, to express different combinations of
costimulatory molecules and cytokines to establish the most potent conditions to refunctionalize
T cells. Using engineered dendritic cells, costimulatory and cytokine systems could be
established that surpass natural dendritic cell support, such as combinations of CD40, CD80,
CD86, CD137L (4-1BBL), CD252 (OX40L), IL-2, IL-7 and/or IL-15. The costimulatory
molecules 4-1BBL and OX40L interact with the TNF receptor family members 4-11313 and
OX40, respectively, on the surface of activated T cells, promoting T cell function (14-16).
Similar to strategies used for artificial antigen presenting cells (aAPCs) in vitro (15), dendritic
cells could also be exogenously loaded with stimulatory antibodies, such as anti-CD3, prior to
intratumoral injection. Thus, engineered dendritic cells could be used to both characterize and
deliver the optimal signals to refunctionalize TILs in situ.
Our immunotherapy work to date has focused on characterizing the antigen-specific
CD8+ T cell response in TRP-SIY mice before and after treatment. An important next step will
be to evaluate how these therapeutic interventions impact disease progression. One strategy to
monitor disease progression would be to weigh the genitourinary (GU) tracts of treated and
control animals. The lower GU tract, including the bladder, seminal vesicles and prostate, would
be removed and weighed for each animal to capture significant destruction of tumor cells in
prostates through decreases in overall weight (17). The challenge of this approach is that since
individual animals cannot be monitored before and after treatment, and there are significant
stochastic differences in tumor growth, large cohorts of mice would be needed to determine
statistically significant differences in disease progression. It is estimated that approximately 25
mice per cohort would be required to establish statistically significant 15% differences in tumor
size (18). An alternative strategy would be to use magnetic resonance imaging (MRI)
technology to follow tumor progression in individual animals before and after treatment, to
reduce the challenges of cohort size. It has already been established that MRI can be used to
both stage tumors and follow their progression in TRAMP mice (19). Beyond enhancing and
reinvigorating the immune response to tumors, establishing alterations in disease progression
would further increase the clinical potential of this work.
Through this research, we have evaluated factors involved in inducing, maintaining,
dampening and promoting antigen-specific CD8* T cell responses in a tumor environment. We
have demonstrated that tumor-reactive CD8* T cells are tolerized in the tumor and TDLN of
TRP-SIY mice, and have established that tumor-resident dendritic cells are critical in inducing
that tolerance. We have also developed two novel immunotherapeutic approaches to overcome
suppression mediated by dendritic cells: 1) engineering tumor-reactive CD8* T cells to express
CD40L to mature dendritic cells in the TDLN and 2) directly injecting ex vivo matured, antigen-
loaded dendritic cells into tumors to overcome the influence of endogenous suppressive dendritic
cells. These two approaches establish that immunotherapeutic interventions can be rationally
designed to locally overcome tolerizing mechanisms within tumors. Ultimately, combination
therapies addressing multiple tolerizing mechanisms simultaneously may be the most effective
approaches to generating robust long-term immune responses in rapidly evolving tumor
environments.
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Appendix A
Details for Protocols of Interest
A.1 Intracellular IFN-y Staining
Processing of lung samples:
1. Process through metal cell strainer.
2. Filter through 70ptm nylon mesh.
3. Spin down. Discard supernatant.
4. Resuspend in 2mL red blood cell lysis buffer.
5. Leave on ice for 5min.
6. Dilute with 8mL RPML + 5% FBS.
7. Resuspend the cells in 2mL serum-free RPMI plus Img/mL collagenase A.
8. Leave in a 37 C waterbath for lhr.
9. Dilute with 8mL RPMI + 5% FBS and leave on ice.
10. Count.
Processing of prostate samples:
1. Prepare master mix of lmg/mL collagenase A and 175U/mL DNase I in serum-free RPMI.
Place microdissected prostate samples in 15mL tubes with 2mL master mix each.
2. Leave in a 37'C waterbath for lhr.
3. Dilute with 8mL RPMI + 5% FBS and leave on ice.
4. Grind with glass slides.
5. Filter through 70ptm nylon mesh.
6. Count.
Restimulate 2C cells ex vivo:
1. Prepare a master mix of media plus GolgiPlug (with Brefeldin A, BD Biosciences) plus SlY
peptide. Add 1 pL GolgiPlug and 1 lpg SlY per mL of media.
2. Resuspend each sample (~2x 106 cells) in 160ptL master mix, and transfer to a 96 well plate.
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3. Incubate for 4hrs at 37'C.
Prepare samples for FACS analysis:
1. Harvest cells into individual FACS tubes.
2. Spin down and discard supernatant.
3. Add 100ptL master mix consisting of FACS buffer and a 1:100 dilution of F, block.
4. Resuspend and leave on ice for 1 0min.
5. Dilute with 1mL FACS buffer, spin down and discard supernatant.
6. Add 1 00pL master mix consisting of FACS buffer and a 1:100 dilution of 1 B2-biotin.
7. Resuspend and leave on ice for 20min.
8. Dilute with lmL FACS buffer, spin down and discard supernatant.
9. Add 100pL master mix consisting of FACS buffer and a 1:100 dilution of streptavidin-APC
and a FITC-conjugated antibody of interest (anti-Thy 1.1).
10. Resuspend and leave on ice for 20min.
11. Dilute with ImL FACS buffer, spin down and discard supernatant.
Stain samples with a LIVE/DEAD@ Fixable Red Dead Cell Stain Kit (Invitrogen):
1. Bring vial of dye and vial of DMSO to room temperature.
2. Add 50pL DMSO to the vial of dye. Mix well and visually confirm that all of the dye has
gone into solution. Use solution as soon as possible.
3. Add 40piL resuspended viability dye to 40mL PBS.
4. Resuspend cells at 2x 106 cells/mL in the diluted dye stock. Vortex.
5. Add an additional ImL of diluted dye stock to each sample.
6. Incubate on ice for 30min.
7. Wash with PBS.
Stain samples intracellularly using a BD Cytofix/Cytoperm Plus Kit (BD Biosciences):
1. Fix and permeabilized the cells. Resuspend the cells in 250pL Fixation / Permeabilization
solution. Do not vortex. Incubate for 1 0min at 4'C.
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2. Dilute cells with 2mL BD Perm/Wash buffer. Spin down and discard supernatant by
inverting.
3. Wash Ix with ImL BD Perm/Wash buffer. Spin down and discard supernatant by inverting.
4. Prepare stock solution of antibodies in BD Perm/Wash buffer. Prepare 100ptL per sample
with 1pL anti-IFN-y-PE and 2ptL normal rat serum. Resuspend cells in 100ptL final volume.
Incubate for 20min on ice.
5. Dilute with BD Perm/Wash buffer. Spin down and discard supernatant.
6. Resuspend cells in 50ptL FACS buffer.
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A.2 Retrovirus Production
Day 0:
Inoculate 293FT cells so that they will be -30% confluent at seeding. The cells should be 70%
confluent in 24hrs. (Note: Seed 2mL per well at 3x10 5 cells/mL for a 6 well plate)
Day 1:
Transfect 293FT cells. If using a 6 well plate, add 2pg of desired plasmid plus 2pg of pCL-Eco
plasmid plus 3ptL transfection reagent per [tg of plasmid (12pL transfection reagent, TransIT-
LT1 (Mirus)) to each well.
1. Prepare a master mix of DNA.
2. In a fresh 2mL tube, add 150pkL of serum-free media (lOx the total volume of plasmid
plus transfection reagent) and the transfection reagent.
3. Allow to stand for 5min.
4. Add the DNA master mix to the transfection mix.
5. Allow to stand for I 0min.
6. Add transfection mix to the cells.
Incubate the cells overnight.
Day 2:
Change the media on the 293FT cells (4mL media per well).
Day 3:
Harvest the retrovirus-containing supernatant for spin infection (see A.3 Spin infection).
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A.3 Spin Infection
1. Harvest the retrovirus-containing supernatant from 293FT cells (see A.2 Retrovirus
production) into 50mL tubes.
2. Centrifuge the retrovirus supernatant for 5min at 1300rpm. Save the supernatant and discard
the cell pellet.
3. Add polybrene (American Bioanalytical) to the retrovirus supernatant. The final
concentration should be 4pg/mL for T cells and 8pg/mL for cell lines. Add IL-2 to the
supernatant at 50U/mL.
4. Add retrovirus supernatant directly to activated 2C cells (see A.4 Generation of in vitro
memory T cells following retroviral transduction). The retrovirus supernatant from 1 well of a 6
well plate should be added to 2C cells in I well of a 6 well plate.
5. Spin plates at 30'C, 2500rpm for 90min.
6. Following centrifugation, remove the plates and incubate overnight at 37'C.
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A.4 Generation of In Vitro Memory T Cells Following Retroviral Transduction
1. Isolate naYve 2C cells from the spleens and lymph nodes of 2C/RAG mice.
2. Resuspend cells at 2x10 6 cells/mL in T cell media (RPMI plus 10% FBS, 50tM 2-
mercaptoethanol, 10mM HEPES, Ix non-essential amino acids, lx sodium pyruvate, 4mM L-
glutamine, 1OOU/mL / 100pg/mL penicillin-streptomycin) plus 50U/mL IL-2 and 1Ig/mL SlY
peptide.
3. Seed ImL per well of a 24 well plate. Incubate for 36hrs at 37'C.
4. Dilute 2C cells 1:2 into fresh T cell media plus 50U/mL IL-2. Transfer 1 well of a 24 well
plate into 1 well of a 6 well plate, and spin infect with retrovirus-containing supernatant (see A.3
Spin infection).
5. The following day, harvest 2C cells and resuspend at 5x10 5 cells/mL in fresh T cell media
plus 50U/mL IL-2.
6. The following day, evaluate the transduction efficiency and sort cells (if necessary). Count.
Resuspend cells at 5x1 05 cells/mL in fresh T cell media plus 5ng/mL rIL-7 (Peprotech).
7. Incubate for 3-4 days.
8. Harvest cells. Count. Resuspend cells at 5x10 5 cells/mL in fresh T cell media plus 1Ong/mL
rIL-7.
9. Incubate for 3-4 days.
10. Harvest and analyze between days 10 and 16.
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Appendix B
Murine CD40L Sequences
Start and stop codons are highlighted in red.
pMemCD40L, wild type:
gcctctgtcc
catacagcca
ttatgtattt
tgtatcttca
tattcataaa
gtgaggagat
agaaaaaaga
acgttgtaag
attataccat
gagaaggact
gtcaacgccc
tactcaaggc
tgggcggagt
gccaagtgat
gctgtcctag
cattcttggt
accttccccc
acttactgtt
tagaagattg
aaagctaaag
gagaaggcaa
aaacagcttt
cgaagccaac
gaaaagcaac
ctattatgtc
attcatcgtc
ggcaaatacc
gtttgaatta
ccacagagtt
gctgcagcag
cagaagacac
agatccgtgg
ttccttatca
gataaggtcg
agatgcaaca
tttgaagacc
gaaatgcaaa
agtaatgcag
ttggtaatgc
tacactcaag
ggcctctggc
cacagttcct
caagctggtg
ggcttctcat
catttcagct
caactggact
cccaaatgat
aagaggaagt
aaggagaagg
ttgtcaagga
gaggtgatga
catccgttct
ttgaaaatgg
tcaccttctg
tgaagcccag
cccagctttg
cttctgtgtt
cttttggctt
ttcagtcagc
tccagcgagc
tggatctgtg
aaaccttcat
atctttatcc
tataacgtta
ggatcctcaa
acagtgggcc
gaaacagctg
ctctaatcgg
cagtggatct
cgagcagcag
tgtcaacgtg
actcaaactc
atgatagaaa
atgaagattt
ctttttgctg
gaagattttg
ttgctgaact
aacaaagaag
attgcagcac
aagaaaggat
acggttaaaa
gagccttcga
gagagaatct
tctgttcact
actgaagcaa
tgaacagtgc
CD40L Y5A:
The tyrosine at amino acid residue 5 was converted to alanine through a TAG -> GCC site-
directed mutation. The underlined nucleotides highlight this mutation.
gcctctgtcc
cagccagcca
ttatgtattt
tgtatcttca
tattcataaa
gtgaggagat
agaaaaaaga
acgttgtaag
attataccat
gagaaggact
gtcaacgccc
tactcaaggc
tgggcggagt
gccaagtgat
gctgtcctag
cattcttggt
accttccccc
acttactgtt
tagaagattg
aaagctaaag
gagaaggcaa
aaacagcttt
cgaagccaac
gaaaagcaac
ctattatgtc
attcatcgtc
ggcaaatacc
gtttgaatta
ccacagagtt
gctgcagcag
cagaagacac
agatccgtgg
ttccttatca
gataaggtcg
agatgcaaca
tttgaagacc
gaaatgcaaa
agtaatgcag
ttggtaatgc
tacactcaag
ggcctctggc
cacagttcct
caagctggtg
ggcttctcat
catttcagct
caactggact
cccaaatgat
aagaggaagt
aaggagaagg
ttgtcaagga
gaggtgatga
catccgttct
ttgaaaatgg
tcaccttctg
tgaagcccag
cccagctttg
cttctgtgtt
cttttggctt
ttcagtcagc
tccagcgagc
tggatctgtg
aaaccttcat
atctttatcc
tataacgtta
ggatcctcaa
acagtgggcc
gaaacagctg
ctctaatcgg
cagtggatct
cgagcagcag
tgtcaacgtg
actcaaactc
atgatagaaa
atgaagattt
ctttttgctg
gaagattttg
ttgctgaact
aacaaagaag
attgcagcac
aagaaaggat
acggttaaaa
gagccttcga
gagagaatct
tctgttcact
actgaagcaa
tgaacagtgc
182
1
61
121
181
241
301
361
421
481
541
601
661
721
781
841
1
61
121
181
241
301
361
421
481
541
601
661
721
781
841
.. .............. ........  ........................ ............................
CD40L A1-13, Step 1:
In step 1, a BglII site was introduced through a C -+ T site-directed mutation at the third wobble
position in the serine at amino acid residue 12 (TCC -+ TCT). The underlined nucleotides
highlight this mutation.
gcctctgtcc
catacagcca
ttatgtattt
tgtatcttca
tattcataaa
gtgaggagat
agaaaaaaga
acgttgtaag
attataccat
gagaaggact
gtcaacgccc
tactcaaggc
tgggcggagt
gccaagtgat
gctgtcctag
cattcttggt
accttccccc
acttactgtt
tagaagattg
aaagctaaag
gagaaggcaa
aaacagcttt
cgaagccaac
gaaaagcaac
ctattatgtc
attcatcgtc
ggcaaatacc
gtttgaatta
ccacagagtt
gctgcagcag
cagaagacac
agatctgtgg
ttccttatca
gataaggtcg
agatgcaaca
tttgaagacc
gaaatgcaaa
agtaatgcag
ttggtaatgc
tacactcaag
ggcctctggc
cacagttcct
caagctggtg
ggcttctcat
catttcagct
caactggact
cccaaatgat
aagaggaagt
aaggagaagg
ttgtcaagga
gaggtgatga
catccgttct
ttgaaaatgg
tcaccttctg
tgaagcccag
cccagctttg
cttctgtgtt
cttttggctt
ttcagtcagc
tccagcgagc
tggatctgtg
aaaccttcat
atctttatcc
tataacgtta
ggatcctcaa
acagtgggcc
gaaacagctg
ctctaatcgg
cagtggatct
cgagcagcag
tgtcaacgtg
actcaaactc
atgatagaaa
atgaagattt
ctttttgctg
gaagattttg
ttgctgaact
aacaaagaag
attgcagcac
aagaaaggat
acggttaaaa
gagccttcga
gagagaatct
tctgttcact
actgaagcaa
tgaacagtgc
CD40L A1-13, Step 2:
In step 2, the first 12 amino acids were deleted through a BglII digestion. A new ATG start
codon was introduced at amino acid residue 13 through a GTG -+ ATG site-directed mutation.
The underlined nucleotides highlight this mutation.
eetetgcee
ttatgtattt
tgtatcttca
tattcataaa
gtgaggagat
agaaaaaaga
acgttgtaag
attataccat
gagaaggact
gtcaacgccc
tactcaaggc
tgggcggagt
gccaagtgat
gctgtcctag
eattettggt
acottaccoc
acttactgtt
tagaagattg
aaagctaaag
gagaaggcaa
aaacagcttt
cgaagccaac
gaaaagcaac
ctattatgtc
attcatcgtc
ggcaaatacc
gtttgaatta
ccacagagtt
gctgcagcag
eagaagcaa
agatctatgg
ttccttatca
gataaggtcg
agatgcaaca
tttgaagacc
gaaatgcaaa
agtaatgcag
ttggtaatgc
tacactcaag
ggcctctggc
cacagttcct
caagctggtg
ggcttctcat
eattteaget
caactggact
cccaaatgat
aagaggaagt
aaggagaagg
ttgtcaagga
gaggtgatga
catccgttct
ttgaaaatgg
tcaccttctg
tgaagcccag
cccagctttg
cttctgtgtt
cttttggctt
tccagcgagc
tggatctgtg
aaaccttcat
atctttatcc
tataacgtta
ggatcctcaa
acagtgggcc
gaaacagctg
ctctaatcgg
cagtggatct
cgagcagcag
tgtcaacgtg
actcaaactc
atgaagattt
ctttttgctg
gaagattttg
ttgctgaact
aacaaagaag
attgcagcac
aagaaaggat
acggttaaaa
gagccttcga
gagagaatct
tctgttcact
actgaagcaa
tgaacagtgc
183
1
61
121
181
241
301
361
421
481
541
601
661
721
781
841
1
61
121
181
241
301
361
421
481
541
601
661
721
781
841
.. ........................  .............
Site-directed mutagenesis was performed using a QuikChange II Site-Directed Mutagenesis Kit
(Stratagene).
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